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Abstract 
 
Age-related macular degeneration (AMD) is the major cause of vision loss in the 
developed world. AMD is a chronic progressive disorder of the outer retina 
leading to vision loss from atrophy (geographic atrophy) and/or the development 
of choroidal neovascularisation (CNV). Mounting evidence indicates the 
importance of innate immunity in its pathogenesis. This thesis describes a 
programme of work conducted with the aim of further understanding the role of 
innate immune cells in AMD.  
 
Analysis of mouse cell suspensions by flow cytometry demonstrated 
significantly greater densities of innate immune cell populations in the RPE-
choroid than in the neurosensory retina. Dendritic cells accumulated in both 
tissues with increasing age, and this process was accelerated in mice deficient 
in a chemokine upregulated in the aged choroid - CCL2. Innate immune cells 
were recruited to CNV lesions in mouse models of laser-induced and 
spontaneous CNV. Increasing age was found to correlate with the extent of 
laser CNV lesion size but not with recruitment of innate immune cells. Impaired 
recruitment of innate immune cells in CCL2-deficient mice was associated with 
a smaller laser-CNV lesion size, which nonetheless increased with age. 
Attenuation of CNV lesion size by targeting key angiogenic pathways using the 
small molecule pazopanib or by direct targeting of innate immune cells by 
induction of alternative activation using a CD200R agonist was associated with 
subtle increases in the recruitment of innate immune cell subpopulations to 
CNV lesions. 
 
Findings did not support the hypothesis that age-related vulnerability to laser 
CNV is a consequence of age-related changes in innate immune cell 
populations. However, the results indicated that CCL2 controls dendritic cell 
migration in the ageing retina and the recruitment of innate immune cells to 
CNV lesions. Further investigation of these pathways may lead to better 
treatments in the prevention and management of AMD.  
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Introduction  
 
 
1.1 The challenge of age-related macular degeneration 
 
1.1.1 The epidemiology of AMD 
 
First described in 18741, age-related macular degeneration (AMD) is the 
commonest cause of blindness in persons aged ≥50 years old in the developed 
world2-4. AMD affects 1.75 million people in the United States and the 
prevalence is expected to increase by 50% in the United States and countries 
with similar demographics by the year 20205, posing a considerable burden in 
terms of the costs to affected individuals and society unless effective strategies 
aimed at prevention or treatment can be identified. The ‘dry’ form of the 
disease, also known as Geographic Atrophy (GA), is characterised by a 
gradual, irreversible loss of tissue and accounts for 90% of cases - there is no 
proven treatment for preventing or slowing it. The ‘wet’ form of AMD, 
characterised by choroidal neovascularisation (CNV), is less prevalent than GA 
but accounts for 90% of all cases of severe visual loss arising from the disease.  
1.2 The pathology of AMD 
 
1.2.1 The functions of the RPE-choroid complex 
 
AMD is a clinical diagnosis based on fundoscopic findings at the macula - the 
area of the retina that allows us to read and recognise faces - in patients aged 
50 or more. The tissues primarily involved are the retinal pigment epithelium 
(RPE), Bruch’s membrane (BM) and the underlying choroid.  
 
The RPE is a polarised monolayer of epithelium sited between the 
photoreceptors of the neurosensory retina and Bruch’s membrane and has a 
multiplicity of functions in the eye (Figure 1), these include: daily phagocytosis 
Chapter 1  Introduction 
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of outer segment tips shed from photoreceptors adjacent to apical microvilli;   
maintenance of the blood-retinal barrier via tight junctions between adjacent 
RPE cells; absorption of light energy by melanosomes in the RPE cytosol; 
enzymatic participation in the visual cycle; exchange of nutrients and 
metabolites with the blood and the secretion of a variety of factors which serve 
either to maintain the choriocapillaris and its fenestrated endothelium (through 
VEGF for example) or to regulate the local immune system6. The latter function 
has assumed greater prominence in recent years with growing evidence for the 
role of inflammation in AMD.  
 
Bruch’s membrane is a pentalaminar complex of extracellular matrix material 
comprising a thick elastin layer bounded on either side by layers of collagen IV 
with the basement membranes for the RPE and choroid outermost. Structural 
changes in this layer occur with ageing and in AMD. 
 
The choroid is composed of a complex network of capillaries lying on a 
pigmented stroma and contains melanocytes, fibroblasts and an extensive and 
highly organised array of macrophages/dendritic cells and mast cells distributed 
throughout. Tissue macrophages are phagocytic immune cells of the myeloid 
lineage that serve to maintain tissue homeostasis through the clearance of 
senescent cells and the remodelling and repair of tissues after inflammation7.  
 
The choroid may be divided into layers according to blood vessel calibre with an 
outermost layer of larger blood vessels (Haller’s layer), a middle layer of 
medium-sized vessels (Sattler’s layer) and the innermost choriocapillaris layer. 
Its primary purpose is to supply oxygen and nutrients to the RPE and 
photoreceptors but, as with the RPE, the rise of inflammatory hypotheses for 
AMD has recently generated significant interest in its immunological profile. 
 
Normal functioning of the RPE-choroid complex is essential to the health of the 
photoreceptor layer of the neurosensory retina. A breakdown in function 
Chapter 1  Introduction 
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Figure 1. Summary of Retinal Pigment Epithelium functions (A) and the molecules 
involved in the initiation of photoreceptor outer segment phagocytosis (B).  
a, The RPE is a monolayer of pigmented
 
cells forming a part of the blood/retina barrier. The 
apical membrane of the RPE faces the photoreceptor
 
outer segments. Long apical microvilli 
surround the
 
light-sensitive outer segments establishing a complex of close
 
structural 
interaction. With its basolateral membrane the RPE
 
faces Bruch’s membrane, which separates 
the RPE from fenestrated
 
endothelium of the choriocapillaris. b, Phagcytosis of outer segments 
starts with binding of photoreceptor outer membranes. The event of binding is transduced into 
an intracellular signal, a rise in intracellular inositol 1,4,5-trisphosphate (InsP3), which in turn 
leads to ingestion of the bound photoreceptor outer segment membranes. Binding is likely 
mediated by integrins, and signal transduction occurs through the receptor tyrosine kinase 
MerTK. Ingestion involves the macrophage receptor CD36. Coordinate signal transduction 
occurs through integrin and MerTK interaction through the focal adhesion kinase. CD36, 
macrophage phagocytosis receptor; FAK, focal adhesion kinase; Gas6, growth-arrest-specific 
protein 6; MerTK, receptor tyrosine kinase c-mer; PLC, phospholipase C; POS, photoreceptor 
outer segment. The importance to RPE and photoreceptor health of normal processing of 
photoreceptor outer segments is highlighted in forms of autosomal retinal dystrophy that arise 
from mutations such as those in MerTK. Adapted from Strauss 2004. 
A 
B 
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 often has serious implications for vision not just in the context of ageing but 
also in a number of retinal dystrophies of early onset. Mutations in genes such 
as MerTK (responsible for an autosomal recessive form of retinitis pigmentosa) 
and ABCA4 (responsible for forms of Stargardt’s disease – a degenerative 
condition affecting the macula) can result in a build-up of lipofuscin in RPE cells 
- a phenomenon not unlike that seen in early AMD. The accumulation of 
lipofuscin-containing, autofluorescent lysosomal storage bodies over time in 
post-mitotic cells is also a feature of normal ageing. In the RPE, lipofuscin is 
largely derived from phagocytosed photoreceptor outer segments and the level 
of oxidation of this material has some impact on the rate of lipofuscin deposition 
in cultured RPE cells. Lipofuscin itself is also a potent generator of reactive 
oxygen intermediates8. Whether the accumulation of lipofuscin occurs because 
once formed it is not possible for cells to eliminate it or whether the rate of its 
formation ultimately exceeds the rate of elimination is not known, however it is 
possible to reverse the build-up in experimental models and the age-dependent 
accumulation of lipofuscin in perivascular and subretinal microglia in mice 
suggests a role for these cells in lipofuscin turnover9, 10. 
 
1.2.2 Early AMD 
 
Early AMD is characterised by the presence of drusen. These pale yellow 
deposits, which can be seen on clinical examination (Figure 2), consist of lipid 
and protein located in the space between the basal lamina of the RPE and the 
inner collagenous layer of Bruch’s membrane. The aetiology of drusen is not 
fully understood, however their composition features a variety of proteins and 
lipids commonly found in a sub-population of morphologically abnormal RPE 
cells, these include: C-reactive protein (CRP), immunoglobulin G (IgG), 
vitronectin (Vn), Apolipoprotein E (ApoE), clusterin (Apolipoprotein J, Sp40, 
40), fibroblast growth factor-2, and several terminal complement components. 
The identification of recognisable RPE organelles, melanin granules, lipofuscin 
and nuclear material in association with drusen suggests that their components 
may be derived from degenerated RPE cells and various inflammatory 
pathways (though the temporal relationship has yet to be determined).
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Figure 2. Colour photographs illustrating the fundal appearances in right eyes of normal ageing and AMD.  
a, normal >60 year old subject; b, a case of GA. c, a case of CNV. A normal clinical appearance in a subject >60 belies subclinical changes associated 
with aging: loss of neuronal cells (particularly rods), loss of RPE cells, accumulation of lipofuscin within the RPE as well as thickening of Bruch’s 
membrane and alterations in its biophysical properties that may influence the development of RPE dysfunction. Note widespread soft drusen (arrow) 
bordering a large area of RPE atrophy in the subject with GA and intraretinal haemorrhage (arrowhead) and underlying RPE atrophy in the subject with 
CNV.
cba
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Evidence also suggests a role for zinc in drusen biogenesis - high levels of zinc 
have been detected in the maculae of aged humans and high levels of 
bioavailable zinc in sub-RPE deposits. 
 
Of the two clinical types, termed ‘hard’ and ‘soft’ drusen, the latter – 
characterised by irregular borders and a larger size – occurs in younger patients 
with better vision and is most strongly associated with progression to advanced 
AMD, in particular CNV11, 12. Drusen have also been classified according to the 
amount they autofluoresce – it has been demonstrated that drusen located in 
the equatorial region of the fundus will autofluoresce whilst those located 
centrally do not. Drusen located at the equator have been shown to be 
associated with the intercapillary pillars of the choriocapillaris and it has been 
suggested that impaired clearance of waste material by innate immune cells at 
such sites may be responsible for the development of drusen13. 
 
Various other by-products of RPE metabolism and precursors of drusen have 
been identified and attempts made to establish their significance with regards to 
AMD: the terms basal laminar deposit (BLamD) and basal linear deposit 
(BLinD) have been used to describe extracellular material found between the 
RPE basal plasma membrane and its basement membrane that is not visible on 
clinical examination but represents changes associated with sub-threshold 
AMD. In the case of BLinD this material may also involve the inner and outer 
collagenous zones of Bruch’s membrane and its presence may form a cleavage 
plane in which new vessels can spread. Certain components of these deposits 
may also be chemotactic for macrophages14. Over time, morphological changes 
in the retinal pigment epithelium (RPE) may eventually become apparent, 
manifesting as areas of hyper- or hypopigmentation.  
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1.2.3 Late AMD 
 
A proportion of patients with drusen and RPE changes will go on to develop 
severe visual loss as a result of GA and/or CNV. The appearance of GA arises 
from atrophy of the RPE at the macula, the affected area having a scalloped-
border with choroidal vessels clearly visible beneath the retina (Figure 2b).  
 
The mechanism of RPE loss in GA is unknown; however the aged RPE 
accumulates N-retinylidene-N-retinylethanolamine (A2E), a by-product of 
photoreceptor outer segment metabolism and the autofluorescent constituent of 
lipofuscin (and therefore drusen). A2E has been found to selectively inhibit 
phagolysosomal degradation of photoreceptor phospholipid by the retinal 
pigment epithelium in vitro and such effects could ultimately contribute to the 
accelerated loss of RPE and photoreceptor cells seen in AMD (failure to 
phagocytose outer segments has been demonstrated to result in retinal 
degeneration in animal models15). The accumulation of lipofuscin and drusenoid 
deposits in disorders such as Stargardt’s disease indicates a role for lipofuscin 
in AMD - whether its presence consititutes a primary or secondary element of 
AMD pathology and whether its effects stem from direct cellular toxicity, 
disrupted metabolic exchange or ischaemia resulting from the increased 
thickness of Bruch’s membrane is not known.  
 
CNV typically results from a breach of Bruch’s membrane and the rapid 
extension of fenestrated vessels from the choroidal circulation into the sub-RPE 
or subretinal space – again the precipitating factor is unknown. The vessels in 
CNV have an increased tendency to leak resulting in anatomical abnormalities 
such as retinal pigment epithelial detachment (and tears), fluid accumulation in 
the retina and the sequelae of toxic effects from blood on neuroretinal tissue. 
Leakage from CNV disrupts photoreceptor alignment in the short term and in 
the long term results in cell death and fibrosis at the macula (referred to 
clinically as a ‘disciform macular scar’). 
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1.3 Current treatments for AMD 
 
Current treatments for AMD focus on the ‘wet’ form of the condition. There is, 
however, evidence to suggest that high doses of antioxidants and zinc slow 
down progression of the disease in individuals at high risk of developing both 
forms of advanced AMD16. 
 
Vascular endothelial growth factor (VEGF), of which there are a number of 
different isoforms, is a pivotal regulator of angiogenesis.  Recent years have 
seen the advent of therapies targeted at blocking its effects in tumours and 
pathological neovascularisation in the eye. VEGF inhibitors such as 
ranibizumab (a humanised antibody that binds VEGF-A with high affinity) and 
pegaptanib (an aptamer that selectively binds the VEGF165 isoform) have 
revolutionised the treatment of CNV with up to 95% of those undergoing 
treatment experiencing stabilised or improved levels of vision 1 year after 
commencement of therapy17.  
 
A key disadvantage of VEGF inhibitors is that they require delivery by 
intravitreal injection on a monthly basis (at least initially), which adds to their 
already considerable expense and contributes an added element of risk to 
patients’ vision during therapy. VEGF inhibitors do not induce significant 
regression of the neovascular complex and instead act to reduce leakage from 
these vessels. In addition, the long-term efficacy and side effects of VEGF 
inhibitors have yet to be fully established18, 19. Evidence is mounting that VEGF 
has an important role in maintaining vascular homeostasis20, that it has 
neuroprotective properties21 and that alternative splicing gives rise to isoforms 
(such as VEGF-A165b) that may affect the balance of angiogenic drivers both in 
disease and normal conditions with associated effects on the survival of non-
endothelial cells important for blood vessel growth22.  
 
Crucially, the use of VEGF inhibitors is only indicated in <10% of cases and 
even then only at a late stage of AMD - these drugs therefore have no effect on 
the underlying causes of the disease. Evidence also suggests that the longterm 
loss of RPE cells and photoreceptors in wet AMD remains unchecked even 
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when leakage from CNV is controlled23. Since both ‘wet’ and ‘dry’ forms of AMD 
share a common aetiopathophysiology - with the potential for CNV and GA to 
develop together in the same eye, or CNV in one eye and GA in the other for 
any given patient – identification of the relevant pathways could potentially open 
new avenues in the prevention and treatment of both manifestations of the 
disease, possibly involving the use of viral vector-mediated gene transfer or 
cell-based and technologies. 
 
1.4 Risk factors for AMD 
1.4.1 Complement and AMD 
 
Until relatively recently the only confirmed risk factors for the development of 
AMD, aside from the principle effects of aging, were smoking24, 25 and to a 
lesser extent light exposure26, 27. These associations indicated a role for 
cumulative damage, most likely mediated by reactive oxygen species - a 
hypothesis supported by the evidence for reduced progression to advanced 
AMD in high-risk subjects administered high doses of antioxidants and/or zinc16 
and the increased metabolic and oxidative stress born by retinal and RPE cells 
as a normal part of the aging process. Familial associations were known of for 
many years but it was not until the presence of a number of complement system 
components, complement activators and complement regulatory proteins was 
established in the choroid and drusen28, 29 (Figure 3) that genetic studies 
revealed  significant associations with variants of several complement pathway-
associated genes, namely: complement factor H (CFH)30-33, complement factor 
H-related 1 and 3 (CFHR1 and CFHR3)34, 35, complement factor B (CFB), 
complement component 2 (C2) 36, 37 and complement component 3 (C3)38-41. 
 
Complement is central to the functioning of the body’s innate (non-adaptive) 
immune system with roles in the opsonisation and lysis of microorganisms, 
removal of foreign particles and dead cells, recruitment and activation of 
inflammatory cells, regulation of antibody production and elimination of immune 
complexes42. It is a highly conserved system made up of inactive precursor 
proteins (rendered active through a series of proteolytic steps that also amplify 
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the response) and various membrane-bound regulators and receptors43. 
Components are found in the plasma, body fluids and on cells surfaces. The 
anaphylatoxin C5a has a particular role in the recruitment and activation of 
innate immune cells such as macrophages and both C3a and C5a have been 
implicated in the development of CNV44. Activation of complement ultimately 
results in formation of the membrane attack complex (MAC) - an aggregation of 
components C5b, C6, C7, C8 and C9 that generates a pore in the target cell’s 
lipid bilayer resulting in cell lysis. The system is tightly regulated and there are 
four pathways of activation: The classical pathway is activated by the binding of 
C1q to immune complexes (antigen-antibody complexes), the lectin pathway by 
pattern-based recognition of molecules on pathogen surfaces, the intrinisic 
pathway (a recently discovered pathway as yet poorly defined) by direct 
cleavage of C3 and C5 by proteases and the alternative pathway by 
spontaneous hydrolysis of C3 to components C3a and C3b with subsequent 
steps mediated by complement factors B (CFB) and (CFD) in a process that 
turns over continuously at a low-level under normal conditions (Figure 4). 
Genetic studies have revealed that variants of CFH and CFB/C2 alone may 
account for up to 75% of all AMD cases in European and North American 
populations36 with C3 variants estimated to account for up to 14.5% of cases38. 
Other variants, such as certain CFH haplotypes, may in fact be protective35. 
How such variants exert their effects is poorly understood but the process is 
likely to involve many decades of complement activity at interfaces between the 
choroid, Bruch’s membrane and the basolateral RPE surface. The CFH402H 
variant associated with AMD exhibits a strongly reduced affinity for C-reactive 
protein (CRP)45-49 – a key component of drusen and a possible biochemical 
marker for AMD. The existence of two forms of CRP and this protein’s pro- and 
anti-inflammatory potential complicate its relationship with complement50, 51, 
however CFH402H also exhibits reduced affinity for cultured endothelial and RPE 
cells47. 
 
Complement is primarily produced in the liver but certain tissues, such as the 
brain, are capable of production locally. Quantitative PCR (qPCR) analysis of 
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Figure 3. Localization of alternative pathway components and inhibitors in human RPE 
and choroid (CHOR) by confocal immunofluorescence microscopy.  
a, Albumin immunoreactivity is distributed throughout the choroid (green). Lipofuscin 
autofluorescence is present in the RPE cytoplasm (red) b, Factor H is localized to choroidal 
capillaries and the intercapillary pillars (arrowhead) (green). Lipofuscin autofluorescence (blue), 
C-reactive protein (red). c and d, the complement regulator human membrane cofactor protein 
(MCP; CD46) is localized to choroidal vessel walls (arrowhead) and to the basolateral surface of 
the RPE (arrow). Photoreceptor layer of the retina (PH) (green). The polarized basolateral 
distribution of MCP is preserved in cultured human fetal RPE cells (shown in d) (green). RPE 
cell nuclei are stained by the DNA binding dye Hoechst 33258 (violet) (d). e, complement 
regulator, decay accerlerating factor (DAF; CD55) immunoreactivity is associated with choroidal 
vessel walls, but absent in the RPE and in drusen (arrows) (green). f and g, Factor B/C5b-9 co-
localization [anti-Factor B (green); anti-C5b-9 (red)]. Diffuse anti-Factor B labeling is present 
throughout the choroid; choroidal capillary vessel walls are heavily labeled (arrowhead). Factor 
B immunofluorescence can be localized to the cores of some drusen (Dr). From Anderson et al. 
2009. 
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Figure 4. Schematic illustrating components and regulators of the complement system.  
The complement cascade consists of 4 activation pathways, including the recently 
characterized intrinsic pathway, all of which converge upon a terminal pathway that results in 
the assembly of the membrane attack complex (MAC). Multiple complement regulatory proteins 
act at different levels to modulate the system. The complement components and regulatory 
molecules that are localized in drusen are highlighted by an asterisk. From Anderson et al. 
2009. 
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complement gene expression in the human eye indicates that cells in the RPE-
choroid complex express components and regulatory molecules of both the 
classical and alternative complement pathways with the choroid being the main 
source52. The specific cells responsible for complement production in the 
choroid have yet to be identified.  
 
Whilst the choroid is a key source of complement in the eye, certain 
components such as the alternative pathway regulator MCP are also robustly 
expressed in the neural retina and RPE. MCP has been localised to RPE cells 
overlying drusen and at the basolateral surface of RPE in vivo and in vitro 
making it, together with CFH, one of the two main cell surface-associated 
alternative pathway inhibitors in the RPE-choroid53-55. The discovery of a local 
complement system in the RPE-choroid adds an extra layer of complexity in 
understanding the nature of ageing and AMD in the eye. Local expression of 
complement may serve to confer protection on tissues and organs more 
susceptible to the effects of aging and inflammation whereas ‘risk’ variants of 
CFH and C3 may effectively ‘skew’ the immune system in such a way that 
drives pathogenesis (the role played by systemic complement in this is unclear 
though evidence is emerging that circulating levels of several complement 
proteins and markers of activation are correlated with AMD56, 57). Such 
mechanisms are in evidence in other diseases with underlying inflammatory 
components such as Alzheimer’s, rheumatoid arthritis and glomerulonephritis. It 
was in fact the recognition that a form of glomerulonephritis known as dense 
deposit disease (DDD also known as MPGN II) bears histological hallmarks not 
dissimilar to drusen that led to the identification of abnormalities in the CFH 
gene as a risk factor58. Patients with DDD develop subepithelial deposits 
containing C3 beneath the glomerular basement membrane and the condition is 
sometimes associated with the development of drusen in the eye clinically 
indistinguishable from those found in AMD. 
 
The interactions between local and systemic complement systems, the by-
products of RPE and photoreceptor metabolism and the innate immune cells of 
the chorio-retinal complex are likely to be finely balanced and critical to 
understanding the causes of AMD. Hypothesised imbalances in these 
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interactions constitute the ‘inflammation’ model for AMD pathogenesis and 
progression, in which drusen are regarded as the result of chronic inflammatory 
events at the level of Bruch’s membrane (Figure 5). 
 
1.4.2 The role of innate immune cells in AMD 
 
As well as complement, the innate immune system comprises two principal cell 
types: granulocytes (neutrophils, basophils and eosinophils) and cells derived 
from the mononuclear-phagocyte system (MPS) (Figure 6). The MPS is 
composed of tissue-specific macrophages (termed microglia in the CNS and 
retina), dendritic cells (DCs) and monocytes. Monocytes share a common 
precursor with neutrophils in the bone marrow (as part of the myeloid lineage) 
and on infiltration of tissues from the circulation they are capable of 
differentiating into macophages (and DCs) of various phenotypes depending on 
cues taken from the local milieu of cytokines and chemokines.  
 
Activated microglia may be found in the degenerating retina of patients with 
advanced AMD59 (Figure 7) and the role of macrophages in pathological 
neovascularisation and vasculogenesis is well-documented. Direct evidence for 
involvement of these cells in early AMD, however, is relatively limited and 
comes from the presence of the Major Histocompatibility Class II (MHC II) 
molecule HLA-DR in drusen and evidence for the extension of processes from 
choroidal dendritic cells into drusen60 (a feature reminiscent of gut DCs and 
their ability to extend their dendrites, penetrate epithelial tight junctions and 
sample bacteria in the intestinal lumen61). Analysis of cadaveric tissue from 
normal eyes, normal-aged eyes and eyes with early AMD has confirmed that 
choroidal macrophages in normal eyes, positive for the phagosomal marker 
CD68+, do not express iNOS (an indicator of their activation status). Expression 
of iNOS by choroidal macrophages appears to be associated with the 
recruitment of macrophages to Bruch’s membrane in eyes with early AMD, soft 
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Figure 5. Inflammation model of macular degeneration.  
According to the model, AMD may triggered by one or more environmental risk factors that 
occur against the background of a genetic susceptibility profile conferred by variants in the CFH, 
CFB/C2, and/or C3 gene triad. This confluence of environmental and genetic risk factors gives 
rise to pathological changes in the RPE–choroid late in life which generate a chronic, local 
inflammatory response that includes complement activation and other inflammation-mediated 
events characterized, in part, by alterations in Bruch's membrane, drusen formation and the 
accumulation of other sub-RPE deposits, bystander cell lysis, and dendritic cell involvement. 
Over time, these processes/events result in photoreceptor degeneration and the loss of central 
vision that defines the clinical entity of AMD. From Anderson et al. 2009 
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Figure 6. The Mononuclear Phagocyte System.  
Developing macrophages are first found in the yolk sac, as identified by morphological 
characteristics, as well as by expression of macrophage markers such as CD11b. Later in 
development, haematopoiesis in the foetal liver becomes a source of macrophages that 
resemble those that are present in adults. Monocytes can be precursors for the replenishment 
of tissue-resident macrophage populations, however there is evidence to suggest that many of 
these macrophages may be derived from local proliferation in the adult rather than from 
recruited peripheral monocytes. When bone-marrow monocytes are released into the peripheral 
blood (having a Ly6C+ phenotype), they are thought to differentiate into a phenotypically distinct 
(Ly6C-) cell subset. From Gordon and Taylor 2005. 
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drusen or thick continuous BLamD and also with active disciform scarring. 
Expression of iNOS was found to be absent from macrophages associated with 
Bruch’s membrane in the same study62. There is also limited evidence for 
patients with wet AMD being more likely to have circulating, activated 
monocytes that produce high amounts of pro-inflammatory TNF-α63. 
 
More compelling has been the identification of variants I249/M280 of the 
chemokine receptor CX3CR1 (expressed on neutrophils, monocytes, T cells 
and, in particular, all retinal microglia) as risk factors for AMD64 and the 
subsequent confirmation of the accumulation of CX3CR1-positive microglia in 
the macular subretinal space of both human subjects with AMD (including those 
with CNV) and CX3CR1-/- mice65. This has resulted in parallels being drawn 
between lipid laden subretinal microglia and the ‘foam cells’ found in 
atherosclerotic plaques. Similar changes are thought to occur in the ageing 
brain with evidence for increased numbers of activated microglia in the brains of 
those with Alzheimer’s disease, the identification of age-related dystrophic 
changes in microglia and evidence indicating that the composition of 
extracellular debris found in AMD and diseases such as atherosclerosis and 
Alzheimer’s shares similar characteristics60, 66, 67 . Microglia have also been 
implicated in a number of other diseases of the CNS and retina including 
multiple sclerosis and diabetic retinopathy. The link between inflammation and 
AMD is further reinforced when one considers the well-known low-grade chronic 
inflammatory effects of smoking. 
 
The significance of these findings is better appreciated with an understanding of 
inflammation, the changes in the immune system that occur with age, the 
various monocyte subsets, their markers and receptors, how myeloid cells 
traffic through the eye and how their phenotypes relate to key experimental 
models of AMD (including models of CNV). 
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Figure 7. Confocal microscopy of a macula with AMD.  
Rods are labelled with anti-rhodopsin (green). Microglia (MG) and blood vessel walls are 
positive with the lectin marker RCA-I (red). R, retinal pigment epithelium. Bars=100 μm. (A) In 
addition to stellate MG in the ganglion cell layer (GCL) and inner nuclear layer (INL), note large, 
RCA-I positive MG (arrowheads) among the degenerating rods and in the sub-retinal space. 
Most of these activated MG cells contain rhodopsin positive (green) cytoplasmic inclusions. 
Inset shows a MG cell at higher magnification (4X)-note rhodopsin positive (green, small 
arrowheads) inclusions in the cytoplasm. Nuclei are stained blue with TO-PRO-3. (B) Cones are 
positive (blue) with mAb 7G6 and rods, including a neurite (arrow), are labeled (green) with anti-
rhodopsin. Large, RCA-I positive MG (red, arrowheads) in the outer nuclear layer contain 
rhodopsin positive cytoplasmic inclusions. From Gupta et al. 2003. 
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1.5 The innate immune system 
 
1.5.1 The leukocyte adhesion cascade 
 
Inflammation constitutes the body’s response to tissue injury. Uncontrolled 
inflammation, however, can result in tissue damage and in itself be the cause of 
disease - making it of key importance in the pathology of a great many tissue-
specific diseases. The process may be characterised as acute or chronic 
depending on the timecourse of the response and the predominating cell type. 
Acute inflammation, driven largely by neutrophil recruitment in the initial phase, 
may begin within seconds of onset of a stimulus and continue for hours or even 
days. Should a stimulus persist, chronic inflammation may ensue with 
macrophages the predominating cell type in a process of continual injury and 
healing that may last many years (Table 1). 
 
Both acute and chronic inflammatory events rely on cells already present in the 
affected tissue to recruit circulating leukocytes to the site of injury. Activation of 
cells in the tissue triggers a cascade of events which, through the secretion of a 
range of cytokines and chemokines (small molecules involved in cell-cell 
signalling), leads to adhesion of circulating cells and their transmigration 
through blood vessel walls.  This ‘leukocyte adhesion cascade’ classically 
consists of three steps: rolling, activation and firm adhesion, however recent 
refinements have been made to this model including the addition of slow-rolling, 
adhesion strengthening, intraluminal crawling and paracellular and transcellular 
migration (Figure 8). The rolling phase is mediated mainly by selectins, 
molecules expressed either on the activated endothelial luminal surface or by 
the leukocytes themselves, with subsequent rolling and firm adhesion 
established through the binding of β1- and β2-integrins. The myeloid-derived cell 
marker CD11b/CD18 (also known as complement receptor 3, Mac-1, αMβ2-
integrin or simply CD11b) is one such example of an integrin - its rapid 
activation through G-protein-coupled receptor signalling leading to leukocyte 
arrest.  
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Table 1. Trafficking molecules involved in inflammatory disease processes.  
From Luster et al. 2005 
  
Disease Key effector cell Proposed leukocyte receptors for endothelial traffic signals
L-selectin, ligand GPCR Integrina
Acute inflammation
Myocardial infarction Neutrophil PSGL-1 CXCR1, CXCR2, PAFR, BLT1 LFA-1, Mac-1
Stroke Neutrophil L-selectin, PSGL-1 CXCR1, CXCR2, PAFR, BLT1 LFA-1, Mac-1
Ishaemia reperfusion Neutrophil PSGL-1 CXCR1, CXCR2, PAFR, BLT1 LFA-1, Mac-1
TH1
Atherosclerosis Monocyte PSGL-1
CCR1, CCR2, BLT1, CXCR2, 
CX3CR1 VLA-4
TH1 PSGL-1 CXCR3, CCR5 VLA-4
Multiple sclerosis TH1 PSGL-1 (?) CXCR3, CXCR6 VLA-4,LFA-1
Monocyte PSGL-1 (?) CCR2, CCR1 VLA-4,LFA-1
Rheumatoid arthritis Monocyte PSGL-1 CCR1, CCR2 VLA-1, VLA-2, VLA-4, LFA-1
TH1 PSGL-1 CXCR3, CXCR6 VLA-1, VLA-2, VLA-4, LFA-1
Neutrophil L-selectin, PSGL-1 CXCR2, BLT1 LFA-1b
Psoriasis Skin-homing TH1 CLA CCR4, CCR10, CXCR3 VLA-4c ,LFA-1
Crohn disease Gut-homing TH1 PSGL-1 CCR9, CXCR3 α4 β7 , LFA-1
Type 1 diabetes TH1 PSGL-1 (?) CCR4, CCR5 VLA-4,LFA-1
CD8
L-selectin (?), PSGL-1 
(?) CXCR3 VLA-4,LFA-1
Allograft rejection CD8 PSGL-1 CXCR3, CX3CR1, BLT1 VLA-4,LFA-1
B cell L-selectin, PSGL-1 CXCR5, CXCR4 VLA-4,LFA-1
Hepatitis CD8 PSGL-1 CXCR3, CCR5, CXCR6 VLA-4
Lupus TH1 None CXCR6 VLA-4d
Plasmacytoid DC L-selectin, CLA CCR7, CXCR3, ChemR23 LFA-1, Mac-1
B cell CLA (?) CXCR5, CXCR4 LFA-1
TH2
Asthma TH2 PSGL-1 CCR4, CCR8, BLT1 LFA-1
Eosinophils PSGL-1 CCR3, PAFR, BLT1 VLA-4,LFA-1
Mast cells PSGL-1 CCR2, CCR3, BLT1 VLA-4,LFA-1
Atopic dermatitis Skin-homing TH2 CLA CCR4, CCR10 VLA-4,LFA-1
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Figure 8. The Leukocyte Adhesion Cascade.  
The original three steps are shown in bold: rolling, which is mediated by selectins, activation, 
which is mediated by chemokines, and arrest, which is mediated by integrins. Progress has 
been made in defining additional steps: capture (or tethering), slow rolling, adhesion 
strengthening and spreading, intravascular crawling, and paracellular and transcellular 
transmigration. Key molecules involved in each step are indicated in boxes. ESAM, endothelial 
cell-selective adhesion molecule; ICAM1, intercellular adhesion molecule 1; JAM, junctional 
adhesion molecule; LFA1, lymphocyte function-associated antigen 1 (also known as L 2-
integrin); MAC1, macrophage antigen 1; MADCAM1, mucosal vascular addressin cell-adhesion 
molecule 1; PSGL1, P-selectin glycoprotein ligand 1; PECAM1, platelet/endothelial-cell 
adhesion molecule 1; PI3K, phosphoinositide 3-kinase; VCAM1, vascular cell-adhesion 
molecule 1; VLA4, very late antigen 4 (also known as 4 1-integrin). From Ley et al. 2007. 
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In addition to mediating adhesion, integrins are capable of generating 
intracellular signals that regulate a variety of cellular functions. Binding of 
CD11b/CD18 to its ligand, Intercellular Cellular Adhesion Molecule 1 (ICAM-1), 
on the luminal side of the endothelium is a critical step in the transmigration of 
leukocytes through venular walls. Integrin activation drives the expression of 
other surface molecules on both immune cell and endothelium, reducing 
interendothelial contact and allowing penetration of the endothelial cell barrier 
and its pericyte sheath usually between cells (termed the ‘paracellular’ route). 
Certain cells, such as neutrophils infiltrating the CNS, have also been found to 
be capable of migration through cells (the transcellular route68). Subsequent 
penetration into the tissues is a dynamic process that begins during 
transmigration and involves the interaction of integrins and their ligands, the 
cadherins and, in some cells, the expression of matrix metalloproteases 
(MMPs). 
 
During inflammation endothelial cells are triggered by cytokines not only to 
express adhesion molecules on their surfaces but to synthesise chemokines. 
They are also capable of actively transporting chemoattractants originating at 
the site of injury from their abluminal surface69. The recruitment of specific 
leukocyte populations depends not only on the differential expression of 
integrins and their ligands but also on the expression of chemokines and their 
receptors. Chemokines are powerful physiological activators of integrin-
mediated adhesion and their effects are mediated via G-protein-coupled 
receptor signalling. They are small molecules which can be classified into C, 
CC, CXC and CX3C categories depending on the arrangement of their N-
terminal residues. A degree of pleiotropy and redundancy exists and chemokine 
receptors are expressed on a variety of cell types including immune cells, 
endothelial cells and neurones. The CCR2 receptor for example is expressed 
most highly on monocyte/macrophages and has an important role in their 
recruitment to non-lymphoid sites of inflammation,70-72 however expression 
levels vary between monocyte subsets73 and the receptor has also been 
demonstrated to be present on a number of other cell types including DCs at 
certain stages of maturation74, neutrophils75, 76, mast cells76, ~15% circulating 
CD4+ T cells77 and even brain microvascular endothelial cells where it is thought 
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to be critical for macrophage transmigration78. CCR2 has multiple ligands that 
include CCL2 (which is specific for this receptor but expressed in a wide variety 
of tissues), CCL7, CCL8 and CCL13. It is not unusual for chemokine receptors 
to bind multiple ligands with varying degrees of affinity, some however, such as 
CCR8, are limited to only one.  
 
Inflammatory cells are capable of expressing a range of chemokine receptors, 
only some of which are essential during the recruitment of a cell to a specific 
tissue - others may act to regulate the level of activation in a cell or influence 
the pattern of cytokine expression and cell-to-cell interactions. It has been 
demonstrated, for example that, despite strong CCL2 expression in the retina 
and CCR2 expression by recruited monocytes, CCR2 deletion does not lead to 
a reduction in disease severity in the experimental autoimmune uveitis model – 
suggesting that the effects of CCR2 deficiency are likely to be compensated for 
by other chemokine/chemokine receptor interactions79. Some chemokines may 
have more direct effects on inflammatory cell transmigration, for example the 
chemokine fractalkine (also known as CX3CL1 – a ligand for the CX3CR1 
receptor expressed highly on specific monocyte subpopulations) exists in both 
soluble and membrane-bound forms and a role for this chemokine in cell 
adhesion has been proposed80.  
 
The importance of integrins and chemokines in regulating leukocyte activation 
and arrest has made and continues to make them prime targets for 
pharmacological intervention81. Chemokines and chemokine receptors are 
particularly attractive targets for cancer immunotherapy as they are involved in 
almost every step of tumourigenesis, including the growth and metastatic 
spread of malignant cells, neovascularisation and the recruitment of 
immunosuppressive cells – it is therefore conceivable that their manipulation 
might render similar benefits at different stages of AMD pathology. The results 
of clinical trials involving immunotherapy have been mixed however – a failure 
to demonstrate efficacy in trials designed to test CCR1, CCR2 and CXCR3 in 
various autoimmune diseases has been attributed to the nature of the drugs 
themselves, differences between the immune systems of animals and humans 
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and the fact that multiple receptors can be involved in driving the 
pathophysiology of disease. 
 
1.5.2 The role of innate immune cells in inflammation 
 
1.4.2.1 Interactions with the adaptive immune system 
 
The innate immune system constitutes a phylogenetically ancient defence 
mechanism. As mentioned previously, innate immune cells may be broadly 
divided into two categories – the granulocytes and the cells of the MPS (Natural 
Killer cells forming a smaller subset). Components of either group may 
predominate during specific phases of the inflammatory process. However, 
despite these differences in their behaviour, innate immune cells are united in 
their expression of the myeloid cell marker CD11b.  
 
For many years the innate immune system was considered separate to the 
adaptive immune system: Innate immune cells tend to be more responsive to 
inflammation-induced trafficking cues compared to naive lymphocytes of the 
adaptive immune system - this is largely because the former are capable of 
responding to less specific activation signals. These signals include Pathogen 
Associated Molecular Patterns, or ‘PAMPS’ (LPS being an example), which 
bind to ‘PRPs’ (Pattern Recognition Receptors) on the cells - examples of such 
receptors include Toll-like recepetors (TLRs). In contrast to innate immune cells, 
the migration of activated T and B cells is more dependent on the nature, quality 
and strength of an antigenic stimulus. Until recently the majority of 
immunological research focused on the intricacies of the adaptive immune 
system, with the role of the innate immune system regarded primarily as one of 
antigen presentation. However focus has shifted with growing recognition of the 
importance of the innate immune system in instigating, directing and regulating 
adaptive immune responses. Changes in the innate immune system associated 
with healthy (and morbidity-associated) ageing and pathological 
neovascularisation make them of particular interest in the study of AMD. The 
role of innate immune cells in antigen presentation and cytokine production 
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makes them key players in directing any subsequent lymphocyte responses, 
with particular cell types instigating particular patterns of inflammation. Broadly, 
patterns of inflammation can be divided into two categories mediated by the 
principal CD4+ T lymphocyte populations (T lymphocytes being distinguishable 
from other cells of the adaptive immune system by their expression of a T cell 
receptor): T helper type 1 (TH1) and TH2 responses. Cytokines are small 
proteins which carry messages between cells in the immune system – the 
myriad interleukins (IL-), leukotrienes (LT-) and interferons (IFN-) are prominent 
examples. The cytokines interferon-γ (IFN-γ) and TNF-β (tumour necrosis 
factor-β) tend to predominate in TH1 responses and as such drive a more pro-
inflammatory and tissue-destructive environment. TH2 responses may be 
regarded as more anti-inflammatory in nature, resulting in the production of IL-4, 
Il-5 and IL-13 (cytokines best known for their ability to modulate the behaviour 
of eosinophils in parasitic and atopic disease) and IL-10 a key ‘suppressor’ 
cytokine which can downregulate expression of IL-2 (a T cell activator), IFN-γ 
and IL-12. 
 
A number of other T cell subsets may be influenced either directly or indirectly 
by myeloid cell activity in the retina, ciliary body and iris. These include cytotoxic 
CD8+ T cells that have anti-viral and anti-tumour effects and also modulate 
transplant rejection, and regulatory CD4+ T cell (Treg) populations. The latter, 
formerly known as suppressor T cells, may be identified by their expression of 
an intracellular protein known as Foxp3 and play a critical role in the induction 
of immune tolerance – this has been most extensively characterised in models 
of anterior chamber-associated immune deviation (ACAID). ACAID is a feature 
of ocular immunity whereby the usual responses to antigenic material are 
downregulated such that damage to the delicate structures of the ‘immune 
priveleged’ eye is limited. Inoculating an eye with antigen may therefore be 
seen to result in a form of systemic immunity characterised by T cells that 
eliminate pathogens and virulence factors in the absence of inflammation, an 
exclusion of effector CD4+ T cells and the upregulation of regulatory T cells. A 
critical step in this process is the uptake of antigen by the resident F4/80+ cells 
of the eye including (macrophages and DCs) and their migration to the spleen 
where T cell-mediated responses occur82.  
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The role of the recently discovered TH17 T cell population (thought to be 
involved in the aetiology of autoimmune diseases) in ocular pathology has yet to 
be determined but it has been established that certain myeloid cell populations 
have pivotal roles in modulating the balance of  TReg and TH17 populations with 
CD14+HLA-DR(-/low) myeloid-derived suppressor cells (MDSCs) inducing 
Foxp3+ regulatory T cells and CD14+HLA-DR+ monocytes promoting the 
generation of TH17 cells
83. 
 
 
1.4.2.2 Granulocytes 
 
Granulocytes contain specialised granules released in the first phase of an 
immune response and comprise neutrophils, eosinophils and basophils. 
Neutrophils constitute the most abundant circulating leukocytes in healthy 
humans. Short-lived, they are recruited rapidly to sites of acute inflammation, 
particularly during bacterial and fungal infections, and have the potential to 
either cause tissue damage through the release of cytotoxic mediators such as 
TNFα (and hence may be said to drive TH1-mediated responses) or implement 
a healing response, through the production of factors such as VEGF. 
Neutrophils express the chemokine receptor CCR2 (amongst others) and their 
response to the chemokine CCL2 has been found to be enhanced in the context 
of chronic inflammation84. Evidence suggests that neutrophils adopt a more 
complex profile of chemokine receptor expression (that includes CCR1, CCR2 
and CCR3) compared to peripheral neutrophils in the context of chronically 
inflamed environments and that this affects their migratory capacity and 
function85. Eosinophils are much rarer in the circulation and are classically 
involved in modulating parasite-directed and allergic (TH2-mediated) immune 
responses. Eosinophils share a number of surface markers with neutrophils, 
though expression of the chemokine receptor CCR3 is largely restricted to 
eosinophils and mast cells (mast cells are primarlily associated with allergic 
immune disorders and are derived from circulating basophils). CCR3 has 
recently been identified in choroidal neovascular endothelial cells in early AMD 
and antagonising this receptor has been demonstrated to result in inhibition of 
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CNV in experimental models (though this was appears not to be mediated by 
mast cells or eosinophils).86. 
 
1.4.2.3 Monocytes 
 
Monocytes are much longer-lived cells than neutrophils and peripheral blood 
monocytes exhibit considerable morphological variability in terms of size, 
granularity and nuclear morphology. Identification of their differential expression 
of various antigenic markers has revealed them to be heterogeneous cells with 
varied physiological activities – these properties are largely conserved between 
mice and humans (Table 2). Until recently it was thought that monocytes 
circulated in the peripheral blood and patrolled vessels before differentiating into 
DCs or macrophages, however it has now been established that the spleen 
plays a significant role in the storage of undifferentiated monocytes and these 
may be deployed rapidly in response to inflammatory cues87. 
 
Monocytes have been implicated in many inflammatory diseases - they are 
recruited to atherosclerotic plaques, for example, where they ultimately become 
the lipid laden foam cells characteristic of the disease. They are also involved in 
combating chronic bacterial infections and responding to the presence of 
foreign material and injury. Certain subsets may also play critical roles in 
healing and immunological homeostasis - from clearing cell debris to directing 
angiogenesis. Monocytes are capable of producing large amounts of reactive 
oxygen species and cytokines such as TNF-α, IL-1β, IL-6 and IL-10 as well as 
VEGF and proteolytic enzymes. Most of these functions are carried out as 
macrophages in the tissues but monocytes also have the capacity to 
differentiate into DCs, cells that bridge the innate and adaptive immune systems 
through their capacity to trigger and regulate T-cell responses - essentially fine- 
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Figure 9. Cytokines produced by immune cells can give rise to macrophages with 
distinct physiologies. 
Ly6C
+
 bone-marrow monocytes are released into the peripheral blood, a, and are thought to 
adopt a Ly6C
mid
 phenotype b, which is associated with retention of CCR2, before (under steady-
state conditions) they form CCR2
-
Ly6C
-
 monocytes, c, that are characterized by high CX3CR1 
expression. Both Ly6C
+
 and Ly6C
mid
 monocytes respond to pro-inflammatory cues, such as 
CCL2, and are recruited to inflammatory lesions, d. Of these, 'inflammatory' monocytes are 
thought to differentiate into macrophages, which are important for clearance of pathogens and 
for the resolution of inflammation, e. Some monocytes emigrate from the tissues to the draining 
lymph nodes, a process that uses CCR7 and CCR8 receptor–ligand interactions, f. CCR7
+ 
CCR8
+
 monocytes that are present in the tissue must have been recruited directly from the 
peripheral blood to the inflammatory site or must have differentiated from Ly6C
+
 monocytes in 
situ. The expression of CCR7 and CCR8 by these cells makes them uniquely disposed to 
emigrate into the lymphatic vessels. In the draining lymph nodes, these monocytes acquire 
dendritic cell (DC)-like characteristics, g, which they do not obtain if they are retained in the 
tissue by selective chemokine-receptor deficiency. In the absence of inflammation, CX3CR1
High 
Ly6C
-
 monocytes are thought to enter the tissues and replenish the tissue-resident macrophage 
and DC populations, h. Solid arrows represent pathways that are supported by established 
data, whereas dashed arrows represent pathways that are indicated from a compilation of more 
recent data and speculation. Adapted from Gordon & Taylor 2005. 
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tuning the balance between inflammation and tolerance. Initially monocytes 
were considered the major antigen presenting cells of the immune system 
however the identification of discrete subsets of DCs suggests that these cells 
are in fact much more potent in this regard than the monocytes they are closely 
related to. 
 
Monocytes in mice may be identified by their CD11b+ F4/80low phenotype. F4/80 
is a surface marker involved in T cell regulation that is restricted to the 
monocyte/macrophage pool and upregulated in states of activation88, 89. 
Monocytes can be further subdivided according to their differential expression of 
the chemokine receptors CCR2 and CX3CR1: one subset expresses CCR2, 
cluster determinant (CD) 62L (also known as L-selectin) and lower levels of the 
chemokine receptor CX3CR1 whereas the other expresses no CCR2 or CD62L 
but higher levels of CX3CR17, 90.  
 
CCR2+ monocytes migrate towards CCL2, a chemokine central to the 
recruitment of monocytes and other leukocytes such as basophils, natural killer 
(NK) cells, T cells, DCs and neutrophils to sites of inflammation91. This 
characteristic has led to CCR2+ monocytes being referred to as the 
‘inflammatory’ subset. In keeping with this moniker these cells migrate to 
inflamed tissues and lymph nodes and produce high levels of the pro-
inflammatory cytokines TNF-α and Il-1. The acquisition of an inflammatory 
monocyte phenotype has been demonstrated to be a time-limited property that 
is independent of external inflammatory signals – monocytes require a period of 
up to 48 hours in the circulation upon release from the bone marrow before they 
are capable of recruitment to inflamed tissues92. Inflammatory and TNF-α/iNOS-
(inducible nitric oxide synthetase) producing DCs (Tip-DCs) can derive from 
CCR2+ monocytes – these cells either take up antigen in peripheral tissues and 
then migrate into lymphoid organs or, in the case of Tip-DCs, may
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Table 2. Phenotype of the two best-characterized monocyte subsets in various mammals 
 
'Inflammatory' and 'resident' nomenclature is based on studies carried out in mice and 
extrapolated to other species. Data have been assigned arbitrary symbols that represent no 
expression (-), marginal expression (+/-) and increasing amounts of expression (+, ++, +++).  
‡
These receptors show good conservation of expression-pattern differences between the 
subsets of at least three species. 
§
There is no available commercial reagent that recognizes the extracellular domain of mouse 
CD116 (also known as granulocyte/macrophage colony-stimulating-factor receptor -chain).  
7/4, an unidentified mouse antigen recognized by monoclonal antibody 7/4; CCR, CC-
chemokine receptor; CD200R, CD200 receptor; CXCR, CXC-chemokine receptor; CX3CR1, 
CX3C-chemokine receptor 1; EMR1, epidermal-growth-factor-module-containing mucin-like 
hormone receptor 1; F4/80, monoclonal antibody that recognizes the mouse homologue of the 
human protein EMR1; ND, either differences between the subsets have not been determined or, 
in some cases, there is no clear species conservation of the antigens.  
(Adapted from Gordon & Taylor 2005)
Antigen Human CD14hi 
CD16- 
'inflammatory' 
monocytes 
Human 
CD14+CD16+ 
'resident' 
monocytes 
Mouse CCR2+ 
CX3CR1
low 
'inflammatory' 
monocytes 
Mouse CCR2- 
CX3CR1
hi 
'resident' 
monocytes 
Rat CD43low 
'inflammatory' 
monocytes 
Rat CD43hi 
'resident' 
monocytes 
Pig CD163- 
'inflammatory' 
monocytes 
Pig CD163+ 
'resident' 
monocytes 
Chemokine receptors 
CCR1 + - ND ND ND ND ND ND 
CCR2‡ + - + - + - ND ND 
CCR4 + - ND ND ND ND ND ND 
CCR5 - + ND ND ND ND ND ND 
CCR7 + - ND ND + - ND ND 
CXCR1 + - ND ND ND ND ND ND 
CXCR2 + - ND ND ND ND ND ND 
CXCR4 + ++ ND ND ND ND ND ND 
CX3CR1
‡ + ++ + ++ - + ND ND 
Other receptors 
CD4 + + ND ND +/- ++ ND ND 
CD11a ND ND + ++ ND ND + ++ 
CD11b ++ ++ ++ ++ ++ ++ ND ND 
CD11c‡ ++ +++ - + - + + ++ 
CD14 +++ + ND ND ND ND ++ + 
CD31 +++ +++ ++ + ND ND ND ND 
CD32 +++ + ND ND +++ + ND ND 
CD33 +++ + ND ND ND ND ND ND 
CD43 ND ND - + - + ND ND 
CD49b ND ND + - ND ND ND ND 
CD62L‡ ++ - + - + - ND ND 
CD80 ND ND ND ND ND ND + ++ 
CD86 + ++ ND ND ND ND + ++ 
CD115 ++ ++ ++ ++ ND ND ND ND 
CD116 ++ ++ ++§ ++§ ND ND ND ND 
CD200R ND ND ND ND + - ND ND 
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migrate from the red pulp to the white pulp of the spleen. Additional markers for 
the ‘inflammatory’ population include Ly6-G (also known as Gr-1 – a granulocyte 
marker highly expressed on neutrophils, approximately 40% of NK cells and 
plasmacytoid DCs) and Ly6-C73. Gr-1 and Ly6C are epitopically distinct 
members of the same molecular family93, though this is not always evident from 
the literature where the two markers are often referred to interchangeably, 
nevertheless CCR2+ monocytes have been variously described as being Gr-1+, 
Ly6-C+ or Ly6-CHigh.  
 
CCR2- monocytes (Gr-1-, Ly6-C- or Ly6-CLow) are referred to as ‘resident’ 
monocytes because they are thought to migrate to tissues in the absence of 
inflammation and replenish tissue-resident macrophage and DC populations7. 
More recently, CCR2- Gr-1- monocytes have been found to exhibit a constitutive 
long-range crawling phenotype on the luminal side of the endothelium under 
steady state conditions that is CD11a/18 (β2-integrin LFA-1) and CX3CR1 
dependent94. This suggests that these monocytes patrol blood vessels and may 
play important functions in the scavenging of oxidised lipids, dead cells and 
pathogens90. 
 
The differential behaviour of CCR2+ Gr-1+ and CCR2- Gr-1- monocyte 
populations has been investigated using a number of different models. The 
CCR2- Gr-1- subpopulation appears to extravasate rapidly in response to 
peritoneal infection with Listeria monocytogenes for example and at 1h after 
infection is the major producer of the inflammatory cytokine TNF-α90. These 
cells continue to participate in the recruitment and activation of other effector 
cells such as granulocytes, NK cells and T-cells, before differentiating into 
macrophages of the so-called ‘alternative’ M2 phenotype. In contrast CCR2+ Gr-
1+ monocytes, after becoming the main inflammatory cytokine producers later 
on in the inflammatory process (at an 8hr timepoint) go on to initiate a more DC-
like differentiation programme (Error! Reference source not found.)90. Distinct 
patterns of recruitment and differentiation have also been identified in models of 
injury: sequential mobilisation of monocyte populations has been demonstrated 
in the healing mouse myocardium with CCR2+ Gr-1+ monocytes performing 
phagocytic, proteolytic and inflammatory functions before CCR2- Gr-1- cells with 
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attenuated inflammatory properties express VEGF and promote angiogenisis 
and healing of the tissue (Error! Reference source not found.)95.  
 
The effects of knocking-out the various monocyte chemokine receptors (CCR2 
and CX3CR1 for example) and their cognate ligands have also been examined 
along with the effects of adoptive transfer of specific monocyte subsets and 
GFP-labelling of cells. This has proved useful, particularly in the field of 
atherosclerosis research but also in the investigation of inflammation in the 
brain and AMD in the eye, and will be discussed in more detail when the roles 
of these cells in the chorioretinal complex are considered. 
 
1.4.2.4 Macrophages 
 
Macrophages are a heterogeneous group cells capable of phagocytosing 
invading organisms, initiating inflammatory responses that drive the recruitment 
of neutrophils and NK cells and facilitating the maturation, differentiation and 
migration of DCs. They are also capable of secreting a wide array of cytokines, 
chemokines, growth factors and enzymes. Whilst the differential behaviour of 
monocyte populations gives some insight into the spectrum of macrophage 
activation, these populations were only discovered relatively recently and there 
remain many unanswered questions regarding whether specific monocyte 
populations give rise to specific macrophage populations and the contribution 
made by local proliferation to the pool of macrophages in the tissues (microglia 
are capable of proliferation in the CNS for example and this turnover may be 
enough to maintain their numbers throughout adult life except in defined 
conditions such as inflammation).  
 
Macrophages may be classified as having an M1 or M2 phenotype, where M1 
represents ‘classically’ activated macrophages and M2 ‘alternatively’ activated 
macrophages. This model, though popular given its simplicity, has been largely 
superseded by other paradigms reflecting a broader spectrum of behavioural 
plasticity (Error! Reference source not found.). Classically activated 
macrophages are cells which respond to IFN-γ and TNF to produce 
inflammatory cytokines such as IL-1, IL-6   
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and IL-23; they are also associated with interactions with TH17 cells that serve 
to recruit neutrophils which in turn contribute to inflammatory autoimmune 
pathologies – in short these macrophages fall neatly into a single category. 
Alternatively activated macrophages were initially defined according to the 
phenotype adopted by cells exposed to IL-4; however recent evidence suggests 
that this group can be further divided into macrophages with a wound-healing 
phenotype and macrophages with regulatory properties (Error! Reference 
source not found.). The IL-4 which drives development of wound-healing 
macrophages may arise either from a TH2-mediated response or from an innate 
immune response promoted by granulocytes - the resulting cells, whilst less 
efficient at antigen presentation and killing pathogens, are able to secrete 
components of the extracellular matrix and interruption of IL-4 signalling 
therefore results in reduced fibrosis and reduced accumulation of wound-
healing macrophages. Regulatory macrophages appear to require two signals 
for their activation - one may arise from immune complexes, prostaglandins, 
adenosine or apoptotic cells whilst a Toll-like receptor ligand may provide the 
other. These cells are prodigious producers of IL-10 (a potent inhibitor of the 
production and activity of a number of pro-inflammatory cytokines) they do not, 
however, contribute to the production of extracellular matrix. Interestingly, IL-10-
/- mice which have an increased inflammatory response to diverse stimuli have 
been found to have reduced CNV following laser-induction compared to wild-
type mice, a phenomenon associated with increased numbers of infiltrating 
macrophages96. 
 
1.4.2.5 Dendritic Cells 
 
Dendritic Cells have been referred to as the ‘quintessential professional antigen 
presenting cells’ of the immune system - superior in this respect to 
macrophages. DCs in the peripheral tissues constantly monitor the local 
environment and in response to the appropriate maturation or ‘danger’ signals 
(usually upon ligation of a pattern recognising Toll-like receptor) migrate to 
lymphoid tissue where they may present processed antigen and trigger T cell 
Chapter 1  Introduction 
51 
 
activation. DCs’ functions straddle the innate and adaptive immune systems. 
They are capable of producing copious amounts of cytokines such as Il-12 and   
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interferons in mounting a host defence against microbes and have the capacity 
to activate not only T cells but regulatory T cells and NK cells. Most interestingly 
there is evidence to suggest that DCs capture antigen against which an immune 
response is usually avoided, including environmental proteins derived from the 
respiratory and digestive tracts and tissues where constitutive cell turnover is a 
feature – this suggests a role for DCs in maintaining homeostatic control over 
recognition of self and the local microenvironment. They are rare in peripheral 
blood but relatively common in lymphoid and various non-lymphoid tissues 
(such as the choroid) 90. In the mouse circulating DCs can express the integrin 
CD11c (DCs are often said to be CD11cHi) and MHC class II antigen whereas 
monocytes do not.  
 
The origins of DCs and the roles of the various subpopulations have yet to be 
fully determined – several subsets exist and there may be multiple precursors 
that include the so-called myeloid/DC progenitor, the common DC precursor 
and CCR2+ Gr-1+ monocyte populations (which have been demonstrated to be 
capable of replenishing DC resident cell compartments in the skin, lung and 
digestive tract as well as contributing to inflammatory/Tip-DC populations 
discussed earlier). Conventional ‘non-myeloid’ DCs (cDCs) represent those 
populations in lymphoid tissue originally identified as being responsible for 
‘mixed lymphocyte reaction activity’ - these cells have a short half life and do 
not have a monocyte intermediate. Plasmacytoid DCs (that are also Ly6C+ and 
Gr-1+) represent a subset that is the most potent IFN-α-producing in response 
to viral infections90 whereas it has been suggested that the Tip-DC subset  is 
primarily responsible for killing bacteria rather than regulating T cell functions90. 
Interestingly, phagocytosis of apoptotic cells by immature DCs induces an anti-
inflammatory response and promotes tolerance through production of TGF-β 
and IL-10 thereby reducing the ability of DCs to stimulate T cells directly. The 
impaired clearance of apoptotic cells that can result from complement 
deficiency, for example, potentiates secondary necrosis and the maturation of 
DCs (via their exposure to ‘damage associated molecular patterns’) - with pro-
inflammatory consequences42. 
 
Chapter 1  Introduction 
55 
 
DCs have become a focus of atherosclerosis research in recent years since 
they have been demonstrated to have a role in atherosclerotic plaque 
destabilisation. CCL2 is thought to be involved in DC migration into vascular 
intimae and DC recruitment is impaired in mouse models of atherosclerosis that 
are deficient in the chemokine CX3CR197. 
 
1.4.2.6 Natural Killer cells 
 
Natural Killer cells (supporters of innate immunity) and Natural Killer T cells (a 
closely related population that bridges the innate and adaptive immune 
systems) are heterogeneous lymphocytes that have a critical role in the innate 
immune response to infections and tumours. NK cells do not require activation 
to kill cells missing ‘self’ markers such as MHC class I, consequently they have 
an important role in killing tumour and virus-infected cells which they do by 
releasing cytoplasmic proteins known as perforin and granzyme. NK cells 
express a number of cytokines and chemokine receptors that modulate their 
cytotoxic properties: NK cells migrate in response to CCL2, and both CCR2 and 
CCR5 on NK cells have been demonstrated to play a role their migration, 
target-binding and recruitment. The cytokines IL-2, IL-12, IL-15, IL-18 and IFN-
α/β have been demonstrated to promote NK cell proliferation and activation and 
induce these cells to produce pro-inflammatory cytokines such as IFN-γ and 
TNF-α. In addition, models of infection suggest that neutrophils play a critical 
role in inducing NK cell IFN-γ production98. NK cells share a progenitor with T 
lineages but develop independently of the thymus and express neither the TCR 
(T cell receptor)/CD3 complex typical of T cells nor surface immunoglobulin. 
They do, however, exhibit a number of unusual markers including CD56 (in 
humans), CD16, CD57 and CD2 and are generally considered to be CD11b+, 
Ly6C+ and Gr-1+90. Expression of the integrins CD11b and CD11c by NK cells 
has sometimes led them to be confused with macrophages. Both NK cells and 
macrophages also express Fc receptors that enable antibody-dependent cell 
cytotoxicity. 
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1.5.3 The innate immune system of the retina and choroid 
 
The mammalian retina is of neuroectodermal origin and consists of two layers of 
neuronal cell bodies separated by two layers of synapses and an outer layer of 
photoreceptors the outer tips of which are enveloped by the apical processes of 
the RPE cells (with a ratio of approximately 30 photoreceptors to each RPE 
cell). In the uninflamed state the retina is invested with a repertoire of innate 
immune cells, the predominating cell type being microglia. 
 
Microglia are the resident immune cells of the central nervous system (CNS) 
and in addition to the functional characteristics in keeping with their 
macrophage phenotype they have a range of other roles. These include: 
interacting with multiple CNS cell types (including the Muller glia, vessels and 
photoreceptors of the retina), participating in vasculogenesis99 and synthesising 
and releasing neurotransmitters and neurotrophic factors that impact on the 
physiology and survival of neurones and photoreceptors100. In the resting state 
microglia adopt a dendritiform or ‘ramified’ appearance where primary 
processes emerge from the cell body and branch before ending in bulbous tips. 
In retinal explants these processes have been observed to exhibit highly 
dynamic properties consistent with their sampling of the extracellular space and 
an exchange of signals between neighbouring microglia. Following laser injury 
these movements increase in frequency, processes may be directed towards 
the site of injury and microglia are seen to migrate to the site of injury and may 
adopt a more ‘amoeboid’ phenotype101.  
 
Under physiological conditions there are two anatomically distinct populations of 
retinal microglia in the adult: a perivascular population located around the inner 
retinal vasculature and a parenchymal population arranged in a stratified 
configuration that is largely confined to the inner retinal layers and is mostly 
absent from a zone that extends from the outer nuclear layer to Bruch’s 
membrane . Evidence derived from adoptive transfer experiments using eGFP-
transgenic mice suggests that bone marrow-derived CD11b+ F4/80- monocytes 
migrate across the blood-barrier and replace the retinal microglia with a 
turnover time of 6 months and that whilst the recruited cells are CX3CR1+ the  
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Figure 10 Phenotype of myeloid and microglial populations within mouse retina 
Microglial populations in a chimaeric bone marrow EGFP-transgenic mouse model used to 
demonstrate microglial repopulation of the retina. Following reconstitution of the bone marrow in 
normal adult C57BL/6 mice with EGFP
+
 bone marrow, replacement of retinal microglia is 
observed over a 6-month period. Further immunohistochemical analysis permits the 
identification of a variety of microglial phenotypes that occupy different locations in the retina. 
F4/80 expression varies in the retina - amoeboid microglia present in the ganglion cell layer are 
F4/80
high
 and ramified parenchymal microglia F4/80
low
. From AD Dick 2008.  
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receptor is not directly involved in the recruitment process102, 103. Whether the 
monocyte/macrophage population in the adult retina is CCR2- Gr-1- in 
phenotype has not yet been confirmed though microglia in CX3CR1gfp 
transgenic mice (in which one or both copies of the CX3CR1 gene have been 
replaced with an  eGPF  reporter gene) appear to be CD45+, CD11b+, F4/80+, 
CD11c- and MHC class II-103. Transferred cells are found initially at the 
peripheral and juxtapapillary retina and subsequently in the ganglion cell layer, 
the inner and outer plexiform layers and ultimately the photoreceptor layer. 
Cells in the ganglion layer assume an amoeboid shape and high levels of 
expression of the leukocyte-specific marker CD45, F4/80 and the microglia-
specific Iba-1 whereas cells in the inner and outer retina are ramified and 
express low levels of the above markers (with perivascular macrophages 
expressing the least). The implications of changes in morphology and surface 
marker expression are unclear in the retina. In the brain there is evidence to 
suggest some regional differences in microglial marker expression although it 
should be noted that changes in microglial morphology and expression of a 
small number of markers cannot be used as simple guides to phenotype and 
function104. 
 
Both perivascular and parenchymal macrophage populations in the retina have 
limited antigen presenting potential and instead act to suppress T cell activation. 
The RPE appears to be actively involved in this process, maintaining the 
immune status of the ‘resting’ retina through the secretion of cytokines, such as 
TGF-β, that drive the retinal microglia to produce Il-10 and direct cells 
stimulated by TNF/IFN-γ towards an ant-inflammatory phenotype105. The 
CD200-CD200R system is also important in regulating retinal microglia under 
physiological conditions. CD200 is a type-1 membrane glycoprotein expressed 
on a variety of lymphoid and non-lymphoid cells including activated T cells, B 
cells, vascular endothelium and neurones106-108. CD200R is expressed 
predominantly on myeloid-derived cells, including microglia, macrophages, 
neutrophils and mast cells108. Ligation of CD200R has been demonstrated to 
dampen microglial activation and limit tissue damage in a variety of 
inflammatory models in the CNS, including experimental autoimmune uveitis 
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(EAU)109 and experimental autoimmune encephalitis (EAE)107. Decreased 
neuronal expression of both ligand and receptor have been linked with the 
chronic inflammation of Alzheimer’s disease and treatment of microglia and 
macrophages with the anti-inflammatory cytokines Il-4 and Il-13 (levels of which 
are reduced in human elderly brains) has been demonstrated to increase 
expression of CD200R110. 
 
In contrast to the microglia, dendritic cells account for a relatively small 
proportion of the innate immune cells of the retina. However a population of 
perivascular MHC class II+ DCs that line the retinal vessels has been implicated 
in the induction of EAE in mice and another small population of MHC class II+ 
33D1+ cells has been identified in the retinal periphery and around the optic 
nerve - sites where the first signs of autoimmune uveoretinitis are known to 
appear111. 
 
In common with the innate immune cell population of the uveal tract (the iris, 
ciliary body and choroid), the innate immune cell population in the choroid is 
composed primarily of macrophages and DCs that have been found to be 
extremely heterogeneous in terms of their morphology, immunophenotype and 
function. The macrophages of the mouse choroid have a perivascular 
arrangement that extends along the length of the medium and large vessels, 
and these cells have been described as being pleomorphic, dendriform or 
fusiform in shape112. In contrast an extensive network of DCs, defined as 
positive for MHC class II (Ia+), were described in the same study as being less 
perivascular in distribution and more dendritiform in shape. Subsequent work 
using CX3CR1gfp transgenic mice has confirmed the pattern of distribution and 
morphology described above and suggests that the majority of eGFP+ cells in 
the choroid in this model are MHC Class II+ (with high expression on the 
processes of dendriform cells) as well as being CD11bLow, CD45+ and CD68+ 
(the latter being a marker for cytoplasmic granules in myeloid populations)103. 
Immunoelectron microscopic studies in the rat choroid suggest that 
macrophages and MHC Class II+ DCs are located directly beneath Bruch’s 
membrane and in the intercapillary pillars of the choroid where they lie in close 
apposition to the basal surface of the RPE and extend processes into a region 
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known to accumulate photoreceptor debris with age113. Uveal tract DCs have 
been further characterised as being CD8α- CD11b+ CD11c+ ie. Cells of 
‘conventional’ DC phenotype (other subsets have not been found) whilst uveal 
macrophages have been found to be predominantly CD11b+ F4/80+ cells, with 
few signs of activation under physiological conditions. Macrophage populations 
cultured from the choroid have been found to potentiate the antigen presenting 
function of certain dendritic cells111. 
 
1.6 Age-related changes in the eye and the role of the 
innate immune system 
 
1.6.1 Parainflammation 
 
The term ‘parainflammation’ has been used to describe levels of inflammation 
that lie between intermediate and basal. Parafinflammation reflects the innate 
immune response mounted by the body in various tissues to restore tissue 
homeostasis. It has been proposed that under basal conditions cells such as 
the perivascular macrophages and microglia of the retina may perform a house-
keeping role that involves clearing the by-products of cell metabolism and 
maintaining neuronal integrity. In situations of more severe tissue damage, cells 
may need to be recruited from the circulation for the purpose of restoring tissue 
homeostasis. Should the response become uncontrolled - in the presence of 
persistent injury for example - chronic inflammation may ensue. Chronic 
inflammation is said to form the core of all age-related pathology and is a 
consequence of the exposure of tissues such as the brain and vasculature to 
free-radical-induced damage over the lifetime of the host beyond a point at 
which cells normally responsible for restoring homeostasis are able to cope 
without triggering further damage. Aside from AMD, diabetic retinopathy and 
glaucoma are the other two key age-related conditions affecting the eye114. 
 
1.6.2 Morphological changes associated with ageing in the 
retina and RPE-choroid 
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As a consequence of the cumulative damage described above (perhaps 
exaggerated in the retina because of the levels of light and oxygen exposure), 
the sensitivity of the retina declines with age. A reduction in the rate of dark 
adaptation is seen coupled by a loss of neuronal cells – particularly rods – and 
this is accompanied by a loss of RPE cells that primarily affects the macula and 
surrounding area115.  The consequences of a failure to deal with apoptotic cells 
and their by-products (a process known as autophagy) by tissue resident 
macrophages have already been described: induction of a pro-inflammatory 
cascade of events and, in the CNS at least, neuronal cell death116. Additional 
changes with ageing include an accumulation of lipofuscin in RPE cells and an 
increased thickness of Bruch’s membrane that is associated with the 
accumulation of drusen precursors described earlier. The changes in Bruch’s 
membrane may have knock-on effects on RPE cell and photoreceptor function 
as a result of impaired hydraulic conductivity117. In AMD, Bruch’s membrane 
may appear thinned with small defects in its structure. There is also a build up 
of complement and fibrinogen in the outer collagenous zone that may be the 
result of macrophage activation in the vicinity (macrophages have been found in 
close association with such changes28). 
 
Ageing changes may also affect the blood-retinal barrier (BRB). The BRB is 
made up of tight junctions between the capillaries of the neuroretina and 
between individual RPE cells. Vascular endothelial cells have been 
demonstrated to increase production of pro-inflammatory cytokines (IL-6, TNF-α 
and CCL2) with ageing and this may account for the observed increase in 
leukocyte-endothelial interactions and the disruption of tight junctions. 
Disruption of tight junctions, either under the direct influence of cytokine 
signalling or as a result of leukocyte transmigration of endothelium, leads to the 
leakage of proteins and platelets into the neuroretinal tissue with injurious 
consequences that may occur acutely or over many years114. Aside from the 
critical effects of oxidative stress, the ageing retina is also exposed to other 
noxious stimuli that drive parainflammatory processes. These include: 
advanced glycation end products, oxidised lipoproteins and hyaluronan 
fragments – all of which are associated with the production of pro-inflammatory 
cytokines and the recruitment/activation of innate immune cells in the retina. 
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Changes associated with ageing in the choroid are perhaps less dramatic 
though probably no less significant than those seen in the retina. The thickness 
of the choroid increases with age in mice by a factor of three and this is 
associated with fibrosis in the outermost layer (Haller’s layer) where fibroblasts 
and elongated melanocytes constitute a significant proportion of the cellular 
population114. The middle layer of the choroid (Sattler’s layer – composed 
primarily of medium-sized blood vessels) is seen to accumulate round giant-
melanocytes with age and these are also found occasionally in the subretinal 
space. In addition, the choriocapillaris becomes distended and, along with 
Bruch’s membrane, is seen to accumulate fibrillar structures in samples of 
human tissue118. 
 
1.6.3 The immune response in the ageing retina 
 
As in the rat brain, an increase in the numbers of innate immune cells (MHC 
class II+) has been found in the parenchyma of ageing rat retina compared with 
young animals. This phenomenon is associated, in the rat at least, with 
impaired blood-retinal-barrier function and a decline in cognitive function119. In 
the mouse, an accumulation of subretinal microglia (positive for the microglial 
marker Iba-1+, CD68+ and MHCLow but said to be negative for CD11c) has been 
observed with normal ageing9, 120. These cells, which have their origins in the 
inner retina, have a bloated, lipofuscin-filled appearance with the large cell body 
and short dendrites associated with microglial activation, and their proximity to 
the underlying RPE makes it likely that they influence RPE function. Lesions 
similar in appearance and with similar constituents to drusen (and therefore 
termed subretinal drusenoid deposits or pseudodrusen) have been 
demonstrated in the subretinal space of aged and AMD-affected humans 
(Error! Reference source not found.)121, 122, 89. Although the cellular nature of 
subretinal drusenoid deposits has yet to be confirmed in humans, their location 
on Spectral Domain Optical Coherence Tomography (SD-OCT) correlates with 
the location of the clinically diagnosed reticular drusen that have long been 
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associated with AMD. Parallels with the phenotype in aged mice therefore make 
this an area of intense interest (Error! Reference source not found.). 
 
The migration of microglia to the subretinal space with age and a general 
increase in numbers of innate immune cells in the retina would require 
attendant changes in the pattern of cytokine and chemokine expression in the 
retinal microenvironment - this is indeed the case. Levels of the cytokine TNF-α 
and chemokines CCL2, CCL3, CCL8 and CCL12 have been found to be 
increased in the retinae of aged mice114. The source of this array of cytokines 
and chemokines has yet to be established but increases in the levels of pro-
inflammatory cytokines associated with injured brain have been linked to 
astrocytes (the retinal equivalent being Muller glia)123. The reduced levels of 
expression of CD200 and CD200R in the brains of Alzheimer’s patients suggest 
that a downregulation of regulatory proteins in the retina may also occur110. 
 
1.6.4 The immune response in the ageing RPE-choroid 
 
Various changes consistent with a parainflammatory response have been noted 
in the ageing RPE-choroid. CD45+ leukocytes have been found to be increased 
in number on examination of choroidal flatmounts in old mice compared to 
young and these cells appear to express CRIg, a receptor expressed on 
macrophage subsets that is involved in complement-mediated phagocytosis114. 
This hints at a possible role for these cells in scavenging cell debris from 
RPE/retina, aided by complement activation. Use of immunofluorescent 
techniques has demonstrated that CD45+ leukocytes appear to be absent from 
Bruch’s membrane in young mice whereas many appear to be attached in aged 
mice; some may also be seen to be attached to the surface of choroidal 
capillaries and some may be seen to be passing through Bruch’s membrane124. 
 
Comprehensive work using microarray techniques and RT-PCR has 
demonstrated that as many as 16 pathways are upregulated in the 
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aged RPE-choroid the first 10, in order of significance, being those involved in: 
1) leukocyte signalling; 2) complement cascades; 3) NK cell signalling; 4) IL-10 
signalling; 5) B cell signalling; 6) T cell signalling; 7) IL-2 signalling; 8) 
granulocyte monocyte colony stimulating factor signalling; 9) Fc epsilon RI 
signalling; and 10) chemokine signalling. In contrast to the RPE-choroid, where 
immunological and inflammatory pathways are upregulated, those increased 
with age in the retina are largely related to stress responses and apoptosis124. 
 
Closer examination of those pathways upregulated in the RPE-choroid suggests 
that leukocyte extravasation activity is highly elevated. Genes responsible for 
leukocyte docking and rolling, including those coding for CD11b/CD18, αL-
integrin and ICAM-1 are most prominent in terms of increased expression. 
Expression of MMPs (also integral to leukocyte extravasation and migration) 
also appears to be upregulated, principally MMP3 and MMP13. In keeping with 
the hypothesis that complement is integral to the clearance of cell debris by the 
choroidal innate immune system, levels of expression of C3 are increased by a 
factor of almost 10 in the aged choroid and immunohistochemistry has 
confirmed large, discontinuous clumps of C3 deposits on Bruch’s membrane in 
aged mice124. 
 
Aside from those genes responsible for generalised leukocyte recruitment, a 
number of genes involved in NK cell signalling are expressed at increased 
levels in the aged RPE-choroid - these include genes encoding proteins that 
mediate the activation of NK cells124. Given that NK cells are generally thought 
to be involved in killing tumour and virus-infected cells it is interesting to 
speculate on their role in the ageing RPE-choroid. 
 
Genes associated with the regulation of immune responses, most notably IL-10, 
are upregulated in the aged RPE-choroid. In contrast, production of pro-
inflammatory cytokines such as IL-12, IL-6 and TNFα is reduced in the aged 
choroid – a pattern that may be linked to increased levels of prostaglandin E2 
(PGE2). The macrophages thought to be responsible for secreting these 
cytokines have been demonstrated to be present in increased numbers in the 
choroid with age (Error! Reference source not found.). A range of techniques 
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has demonstrated that CCL2, a chemokine with a key role in leukocyte 
recruitment, is strongly upregulated in the aged RPE-choroid with 
immunofluorescent labelling demonstrating its presence in both RPE and 
endothelial cells124. Such changes would be consistent with alterations in the 
immune environment of the subretinal space – a low-grade chronic 
inflammatory response that involves the recruitment of innate immune cells not 
present in younger animals. 
 
1.6.5 The ageing innate immune system 
 
Immunosenescence, the deterioration of the immune response associated with 
ageing, is thought to underly the reduced ability of the elderly to combat 
infection and to mount effective immune responses following immunisation 
(particularly to influenza vaccines). It is also thought to be linked to the higher 
incidence of cancer in the elderly. Consequently, research has focused on the 
nature of immunity in successful ageing (those who reach extreme age with little 
or no associated morbidity) and the immune systems in those with increased 
morbidity and mortality at a relatively younger age. Significant differences have 
emerged regarding the behaviour of both the adaptive and the innate immune 
systems with age and evidence suggests that changes in the latter may to a 
certain extent explain those in the former. Evidence suggests that the antigen 
presenting function of DCs is well-retained in the elderly but that their numbers, 
and those of their precursors, are reduced. In addition it has been demonstrated 
that the chemotaxis and phagocytic capacity of both DCs and neutrophils is 
impaired with age – possibily as a result of changes in signal transduction 
pathways125.  
 
The numbers of circulating neutrophils and their precursors are not thought to 
be affected by ageing. However, evidence suggests that as well as exhibiting 
impaired chemotactic and phagocytic capacities, neutrophils in the elderly adopt 
a low-grade inflammatory status in the absence of stimulation that is 
characterised by CD62L shedding, altered signal transduction and constitutive 
production of reactive oxygen intermediates. Such changes suggest a role for  
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aged neutrophils in the pathogenesis of autoimmune diseases, Alzheimer’s 
disease, cancer and atherosclerosis - the latter condition, for example, has 
been associated with higher numbers of circulating neutrophils and the 
decreased activity of NK cells. Stimulated neutrophils from elderly subjects have 
also been demonstrated to release more elastase than in younger subjects 
(which may have direct implications for ruptures in Bruch’s membrane in the 
context of AMD) and higher levels of CD11b expression on neutrophils have 
been associated with Alzheimer’s disease126. 
 
Ageing human and rodent macrophage populations have reduced levels of 
MHC Class II that may contribute to impaired T-cell responses and monocyte 
TLR-mediated induction is also compromised with ageing. Whilst there appears 
to be no difference in the numbers of peripheral blood monocytes between 
elderly and young subjects a slight decrease in macrophages and their 
precursors has been found in the bone marrow of elderly subjects (although the 
reverse appears true of bone marrow macrophage populations in rodents). An 
age-related decline in the ability of macrophages to adhere to surfaces, 
opsonise, kill tumour-infected cells and phagocytose has also been 
demonstrated, and although the affected pathways have yet to be fully 
elucidated, aberrant responses to chemotactic stimuli are likely to be involved.  
In keeping with these findings, macrophages from healthy elderly individuals 
have been shown to have an impaired response to complement-derived factors 
that may contribute to delayed pathogen clearance127.  
 
Increasingly evidence also suggests that microglial ‘dystrophy’, as opposed to 
activation, is linked to Alzheimer’s disease. Microglia exhibit age-related 
changes such as telomere shortening and have been demonstrated to have 
neuroprotective properties that weaken with age and precede the neurofibrillary 
pathology of the disease. Such senescent changes have been demonstrated by 
focusing on morphological changes in the microglia instead of the more 
commonly used markers of activation such as MHC Class II expression that can 
also be upregulated on ramified cells. The principal feature of microglial 
dystrophy in the brain is cytoplasmic fragmentation (also known as cytorrehexis) 
– an appearance not unlike that which precedes apoptosis. The hypothesis that 
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age-related changes in microglia underly the development of Alzheimer’s and 
similar neurodegenerative diseases is considered an attractive one because it 
places the effects of ageing, as the major risk factor, at the centre of the 
disease process128.  
 
The evidence for age-related changes in macrophage cytokine and chemokine 
secretion is mixed. This is partly the result of differences in the genetic 
heterogeneity and health of human cohorts and partly the result of differences 
between the responses elicited following in vivo and in vitro experimentation. 
There also appears to be interspecies variation: rodent studies suggest an age-
related decline in the secretion of macrophage-derived pro-inflammatory 
cytokines such as IL-1, TNFα and IL-6 whereas the majority of human studies 
suggest the opposite. Macrophages from both aged mice and aged humans 
appear to produce more prostaglandin E2 (PGE2) than younger individuals 
however. PGE2 suppresses IL-12 secretion and decreases surface expression 
of MHC class II on APCs and also enhances IL-10 secretion – factors thought to 
contribute to a decline in T cell function with age127. Furthermore EGFP-
expressing brain-derived microglia in rodents exhibit morphological changes 
with age such as the presence of lipofuscin granules, decreased complexity of 
processes, altered granularity and an increased expression of pro-inflammatory 
cytokines such as TNFα, IL-1β, IL-6 and IL-12 that appears to be 
counterbalanced by expression of IL-10 and TGFβ. Aged microglia also exhibit 
increased expression of pro-inflammatory cytokines compared to young 
microglia when challenged with lipopolysaccharide (LPS) accompanied by an 
enhanced Il-10 response and failure to downregulate TGFβ. These changes are 
proportional to the basal levels independent of age and this implies that ageing 
microglia function normally although their response to a challenge is adjusted in 
proportion to the level of basal activation129.  
 
Given that NK signalling is upregulated in the aged RPE-choroid the effects of 
ageing on the body’s NK cell population may be relevant. In rodents, evidence 
suggests that NK cell activity peaks at 5-8 weeks of age before declining to 
nearly undetectable levels at 25 months of age. Similarly elderly subjects 
between 75 and 85 years have decreased NK cytotoxic function, a feature that 
Chapter 1  Introduction 
72 
 
correlates with a history of severe infections or subsequent death due to 
infection. In contrast nonagenarians and centenarians exhibit similar NK cell 
cytotoxicity to subjects aged 60-65 years, indicating that preservation of NK cell 
cytotoxicity in an individual, along with a favourable ratio of subsets, may be 
associated with healthy ageing. In aged mice, NK cell cytotoxicity is preserved 
following stimulation with IL-2 but reduced on stimulation by IFN-γ. In humans, 
the response to Il-2 is also preserved but the cytoxic activity of cells stimulated 
with IL-12, IFN-α and IFN-γ is diminished with an associated age-related decline 
in perforin that affects men more than women. Production of IL-2, IL-12, IFN-α 
and IFN-γ by lymphocytes decreases with age (a shift towards a TH2 
phenotype) with a consequent reduction in production of these cytokines by NK 
cells that impact on the adaptive immune system. Impaired cytotoxicity and IFN-
γ production by NKT cells (which, in contrast to NK cells, tend to exert their 
cytotoxic effects through Fas/Fas ligand interactions) is also a feature of ageing 
in mice and humans – as with NK cells, a feature reversed in examples of 
extreme age in both cases. Decreased IL-4 production by certain 
immunoregulatory NKT subsets also appears to be associated with chronic age-
related pathology. 
 
A factor that unites the age-related changes in NK and NKT cell populations is 
their relationship to zinc ion bioavailability and metallothionein homeostasis. 
Zinc is a trace element essential for the efficient functioning of not only NK and 
NKT cells but also the efficient phagocytic functioning of monocytes, 
granulocytes and macrophages. It is also important in the recruitment of 
neutrophils and maintenance of their levels in the circulation, and the activation 
of mast cells. More recently, the maturation of DCs has been linked to a TLR-
induced reduction in intracellular zinc130. Zinc is a component of over 300 
enzymes and is also found at the core of sub-RPE deposits in AMD and 
deposits in neurodegenerative conditions such as Alzheimer’s disease (its origin 
at these sites is unknown). Zinc bioavailability in cells is regulated by low 
molecular weight proteins known as metallothioneins – these serve as a store 
for zinc and are upregulated in response to high zinc concentrations. 
Metallothioneins have been found to be present at reduced levels in the 
peripheral RPE compared to the macular RPE - a difference that increases with 
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age131. Metallothionein expression is induced by pro-inflammatory cytokines, 
such as Il-6 and TNF-α, that have been demonstrated to be elevated in the 
plasma of the elderly. An abnormal increase in metallothionein expression may 
therefore be responsible for the progressive decrease in circulating levels of 
zinc seen with healthy ageing and this may explain changes in immune system 
functioning, at least systemically132. It is therefore possible that the effects of 
antioxidants and zinc supplementation in reducing progression of AMD16 are 
mediated through immunomodulatory mechanisms. 
 
1.7 Models for AMD 
 
1.7.1 Animal models of AMD 
 
The complexity of tissue and immune cell interactions in AMD means that the 
benefits of in vitro experimentation are limited. Currently, however, there is no 
single animal model that faithfully replicates what is seen in the human disease. 
There are a number of reasons for this: understanding of the underlying 
genotypic risk factors for AMD is incomplete; AMD is largely restricted to the 
macula (an anatomical feature of the human eye shared only with birds and 
non-human primates); AMD is a disease of ageing, and this places restrictions 
on the suitability of certain species for experimentation; and the relative 
contributions of established environmental risk factors have yet to be 
determined. 
 
Rodents, in particular mice, are favoured as models of AMD for the ease with 
which transgenic animals may be developed and the lower cost of their 
maintenance compared to primates, rabbits and pigs. Diseases which might 
take years to manifest in humans also tend to progress at rates measured in 
weeks or months in mouse models. A disadvantage of their use, however, is 
that mice lack a macula and have a low cone-rod ratio (although they do have a 
higher concentration of photoreceptors centrally compared to the periphery and, 
of the total complement, it is rods that are lost earliest in AMD). In addition, the 
results obtained from mouse models with different backgrounds should be 
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interpreted with caution since immunological differences across strains have 
been identified133. 
 
Despite the development of a variety models relying on the controlled exposure 
of mice to dietary and environmental factors, progress towards reliable models 
of ‘wet’, ‘dry’ and ‘mixed’ AMD phenotypes has been slow. There are a number 
of models available that exhibit features of early AMD, these include: the 
‘senescence accelerated mouse’ model, in which progressive abnormalities of 
the RPE and Bruch’s membrane are seen (though the underlying genotype is 
unknown); a model in which D-galactose administered in the diet results in the 
advanced glycation end-product-induction of an ageing phenotype and a model 
in which immunisation of mice with carboxyethylpyrrole (a unique oxidation 
fragment of docasahexaenoic acid which is found in drusen) results in the 
formation of drusen and GA-like lesions in the fundus134. Increasingly, attention 
has focused on models that allow the effects of the innate immune system on 
ageing in mice and potential therapeutic options to be studied in more detail – 
such approaches have yielded valuable data not only in the field of AMD 
research but also in the study of other age-related pathology where chronic 
inflammation is a feature such as atherosclerosis and Alzheimer’s disease. 
 
1.7.2 The effects of chemokine deficiency in mice 
 
1.7.2.1 The effects of CCR2 or CCL2 knockout 
 
Deficiencies in either CCR2 or CCL2 result in impaired macrophage 
mobilisation and trafficking in mice70 - deletion of CCL2 results in reduced 
macrophage recruitment to atherosclerotic lesions and reduced lesion size in 
mice for example. Given that a failure of innate immune cells to effectively 
manage subretinal debris may be linked to the development of drusen and 
given that chemokines such as CCL2 are expressed at higher levels in the aged 
choroid124, a number of studies have examined the effects of deleting 
chemokines or their receptors (sometimes in combination) using transgenic 
mice. 
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Initially it was thought that CCL2-/- and CCR2-/- animals exhibited all the key 
features of AMD. After 9 months of age these mice were thought to develop 
subretinal deposits with the pathological hallmarks of drusen (including 
complement and IgG deposition) together with thickening and disruption of 
Bruch’s membrane and, in mice older than 18 months, spontaneous CNV135. A 
number of these assertions have since failed the test of replication - in particular 
it has not been possible to detect CNV in subsequent investigations of the 
model. Interestingly, however, it has recently been established that the 
lipofuscin-containing deposits claimed as drusen are in fact bloated lipofuscin-
laden macrophages (positive for CD68 and F4/80 markers on immunostaining) 
akin to those seen in aged wild-types. In fact the principle difference between 
senescent wild-type and CCL2-/- mice is that the accumulation of macrophages 
subretinally is accelerated in the knockout model and the cells have a more 
swollen appearance. It has also been observed that up to 50% of macrophages 
in wild-types and CCL2-/- mice contain pigment suggestive of phagocytosed 
RPE cell debris. Other age-related changes such as thickening of Bruch’s 
membrane and RPE damage appear to be unaffected by CCL2 deficiency120. 
Whilst it is most likely that the accelerated accumulation of subretinal 
macrophages in these models is the result of their dysregulated trafficking and 
recruitment, the possibility that their behaviour is part of a compensatory 
mechanism for another disrupted pathway (for example impaired RPE cell 
phagocytosis) cannot be discounted. 
 
CCR2 has been demonstrated to have an important role in facilitating the 
release of Ly6CHi monocytes from the bone marrow and their absence from the 
circulation (rather than a failure to traffic to sites of inflammation) has been 
postulated as the reason for the attenuated inflammation observed in a number 
of disease models employing the CCR2-/- mouse136. 
 
Evidence therefore suggests a role for CCL2 in innate immune cell trafficking at 
the site of the RPE-choroid complex with deficiencies resulting in accelerated 
microglial dystrophic changes possibly in response to debris originating from the 
RPE. The exact nature of the affected microglia and why they appear to fail to 
process debris correctly (instead remaining static and lipofuscin-filled in the 
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subretinal space) is not known, but work on the recruitment of bone marrow 
derived cells to the brain using GFP-transgenic bone marrow chimeric mice 
suggests that Ly6CHi CCR2+ monocytes are the principle cells involved in 
microglial turnover in the CNS – a process that appears to be at least partly 
dependent on CCR2 and CCL2, with double deletion of both receptor and 
ligand resulting in significant deficiencies of monocytic populations and bone 
marrow-derived parenchymal and perivascular microglia under physiological 
conditions137, 138. Manipulation of these populations may prove beneficial in 
delivering new therapies for AMD. 
 
 
1.7.2.2 The effects of CX3CR1 deletion 
 
As with CCL2-/- and CCR2-/- mice, deletion of CX3CR1 also results in the 
accelerated accumulation of bloated subretinal microglia with age (Error! 
Reference source not found.). CX3CR1 is expressed on a variety of innate 
immune cells, including NK cells, T cells and monocyte subpopulations. Its 
ligand, CX3CL1 (also known as fractalkine) exists in membrane-bound and 
soluble forms and, as well as being involved chemokine signalling, is a potent 
mediator of cell adhesion. CX3CL1 is abdundantly expressed in the CNS, the 
retina (particularly by Muller cells) and the choroid139. CX3CL1 deficiency 
attenuates the accumulation of foam cells in the vessel walls of CCR2-/- mice, 
an effect thought to result from a failure to facilitate monocyte arrest140.  
 
Microglia in the normal retina have been identified as the sole cell type to 
express CX3CR1. Combadiere et al. identified that CX3CR1GFP/GFP mice 
accumulated significant numbers subretinal microglia at 6 months compared to 
age-matched CX3CR1GFP/+ mice - a difference seen to increase with age. 
CX3CR1-/- mice also exhibited a substantial degeneration of the outer retina at 
18 months of age. In CX3CR1-/- mice the drusen-like phenotype seen on 
fundoscopy has been confirmed as being the result of CD11b+ microglia 
accumulating lipid droplets derived from partially digested photoreceptor outer 
segments. It has been suggested that such cells may form the origin of drusen 
since drusen contain deposits positive for CX3XCR1 as well as other debris 
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remarkably similar in composition to that found in degenerating microglia. It has 
also been suggested that the apparent migration of bloated microglia from the 
subretinal space to the sub-RPE space where drusen appear to develop may 
actually be the result of RPE cells mobilising to cover microglia. 
 
Combadiere et al. undertook in vitro assays demonstrating the increased 
adhesion of monocytes expressing the M280 variant of the CX3CR1 receptor 
initially thought to account for a percentage of AMD cases (this has been found 
not to be the case with a subsequent study)65, 141. It was hypothesised that the 
accumulation of subretinal microglia was a result of increased adhesion of these 
cells in the subretinal space65. Given that CX3CR1 is also expressed on a 
variety of other innate immune cells and that genes involved in the signalling of, 
for example, NK cells are upregulated in the RPE-choroid with age, the 
possibility that subretinal microglial accumulation in CX3CR1-/- mice is a by-
product of a failure to recruit other types of innate immune cell to the RPE-
choroid cannot be excluded. For example, CX3CL1 has been implicated in the 
recruitment of CX3CR1+ NK cells in a model of experimental autoimmune 
encephalitis (EAE) and a failure to recruit these cells in CX3CR1-deficient mice 
results in increased EAE-related morbity and mortality142. 
 
Despite the apparent effects of CX3CR1 deficiency on the rate of subretinal 
microglia accumulation, a separate study of CX3CR1gfp/+ and CX3CR1gfp/gfp 
mice suggested that this receptor is not essential for the normal turnover of 
resident macrophage and DC populations in retinal and choroidal tissue, 
indicating that CX3CR1 mediates recruitment of circulating cells that may have 
a role in clearing subretinal debris103. 
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Figure 11. Ccl2-knockout (Ccl2
–/–
) mice do not develop abnormal RPE changes with age, 
but show an accumulation of bloated macrophages in the subretinal space.  
Toluidine blue-borax–stained semithin histologic sections of the outer retina, RPE, and choroid 
from young (2–3 months) and old (20–24 months) Ccl2
–/–
 and C57Bl/6 wild-type mice (A–E). No 
obvious histologic differences between young C57Bl/6 wild-type (A) and Ccl2
–/–
 (B) mice were 
observed. In old C57Bl/6 (C, D) and in old Ccl2
–/–
 (E) mice, photoreceptor morphology was also 
normal, but macrophage-like cells were observed in the subretinal space. These cells were 
swollen in Ccl2
–/–
 mice (C, D versus E, white arrows). Swelling/lysis of RPE cells and pyknosis 
(indicated by the darker staining) of RPE cells were observed in senescent animals of both 
genotypes, but are only shown as examples in C57Bl/6 wild-type mice (D, arrowheads). Note 
the higher pigmentation of the choroid in old C57Bl/6 and Ccl2
–/–
 mice compared with young 
mice (C, D, E versus A, B). Scale bar, 100 µm. Quantitative analysis of the number of 
macrophage-like cells in the subretinal space (F). The mean number of macrophages per 
individual animal is depicted [C57Bl/6, ( ); Ccl2
–/–
 mice ( )] and shows a significant positive 
correlation between age and number of macrophages in the subretinal space per section, which 
was much more pronounced in Ccl2
–/–
 mice. (G) Quantitative analysis of alterations in the RPE. 
The RPE damage count (Ccl2
–/–
, solid line; C57Bl/6, dashed line), revealing a similar 
accumulation of RPE alterations with age in both genotypes and an overall positive correlation 
of this accumulation with age (Pearson correlation r = 0.585, P = 0.001, n = 27).From Luhmann 
et al. 2009. 
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1.7.2.3 The effects of CX3CR1 and CCL2 double-deletion 
 
The identification of AMD-like features in CCL2-/- mice and the description of 
loss-of-function single-nucleotide polymorphisms in CX3CR1 associated with 
AMD have prompted exploration of the phenotype resulting from combined 
deficiency of both CCL2 and CX3CR1143. 
 
In comparison with CCL2-/- and CX3CR1-/- mice, double-knockout CCL2-/- 
CX3CR1-/- mice exhibit a focal, early onset, progressive retinal degeneration 
characterised by the development of lesions in the ONL as early as 1-4 months 
of age – a phenotype associated with the appearance of subretinal 
macrophages. Subsequent changes have been noted to include loss of all 
retinal layers, RPE damage (including accumulation of lipofuscin), increased 
RPE-retinal adhesion and vascular inflammation. The features of vascular 
inflammation and increased leakage in this model are supportive of a role for 
microglia/macrophages in maintaining a healthy vasculature in the eye143, 144. 
 
Double knockout of CX3CR1 and CCL2 would therefore appear to have an 
even greater effect on the rate of subretinal macrophage accumulation and 
associated damage in mice compared to single knockout of these genes. 
However, recent evidence has emerged to indicate that many of these double 
knockout animals have a third autosomal recessive gene – the Crb1 gene – that 
is responsible for a well-characterised model of retinal degeneration. 
Consequently, it has been concluded that the phenotype of double knockout 
CX3CR1/CCL2 mice described previously is in fact one of an inherited retinal 
degeneration - with vascular changes more in keeping with retinal telangiectasia 
then CNV - that is differentially modulated by CCL2-CCR2 and CX3CL1-
CX3CR1 signalling (Luhmann et al.; in press). 
 
1.7.2.4 The effects of light exposure on the migration of retinal 
microglia 
 
 
Whilst light exposure is not a risk factor for AMD, ambient light exposure has 
nevertheless been demonstrated to influence the pattern of distribution of 
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microglia in mice. For example albino mice raised in a darkened environment 
retain microglia in the inner retinal layers but after exposure to light for as little 
as a week large numbers of cells positive for the microglial marker 5D4 may be 
seen to accumulate subretinally. Evidence suggests that the subretinal 
microglia originate from the inner retinal layers and that they assist RPE cells in 
the phagocytosis of photoreceptor-derived material - production of which is 
accelerated as a consequence of phototoxicity. Pigmentation appears protective 
for the effects of light exposure but differences in the levels of induced-migration 
between strains suggest other factors may also influence the process145. The 
effects of light exposure in the context of chemokine deficiency have yet to be 
fully explored, however it has been demonstrated that albino CX3CR1-/- mice 
accumulate subretinal microglia at an accelerated rate compared to albino wild-
type mice and this suggests a role for CX3CR1 signalling in the maintenance of 
a healthy retina and RPE-choroid. 
1.7.3 Laser-induced choroidal neovascularisation 
 
1.7.3.1 Background to laser-induction of CNV 
 
Whilst not the only method of inducing CNV in animal models (others, including 
the use of Matrigel containing pro-angiogenic growth factors, have been 
described146), the use of a laser to rupture Bruch’s membrane is perhaps the 
best characterised. Laser injury produces a wound composed of several 
concentric circular areas: a central area where the most energy is delivered and 
all cells are destroyed, a rim surrounding the centre that corresponds to an area 
where energy dissipates producing substantial cellular damage and an outer 
area where cell disruption is minimal and the healing process begins. Early 
morphological changes become visible at 3 days post- induction and precede 
neovascularisation which develops in the first week before becoming maximal 
at 2 weeks (persisting for several weeks thereafter).  
 
First described in 1979, the laser-induced CNV model has a number of 
advantages in the study of wet AMD: principally the shared pathophysiological 
characteristics between disease and model. These features include the rapid 
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migration of choroidal endothelial cells and subsequent formation of fenestrated 
new vessels through defects in Bruch’s membrane; the accumulation of 
subretinal fluid; the accumulation of leukocytes adjacent to developing new 
vessels; and fibrovascular scarring. The angiographic appearances of leakage 
following laser-induced CNV are also similar to those seen in the classic CNV of 
AMD. There is also a shared pattern of cytokine and growth factor expression - 
the presence of VEGF in RPE and leukocytes; VEGF receptors in RPE and 
endothelial cells; basic fibroblast growth factor in RPE cells, choriocapillaris and 
macrophages; TGF-β in RPE, choriocapillaris endothelium and fibroblasts; TNF-
α expression in leukocytes; and the involvement of Fas and Fas-ligand 
interactions having been demonstrated in both laser-induced and wet AMD 
lesions147. 
 
Other advantages of this model include its suitability for use in mouse models, 
thereby permitting the study of genetic defects on pathological 
neovascularisation with relative ease, and its proven use in pre-clinical studies 
designed to test the effects of pharmaceutical compounds and novel therapeutic 
modalities in the treatment of CNV148. Individual lesions following laser delivery 
 often vary in size, however, and this necessitates multiple areas of CNV-
induction per fundus and occasionally many animals to demonstrate significant 
effects. 
 
Laser induction of CNV departs from the natural course of CNV observed in 
AMD by its lack of chronicity. Whereas laser-induced CNV lesions involute 
spontaneously at 30 days (at least in young mice) lesions in subjects with AMD 
often persist for many years, requiring the administration of many treatments to 
control23, 149. In some ways the behaviour of laser-induced CNV is more akin to 
that of myopic CNV in young patients, which also tends to involute 
spontaneously, with much less in the way of functional consequences (although 
interestingly myopic CNV lesions are larger in older subjects)150. 
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1.7.3.2 The complement system and CNV 
 
Whilst several genes encoding complement pathway proteins have been 
implicated in the pathogenesis of AMD, evidence for the role of the complement 
system in the development of CNV is more circumstantial. The complement 
fragment C3 and C3a have been identified in surgically excised CNV lesions 
and elimination of C3 results in attenuation of laser-induced CNV. Similarly 
inhibition of the terminal complement complex C5b-9 using antibodies to C6 
results in the inhibition of CNV formation in mouse models. It is thought that 
fragments C3a and C5a may contribute to the neovascular response by 
stimulating the recruitment of monocytes to the choroid151.  
 
The complement fragment C5 has been found to accumulate in the RPE and 
choroid of CCL2-/- mice leading to the suggestion that a failure to recruit 
monocytes results in the accumulation of immune complexes and the chronic 
inflammation that drives AMD. C5a has also been linked to increased VEGF 
production and the propagation of laser-induced CNV. Whilst it has not been 
possible to demonstrate a clear association between genetic variants of C5 and 
AMD this complement fragment has nevertheless become a focus for 
pharmalological intervention and a number of C5-targetted pharmaceutical 
agents are currently being investigated in clinical trials for AMD151. 
 
1.7.3.3 Innate immune cell responses in laser-induced CNV 
 
Evidence from multiple sources has confirmed a role for macrophages in the 
development of laser-induced CNV: CCR2-/- mice have been found to have 
attenuated CNV following laser-induction as have mice depleted of both 
circulating and choroidal macrophage populations by clodronate liposomes152. 
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Early work examining the kinetics of inflammatory cell recruitment suggested 
that recruitment of neutrophils and macrophages peaks at 48 hours post-laser-
induction, with neutrophils the predominant cell type153. Attempts to attenuate 
macrophage, T cell, NK cell and neutrophil responses - all cell types purported 
to be involved in tumour angiogenesis - using antibodies to markers specific for 
these populations revealed a significant reduction in the neovascular response 
only upon targeting macrophages (antibodies were delivered intraperitoneally in 
the week preceding angiography performed 7 days post-induction of CNV).  
Use of chimeric GFP+ bone marrow transplanted mice has also demonstrated 
that cells recruited from the circulation account for as much as 45% of the total 
F4/80+ cells associated with CNV at 3 days post-laser (a figure that rises to 70% 
at 2 weeks when lesion size is maximal). Further evidence for the role of 
recruited monocytes is provided by the concurrent upregulation of adhesion 
molecules in CNV such as Vascular Cell Adhesion Molecule (VCAM) that also 
coincides with increased size of the lesion (Error! Reference source not 
found.). That recruited monocytes should appear to have a role in laser-
induced CNV is significant given their pro-inflammatory potential exceeds that of 
the microglial population and their close association with activated Muller cells 
(a population which in the quiescent state releases neurotrophic factors 
essential for retinal homeostasis)154. The appearance of monocytes in CNV 
lesions at 3 days post- laser coincides with the proliferation of RPE and 
endothelial cells in this model - at day 4 post-laser isolectin-positive cells 
forming vascular tubes may be visualised and the size of the lesion then 
increases exponentially in the 3 days that follow155.  
 
The role of monocyte subsets in CNV has yet to be fully explored. Work on the 
CCR2-/- mouse confirmed only that recruitment of F4/80+ cells was reduced in 
association with a reduction in lesion size with subsequent experiments 
demonstrating a role for neutrophils in laser-induced CNV153, 156. Conversely, 
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CX3CR1GFP/GFP mice, deficient in CX3CR1, exhibit an enhanced responsed to 
laser-induction of CNV (double that of controls) with many more cells seen to 
accumulate at the site of injury compared to CX3CR1GFP/- mice at 7 days post-
injury. The latter study involved use of 12 month old animals that have already 
accumulated significant numbers of subretinal microglia – it is unclear to what 
extent this may have contributed to the increased levels of neovascularisation 
or whether the effect is mediated by a failure to recruit specific monocyte 
subsets from the blood (particularly as both CCR2+ and CCR2- subsets may be 
affected by CX3CR1 knockout). Nevertheless, as part of the work it was 
demonstrated that VEGF was produced by F4/80+ subretinal microglia following 
laser-induction of CNV65. 
 
A considerable amount of research has focused on the role of monocyte 
subsets in tumour angiogenesis (innate immune cells in general, from 
neutrophils to mast cells, are thought to make a significant contribution to 
tumour angiogenesis). In particular, parallels have been drawn between the 
activities of so-called TEMs (Tie-2-expressing monocytes) and CCR2- Gr-1- 
monocytes; and TAMs (tumour-associated macrophages) and CCR2+ Gr-1+ 
monocytes. Tie-2 is a receptor for angiogenic growth factors known as 
angiopoietins. Both subsets share gene expression profiles, with TEMs 
appearing to have enhanced proangiogenic and tissue remodelling activity and 
lower proinflammatory activity - much like the CCR2- Gr-1- monocyte subset 
that is thought to promote angiogenesis in the post-ischaemic myocardium. 
Consequently, TEMs have become novel targets for anti-cancer therapy. 
Tumours grown in CCR2-/- mice recruit few TAMs and it has been suggested 
this population is derived from the ‘inflammatory’ monocyte subset157-159. 
 
The roles of CCR2+ Gr-1+ and CCR2- Gr-1- monocytes have also been explored 
using models of alkali-induced corneal angiogensis. Lu et al. found that, in 
keeping with the results of laser-induced CNV experiments, CCR2-/- mice exhibit 
a reduced corneal neovascular response whereas CX3CR1-/- mice exhibit an 
increased corneal neovascular reponse. Reduced levels of infiltrating F4/80+ 
cells, but not neutrophils, were noted in CX3CR1-/- animals. Selective depletion 
of macrophages results in reduced corneal infiltration by macrophages but no 
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change in the neovascular response compared with controls. CX3CR1+ cells 
were found to express the antiangiogenic molecules ADAMTS-1 and 
thrombospondin-1, and topical application of CX3CL1 was found to inhibit 
neovascularisation in this model. The role of CX3CL1 in mediating ocular 
angiogenesis remains unclear, however, since the results of other groups have 
suggested a role for this chemokine in the promotion of ocular angiogenesis in 
other models of corneal neovascularisation, the OIR model and in vitro assays. 
 
The use of CXC3CR1GFP/+ mice has yielded data that largely concerns the 
behaviour of the resident microglial population following laser-induction of CNV 
in mice. Eter et al. subjected CXC3CR1GFP/+ mice to laser-induction of CNV 
(Error! Reference source not found.) and, using flow cytometric techniques, 
established the accumulation of macrophages and DCs in both retina and 
choroid 2 days after injury, with evidence of further increases in the numbers of 
microglia in the retina at subsequent timepoints up to 35 days post-laser (in 
contrast Combadiere et al. found numbers of F4/80+ GFP+ cells peaked at 7 
days in CX3CR1GFP/+ mice before a decline was noted at 14 days). Eter et al. 
also found that numbers of innate immune cells remain increased in the choroid 
up to 35 days post-injury. Attempts to distinguish between CX3CR1High and 
CX3CR1Low monocytes did not feature in the study however and the possibility 
that the CX3CR1GFP/+ genotype interferes with CX3CR1-mediated cell 
recruitment cannot be excluded. Findings were in keeping with other work 
suggesting that DCs may have a role in pathological neovascularisation in the 
eye – Nakai et al. having already established that immature DCs (CD11c+ MHC 
class IILow cells) expressing VEGFR2 peak between 2 and 4 days post-induction 
of CNV by laser, appear closely involved with the developing neovascular 
complex and when transplanted intravenously are capable of augmenting CNV 
growth160. Other studies have also confirmed a role for immature DCs in the 
angiogenesis associated with tumour growth161. 
 
In contrast to findings that a failure of macrophage recruitment results in 
reduced choroidal neovascularisation, Apte et al. identified that the increased 
recruitment of CD11b+ F4/80+ cells to CNV lesions was associated with a 
reduction in lesion size at 1 week post-laser-induction in Il-10-/- mice and that 
Chapter 1  Introduction 
87 
 
intravitreal injection of CD11b+ cells (obtained from bone marrow cultures) at 
the time of CNV induction also resulted in an attenuated response. Restoration 
of Il-10 to the eye resulted in a comparative increase in lesion size and overall 
their results indicated a role for both Il-10 (driving pro-angiogenic pathways) and 
macrophages (exerting anti-angiogenic effects - possibly via Fas and FasL 
interactions) in modifying the neovascular reponse96. 
 
Finally, age has been found to be an independent risk factor for severity of 
laser-induced choroidal neovascularisation. Lesions in 16 month old wild-type 
mice are significantly larger than those in 2 month old mice (being thicker and 
more cellular) though no significant difference has been established in terms of 
the amount of leakage from induced-CNV between young and old animals. No 
mechanism for the increased severity of CNV in older animals has been 
established though age-related systemic changes resulting in altered vascular 
biology have been proposed as a cause independent of local changes in the 
retina and RPE-choroid162. 
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1.8 Aims of the thesis 
 
Age-related macular degeneration is a complex disease, for which ageing is the 
main pathogenic driver. The clinical endpoints in AMD are tissue loss in the 
majority of cases (particularly in geographic atrophy) and choroidal 
neovacularisation, resulting in scarring, in the remainder. The identification of 
age-related macular degeneration as a chronic inflammatory disease in which 
dysregulation and dysfunction of the immune system (the complement system 
in particular) features prominently was a major milestone31. However, there 
remain several unresolved questions regarded as being of critical importance to 
our understanding of the pathogenesis of this blinding disease: 
 
● What cellular events lead to complement activation at the RPE–choroid 
interface? It is not known whether complement activation occurs at a systemic, 
or local level. 
● What are the respective roles of acute phase proteins and pro-inflammatory 
cytokines in RPE-choroidal pathology, and when do they come into play? 
● What is the temporal relationship between local inflammation, complement 
activation, dendritic cell involvement, and drusen biogenesis at the RPE–
choroid interface? 
● Does the presence of HLA-DR in drusen, and the invasion of drusen by 
dendritic cells, signify an ongoing process of antigen presentation to the 
immune system? If so, what are the antigens involved? 
The interplay between innate immune cell populations as tissues age and the 
reasons for a divergence into the two phenotypes described above have yet to 
be fully determined. This thesis focuses on questions surrounding the role of 
innate immune cells in AMD pathology. The aims of this thesis are therefore: 
 
1) To define the innate immune cell populations in the retina and RPE-
choroids of young adult wild-type mice. 
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2) To determine the effects of ageing on innate immune populations in wild-
type mice and the effects of a deficiency in CCL2 (a chemokine central to 
innate immune cell recruitment and expressed at higher levels in aged 
tissues). 
3) To determine the effects of ageing and CCL2-deficiency on lesion size 
using experimental models of CNV. 
4) To determine the key innate immune cell populations involved in the the 
development of CNV. 
5)  To determine whether any changes in innate immune cell populations in 
the retina, RPE-choroid and periphery correlate with the observed effects 
of ageing on CNV lesion size. 
6) To explore the effects of experimental therapeutics, both intended and 
unintended, on innate immune cell populations in the context of choroidal 
neovascuarisation. Does targeting members of the receptor tyrosine 
kinase family, such as VEGF receptors and PDGF receptors, in the 
treatment of CNV affect innate immune cell populations that also express 
these receptors? Does targeting the activation pathways of innate 
immune cells confer benefit in the context of CNV and what is the effect 
on cells’ phenotypes? 
 
This is a broad set of aims that reflects the cellular complexity of AMD and 
makes best use of the models currently available.  The approach encompasses 
an analysis of the innate immune cell populations present in young, healthy 
tissue and how these change with normal ageing before examining the effects 
of chemokine deficiency and CNV induction. Finally, the effects of compounds 
targeting angiogenic pathways and innate immune cell activation in the context 
of experimental CNV are determined. The identification of any positive and 
negative effects of these approaches on innate immune cell populations may 
help in informing future therapeutic strategies. This thesis does not address the 
role of complement or the role of cytokines in the pathogenesis of AMD but 
does aim to contribute to understanding of the cells involved. Further work may 
seek to determine how complement and cytokines interact with innate immune 
cells to engender disease. 
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Materials and Methods 
 
2.1 Reagents 
 
Laboratory supplies and powdered reagents were sourced from established 
suppliers. 
2.2 In vivo experiments 
 
2.2.1 Animals 
 
CCL2-knockout (CCL2−/−) mice on a C57Bl/6 background were kept as a 
homozygous line (a kind gift from Kath Else at the University of Manchester 
from the original stock maintained by Barrett Rollins) 163. Age-matched control 
animals (C57Bl/6 6JOla Hsd; Harlan UK Ltd., Blackthorn, UK) were kept in the 
same animal room. The animal experiments were performed in accordance with 
the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research 
and under the UK Home Office project licence (PPL 70/2045). 
2.2.2 Anaesthesia 
 
For in vivo procedures, the mice were anesthetized by a single intraperitoneal 
(IP) injection of a mixture of medetomidine hydrochloride (1 mg/ kg body weight; 
Domitor; Pfizer Animal Health, New York, NY), and ketamine (60 mg/kg body 
weight) in water for injection. Whenever necessary, the pupils were dilated with 
1 drop of 1% tropicamide (Bausch and Lomb, UK). The animal experiments 
were performed in accordance with the ARVO Statement for the Use of Animals 
in Ophthalmic and Vision Research. 
 
2.2.3 Laser induction of choroidal neovascularisation 
 
A slit-lamp-mounted diode laser system (wavelength 680 nm; Keeler, UK) was 
used to injure Bruch’s membrane in each eye (laser settings: 210 mW power, 
100 ms duration, 100 μm spot diameter). These settings consistently generate a 
subretinal gas bubble which strongly correlates with adequate laser-induced 
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rupture of Bruch's membrane and successful induction of CNV. Only eyes in 
which laser-induced subretinal vapourisation bubble formation occurred were 
included in the analysis. Eyes were also excluded if there was significant 
cataract or keratopathy formation which could affect laser energy delivery or 
angiography. For subsequent assessment of CNV lesion size energy was 
targeted at 3 areas approximately 3-4 disc diameters from the optic nerve head 
at the 10 o’clock, 2 o’clock and 6 o’clock positions and avoiding any vessels. 
For subsequent flow cytometric analysis, lesions were induced in 10 locations 
equally spaced throughout the fundus. 
 
2.2.4 Image quantification of choroidal neovascularisation 
 
In vivo FFA was performed at 1 and 2 weeks after induction of CNV by diode 
laser. Images from the early (90 seconds after fluorescein injection) and late (7 
minutes) phases were obtained using a small animal fundus camera with 
appropriate filters (Kowa Genesis, Tokyo, Japan). The pixel area of CNV-
associated hyperfluorescence was quantified for each lesion using image-
analysis software (Image Pro Plus; Media Cybernetics, Silver Spring, MD). 
Where comparison of two eyes in the same animal was required the sequence 
of imaging from right to left was alternated to avoid any bias. 
 
2.3 Intraocular delivery of bioactive compounds 
 
Surgery was performed under direct retinoscopy through an operating 
microscope. Pupils were dilated with topically administered 1% Tropicamide 
(Bausch and Lomb, UK). The eye was gently prolapsed by exerting pressure 
adjacent to the globe. A fundal view was obtained by applying a coupling 
solution (Viscotears, Novartis Pharmaceuticals, UK) and glass cover slip. 
Counter-traction was applied to the globe using toothed forceps to grasp the 
conjunctiva and rectus muscle of the eye. The tip of a 1.5cm, 34G hypodermic 
needle mounted on a 5μl Hamilton syringe (Hamilton, Switzerland) was then 
passed into the posterior vitreous via a sclerotomy made just posterior to the 
limbus and 5ul of either CD200R agonist antibody or isotype control antibody 
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(courtesy of Andrew Dick/DNAX Schering Plough Inc.) slowly injected. The 
cornea was allowed to clear completely before withdrawal of the needle so as to 
minimise reflux. 
2.4 Oral delivery of bioactive compounds 
 
0.2mls of suspension containing pazopanib or vehicle (GSK, UK) was delivered 
by oral gavage using a 22G curved, ball-tipped needle (Braintree Scientific). 
2.5 Blood collection and plasma preparation 
 
Mice were culled by exposure to CO2 and bled immediately by cardiac puncture 
(27G needle on a 1μl syringe). Blood was transferred to EDTA vacutainers (BD, 
Europe) and kept on ice. Samples were centrifuged at 2000RPM for separation 
of plasma and the resulting supernatant transferred to polypropylene tubes and 
stored at -20oC prior to shipping on dry ice for pharmacokinetic analysis. 
Plasma samples were analysed for pazopanib by an analytical method based 
on protein precipitation followed by analysis with high-performance liquid 
chromatography and two stages of mass spectrometry (GSK, UK). 
 
2.6 Flow cytometry 
 
2.6.1 Basis of surface marker selection 
 
Surface markers were selected with the aim of defining monocyte/macrophage 
subsets in the eye and periphery and establishing the role of dendritic cells in 
the ageing process as well as the key cell populations involved in the response 
to laser-induced choroidal neovascularisation, including granulocytes. The 
markers CD11b, F4/80, Gr-1, Ly6C and CD11c were selected for the panel. The 
inclusion of other markers (such as those for NK cells) was limited by the 
availability of suitable fluorophores for conjugation at the time of experimental 
design – analysis of over 16 channels is theoretically possible using the BD 
LSRII flow cytometer and the appropriate fluorophores, however the repertoire 
of quantum dot-conjugated antibodies is restrictive and the use of standard 
fluorophores increases the risk of spectral overlap during analyses. 
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Consideration also had to be given to the likelihood of identifying rarer cell 
populations in retina and RPE-choroid using additional markers when the cell 
yield would in any case be much lower than in the spleen, bone marrow or 
blood. Where possible conjugated antibodies were employed so that handling of 
suspensions and loss of cells was minimised. 
 
2.6.2 Fluorochrome-conjugated antibodies and flow cytometer 
configuration 
 
Monoclonal antibodies directly-conjugated to fluorochromes were selected to 
minimise the risk of non-specific binding and to improve experimental efficiency. 
The PE fluorochrome was reserved for F4/80 staining as F4/80 antigen was 
known to be weakly expressed in the retina and PE has a high quantum yield. 
Cells suspensions were incubated with rat anti-mouse CD16/32 Fc block 
(2.4G2; BD Biosciences) prior to immunostaining to minimise non-specific 
binding of antibodies to innate immune cell Fc receptors. The following 
antibodies were used for staining (Table 3; rat anti-mouse unless stated 
otherwise):  anti CD11b PerCP 5.5 (M1/70; eBioscience), hamster anti CD11c 
PE-Cy7 (N418; eBioscience), anti Ly6G AlexaFluor 488 (RB6 8C5; 
eBioscience), anti F4/80 PE (CI: A3-1; Serotec), anti Ly6C AlexaFluor 647 (ER-
MP20; Serotec). 
 
Three lasers on the BD LSR II were employed to excite the above 
fluorochromes: the 488nm laser was used to excite all except DAPI (355nm 
laser) and AlexaFluor 647 (633nm laser). Filters were configured in such a way 
as to minimise spectral overlap. The BD LSR II cytometer octagon and trigon 
arrays use dichroic long-pass mirrors on their inner rings and band-pass filters 
on their outer rings - these were configured to minimise spectral overlap when 
using the above antibody panel (Figure 12). The band pass filter performance 
with this arrangement was estimated using the BD Multicolour Spectrum Viewer 
(http://www.bdbiosciences.com/research/multicolor/spectrum_viewer/index.jsp). 
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Long pass filtre (LP)Band pass filtre (BP)
PerCP – Cy5.5
PE
SSC
PE Cy7
Alexa Fluor 488
BLUE LASER (488nm)
a
b
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Figure 12 Configuration of BD LSR II flow cytometer 
Optical filters attenuate light or help direct it to the appropriate detector. Dichroic filters transmit 
light of a specific wavelength while reflecting other wavelengths. Long pass filters transmit 
wavelengths that are longer than the specified value and band pass filters pass a narrow 
spectral band of light (a). Filters were configured in such a way as to minimise spectral overlap - 
BD LSR II cytometer octagon and trigon arrays use dichroic longpass mirrors on their inner 
rings (blue) and band pass filters on their outer rings (green); the arrangement for each laser 
used in this work is shown above (b). 
 
 
 
 
Table 3 Primary conjugated monoclonal anti-mouse antibodies used in flow cytometry of 
splenocyte, choroidal and retinal cell suspensions 
Monoclonal antibodies directly-conjugated to fluorochromes were selected to minimise the risk 
of non-specific binding and to improve experimental efficiency. Cells suspensions were 
incubated with rat anti-mouse CD16/32 Fc block (2.4G2; BD Biosciences) prior to 
immunostaining to minimise non-specific binding of antibodies to innate immune cell Fc 
receptors.
DAPI
355 UV LASER (355nm) RED LASER (633nm)
Alexa Fluor 647
Epitope Fluorochrome Host Clone Source
CD11b PerCP Cy5.5 Rat M1/70 eBioscience
Gr-1 AlexaFluor 488 Rat RB6 8C5 eBioscience
CD11c PE Cy7 Hamster N418 eBioscience
F4/80 PE Rat CI: A3-1 Serotec
Ly6C AlexaFluor 647 Rat ER-MP20 Serotec
Chapter 2  Materials and Methods 
97 
 
 
a 355nm laser
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b 488nm laser
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c 633nm laser
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Figure 13 Filter performance estimates for selected fluorophores using the BD LSR II 
 
Estimations of filter performance (filters configured as described in Figure 12). Charts show summated emission signals (normalised to the degree of 
excitation at the indicated laser line wavelength) that fall within a filter specification by wavelength. Estimated filter performances when using 355nm 
laser (a); 488nm laser (b) and 633nm laser (c) are shown. For any given filter/fluorophore combination the efficiency for the primary detector filter 
(shown with light gray background within parentheses) is displayed along with spillage into other detectors. The spill estimate is expressed as a 
percentage of that measured in the primary detector (varies with primary filter).Band pass filters are rendered as rectangles. (Estimates obtained using 
BD Fluorescence Spectrum Viewer - http://www.bdbiosciences.com/research/multicolor/spectrum_viewer/index.jsp) 
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2.6.3 Tissue sample preparation 
 
Samples were kept on ice unless stated otherwise. 
 
2.6.3.1 Retinal/RPE-choroidal tissue 
 
Eyes were dissected microsurgically in 1ml ice-cold RPMI 1640 (Invitrogen) 
containing 5% FCS, 2.38g/L HEPES and 1.5g/L sodium hydrogen carbonate 
(Sigma). The lens was removed and discarded and the retina was removed by 
careful dissection including the ciliary marginal zone but not retinal pigment 
epithelium or choroid. Retina and RPE-choroid were then processed separately 
as follows. Tissue from each eye was diced into approximately 20 pieces with 
Westcott scissors, transferred to 14ml Falcon tubes (BD Falcon) in a total of 
5mls of buffer and centrifuged for 5 mins at 1200RPM. Buffer was decanted and 
tissue re-suspended in 50μl pre-warmed buffer containing 0.5mg collagenase D 
(Roche, Lewes, UK) and 750 U/ml DNase I (Sigma) for 15 min at 37 °C. The 
treated tissue was homogenised and washed through a 70 μm filter (BD 
Biosciences) to obtain a single cell suspension. Suspensions were centrifuged 
at 1200RPM and re-suspended in 100μl of ice-cold buffer. Suspensions were 
incubated with 1μl rat anti-mouse CD1b/CD32 Fc block for 5 mins (BD 
Biosciences) prior to immunostaining.  
 
2.6.3.2 Splenocytes 
 
Spleen was dissected from surrounding connective tissue and homogenised 
and washed with ice-cold RPMI 1640 (Invitrogen) (containing 5% FCS, 2.38g/L 
HEPES and 1.5g/L sodium hydrogen carbonate) through a 70 μm filter (BD 
Biosciences) to obtain a single cell suspension. Suspensions were centrifuged 
at 1200RPM for 5 mins and re-suspended in 1 ml of red blood cell lysing buffer 
Hybri-Max (Sigma Aldrich) for 5mins. Buffer was then added up to 50mls and 
suspensions centrifuged at 1200RPM for 5 mins. Supernatant was decanted 
and cells re-suspended in 50mls of buffer prior to centrifuging for a further 5 
mins at 1200RPM. Cells were re-suspended in 500μl buffer.  10μl of the cell 
suspension was mixed with an equal volume of trypan blue (Sigma Aldrich) and 
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cell counts performed using a haemocytometer (Marienfield, Germany) to obtain 
a suspension of approximately 1 x 106 cells/100μl. Suspensions were incubated 
with 1μl rat anti-mouse CD1b/CD32 Fc block for 5 mins (BD Biosciences) prior 
to immunostaining.  
 
2.6.4 Flow cytometry 
 
2.6.4.1 Compensations 
 
Optimisation of fluorescence compensation settings for multicolour flow 
cytometric analysis was performed using anti-rat and anti-hamster Ig κ negative 
control particles set (BDTM CompBeads; BD Biosciences) and further refined 
using splenocyte suspensions.  
 
BD CompBeads were vortexed thoroughly before use and separate sample 
tubes labelled for each fluorochrome-conjugated mouse Ig, κ antibody. 100μl 
buffer, RPMI 1640 (Invitrogen) containing 5% FCS, 2.38g/L HEPES and 1.5g/L 
sodium hydrogen carbonate, was added to each tube and 1 drop 
(approximately 60μl) of the BD CompBead negative control and 1 drop of the 
CompBead anti-rat/hamster Ig, κ beads added to each tube. Tubes were 
vortexed and 1μl of the fluorochrome-conjugated antibody to be tested added to 
each (including one tube containing a mixture of all 5 antibodies). Samples were 
incubated for 60mins at room temperature and protected from direct light. 
Following incubation, 2mls of buffer were added to each tube and samples 
centrifuged at 1200RPM for 5 mins. Supernatant was discarded and each pellet 
resuspended in 0.5ml of buffer before vortexing. BD LSR II photomultiplier tube 
voltage settings were adjusted using BD CompBeads Negative Control and 
samples run through the BD LSR II flow cytometer at 200-300 events per 
second. Gating was performed on singlet bead populations based on FSC 
(forward-light scatter) and SSC (sidelight scatter) characteristics and median 
fluorescence intensities adjusted as appropriate to achieve suitable 
compensations. 
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Compensations were then optimised using splenocyte suspensions. Briefly, 
tubes for unstained cells and single-colour controls together with one mixture of 
all 5 antibodies were prepared as for beads (except antibody was added to a 
volume of 100μl cell suspension and samples were kept on ice). Samples were 
made up to 5mls with buffer after incubation for 60mins and centrifuged at 
1200RPM for 5mins before repeating. Cells were resuspended in 300μl buffer 
and run at a ‘Hi’ flow rate through the BD LSR II flow cytometer. Compensations 
values were then determined (Figure 23). 
 
2.6.4.2 Data acquisition and gating 
 
Multiparameter flow cytometry was carried out following Fc block and staining 
with the panel of fluorochrome-conjugated monoclonal antibodies as described 
above. Cell suspensions were incubated with fluorochrome-conjugated mAbs 
against cell surface markers (1μl antibody per 100μl of suspension) for 60 
minutes whilst avoiding direct light exposure. Cells were washed twice in RPMI 
1640 (containing 5% FCS, 2.38g/L HEPES and 1.5g/L sodium hydrogen 
carbonate) and resuspended in 300μl of buffer in Falcon FACS tubes (BD 
Biosciences). 10 μl DAPI was added to each cell suspension and samples 
analysed using the BD LSR II flow cytometer at a ‘Hi’ flow rate. Dead cells were 
excluded from the analysis by gating on the DAPI− cells. As a guide for applying 
gates to key innate immune cell populations, fluorescence-minus-one controls 
were performed on samples of the relevant tissues – that is, cell samples were 
incubated with all but one of each fluorochrome-conjugated antibody (Figure 15 
and Figure 26). All flow cytometric analyses were performed using FlowJo 
software (Tree Star). Flow-cytometrical classification of immune cells was done 
in accordance with established criteria73, 95, 164. 
 
2.7 Histological methods 
2.7.1 Cryo-sectioning 
 
Animals were sacrificed by exposure to carbon dioxide and perfused by cardiac 
intraventricular puncture with ice-cold PFA 4%. Eyes and spleens were then 
removed and immersed in ice-cold PFA 4% for 1 hour before being embedded 
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in Optimal Cutting Temperature compound (OCT; RA Lamb, East Sussex, UK). 
Embedded tissue was frozen in isopentane which had been pre-cooled in liquid 
nitrogen and stored at -20oC. Sagittal sections were cut at a thickness of 18μm 
onto poly-lysine coated slides using a a Bright cryostat and then stored at -
20oC. 
2.7.2 Immunohistology 
 
2.7.2.1 Immunostaining for mouse F4/80 
 
Sections were air dried for at least 1 hour before rehydration of the sections with 
PBS. For mouse F4/80 antigen immunohistochemistry, components of a 
catalysed signal amplification kit (CSA kit; K1500; Dako Ltd., UK) were used. 
Reagents were as supplied by Dako Ltd. unless specified otherwise. Sections 
were blocked with avidin blocking solution for 10 minutes followed by biotin 
block for 10 minutes before being washed in PBS-T (2 x 5 mins). Sections were 
then exposed to protein block for 10 minutes. Protein block was tapped off the 
slide and primary antibody (rat anti-mouse F4/80:Biotin; clone CI:A3-1; Serotec, 
UK) added at a dilution of 1/500 in antibody diluent and incubated at room 
temperature for 1 hour. Directly conjugated antibody against Ly6C (1/50; rat 
anti-mouse Ly6C AlexaFluor 647; clone ER-MP20; eBioscience, UK) or Gr-1 
(1/50; rat anti-mouse Gr-1 AlexaFluor 488; clone RB6 8C5; eBiosciences, UK) 
was included at this stage where staining for multiple antigens was undertaken. 
Samples were washed in PBS-T (2 x 10 mins) and streptavidin-biotin complex 
applied for 5 mins (prepared 15 minutes prior to use by adding 1 drop of 
reagent A and 1 drop of reagent B to  streptavidin buffer). Slides were then 
washed in PBS-T (4 x 10 mins) and amplification reagent added to sections for 
5 mins before washing again in PBS-T (4 x 10 mins). Slides were incubated 
with streptavidin-AlexaFluor 546 (1:250, S11225; Invitrogen-Molecular) before 
washing in PBS-T (4 x 10mins) and mounting in and mounted with fluorescence 
mounting medium containing Hoechst 33342 (Dako, Cambridgeshire, UK). 
Images were obtained with a laser scanning microscope (LSM 510; Carl Zeiss 
Microimaging, Jena, Germany). 
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2.7.2.2 Immunostaining for mouse Gr-1 and Ly6C 
 
Sections were air dried for at least 1 hour before rehydration of the sections with 
PBS-T. Non-specific binding sites on the sections were blocked for 1 hour with 
PBS/1%BSA (Sigma Aldrich, Steinheim, Germany)/5% non-specific goat serum 
(AbD Serotec, Kidlington, UK). Directly conjugated antibodies against Ly6C 
(1/50; rat anti-mouse Ly6C AlexaFluor 647; clone ER-MP20; eBioscience, UK) 
and Gr-1 (1/50; rat anti-mouse Gr-1 AlexaFluor 488; clone RB6 8C5; 
eBiosciences, UK) were diluted in blocking solution and added to sections for 1 
hour at room temperature before washing in PBS-T (4 x 10 mins). Slides were 
mounted in fluorescence mounting medium containing Hoechst 33342 (Dako, 
Cambridgeshire, UK). Images were obtained with a laser scanning microscope 
(LSM 510; Carl Zeiss Microimaging, Jena, Germany). 
 
2.7.2.3 Immunostaining for collagen IV 
 
Sections were air dried for at least 1 hour before rehydration of the sections with 
PBS-T. Non-specific binding sites on the sections were blocked for 1 hour with 
PBS/1%BSA (Sigma Aldrich, Steinheim, Germany)/5% non-specific goat serum 
(AbD Serotec, Kidlington, UK). Slides were incubated with rabbit anti-mouse 
collagen type IV antibody (1/300 in block; AbD Serotec; 2159-1470) for 1 hour 
at room temperature before washing in PBS-T (4 x 10mins). Slides were then 
incubated with goat anti-rabbit AlexaFluor 488-conjugated antibody (1/500 in 
block; AbD Serotec) for 4 hours at room temperature before washing in PBS-T 
(4 x 5 mins). Slides were mounted in fluorescence mounting medium containing 
Hoechst 33342 (Dako, Cambridgeshire, UK). Images were obtained with a laser 
scanning microscope (LSM 510; Carl Zeiss Microimaging, Jena, Germany). 
 
2.8 Buffers and solutions 
 
Distilled water (dH2O) was used to prepare all solutions. 
 
Phosphate Buffered Saline (PBS 1x) was prepared using tablets from Oxoid 
Ltd. (10 tablets per litre of dH2O) 
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2.9 Statistical analysis 
 
Power calculations for experiments conducted with the aim of determining CNV 
lesion size between genotypes/age-groups, were based on published data 
(approximately 12 animals per study group)148. N numbers were sometimes 
limited by the availability of mice for study (for aged study groups for example). 
For experiments designed to test the effects of pharmaceutical agents on lesion 
size, smaller N numbers were considered acceptable given that multiple 
dosages were often tested. 
 
The identification of populations derived from the retina and RPE-choroid is 
limited by the relatively small numbers of cells present in the eye87, 138, 165, 166. 
This has implications for interpreting flow cytometry data. The protocols and 
presentation of data in this thesis adhered, as far as possible, to the available 
guidelines167. Where a target population constitutes less than 5% of total 
events, as is the case with many innate immune cell subpopulations in the eye, 
these are referred to in the guidelines as ‘rare’ events. The analysis of rare 
events therefore required particular attention to the reliability and precision of 
data acquired from each sample. Use of the ‘coefficient of variance’ (CV) gives 
some indication of the total number of cells required for reliable identification of 
a change in a target population (CV = 100/r; where r = the number of positive 
events). For a CV of 5%, 400 positive events need to be acquired. Where a rare 
subset is present at a value of 5% of total events, a total of 8000 events should 
be collected for a CV of 5%; if present at 0.5% of total events then 80 000 cells 
should be collected to achieve an equivalent CV. The smallest population 
examined as part of this work was the Gr-1+ macrophage population in young 
wild-type retinae – this constituted 0.01% of total live cells and consequently to 
achieve a CV of 5% it would be necessary to collect a total of 400 positive cells 
ultimately derived from a total of 4 million live cells (depending on how the live 
cell subset is gated). The live cell yield from two pooled retinae using the 
published protocol employed in this study is generally no more than 2 million - 
this exposes the limitations of working with tissue where the viable cell yield is 
so small168. Establishing the viable cell population is essential since dead cells 
can bind or take up antibodies and fluorescent dyes non-specifically. 
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Consequently, it was necessary to accept a CV of 10% and increase n numbers 
to 10 or more to achieve significance in certain experiments. Analysis of 
continuous, non-parametric data between two groups was undertaken using a 
Student t-test. 
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Chapter 3: The effects of ageing on innate 
immune cell populations in mouse retina and 
choroid 
 
3.1 Introduction 
 
This chapter describes the changes in innate immune cell populations that 
occur with age in the retina, the RPE-choroid and systemically in both wild-type 
and CCL2-/- animals. Identification of the innate cell populations and pathways 
involved in normal and abnormal ageing in the eye is important because their 
manipulation may prove essential in furthering understanding of the pathology 
of AMD and aid in the development of better treatments for the disease. 
 
Ageing results in the accumulation of subretinal microglia in the retina and 
leukocytes in the choroid. The exact nature of these cells is unknown though 
evidence suggests that they originate from parenchymal microglia in the retina. 
Similarly, how these cells interact with the complement system to maintain 
homeostasis or drive pathology in the eye is also unknown. Ageing in the retina 
and RPE-choroid is associated with the upregulation of a number of cytokine 
and chemokine pathways yet, somewhat paradoxically, subretinal microglia 
have been demonstrated to accumulate more rapidly in mice deficient in both 
chemokines and their receptors (examples of these include CCL2-/-, CX3CR1-/- 
and CCL2-/- CX3CR1-/- double-knockout mice)120, 169. This suggests that the 
recruitment or trafficking of particular innate immune cell populations is 
important for the maintenance of retinal and RPE-choroidal homeostasis with 
ageing. The effect of chemokine deficiency on these populations in the context 
of ageing was examined using a CCL2-/- mouse model and compared with wild-
type animals. CCL2 is upregulated in the aged wild-type mouse RPE-choroid 
and it was hypothesised that a failure to recruit certain innate immune cell 
populations might underlie the accumulation of subretinal microglia in CCL2-/- 
mice124. 
Chapter 3  The effects of ageing 
109 
 
 
Multicolour flow cytometry was used to characterise cell populations in the 
retina and RPE-choroid. Cell numbers are relatively low in these tissues 
compared to brain or spleen and the inherent variability of immunohistochemical 
staining combined with high levels of autofluorescence would have necessitated 
the sacrifice of many more animals to achieve equivalent results. Multicolour 
flow cytometry has previously been employed to determine innate immune cell 
responses, particularly those involving monocyte subsets, in models of 
myocardial infarction and atherosclerosis (Table 4)95, 170. Patterns of surface 
marker expression were used to define key innate immune cell populations. 
Analyses were performed on live cells so that autofluorescent dead cells might 
be excluded.  
 
Two colour flow cytometry has previously been used in ophthalmic research to 
establish that infiltrating macrophages are critical for the development of laser-
induced choroidal neovascularisation in mice (macrophages being defined as 
CD45+ F4/80+ cells in this instance) 156. Using three colour flow cytometry it has 
been suggested that retinal microglia are CD45Low CD11b/c+ CD4Low and largely 
MHC class II- (except for a small ED2+ population) in rats171. More recently a 
five colour approach was used to confirm that CX4CR1GFP/+ retinal microglia are 
CD45+ CD11b+ F4/80+ CD11c- MHC class II-103 and other work has employed 
the technique to define the retinal cellular infiltrate in experimental autoimmune 
uveitis using markers including Gr-1 and Ly6C168. 
 
It was hypothesised that ageing and CCL2 deficiency would primarily result in 
altered numbers of specific innate immune cell populations either locally or in 
the periphery. The proportions of innate immune cells in the relevant tissues 
using specific cell surface markers was established using gating strategies 
successfully employed in the identification of monocytic populations in models 
of other diseases where macrophage accumulation and chronic inflammation is 
a feature95.  
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Innate immune 
cell population 
Markers expressed Comments/Reference 
Granulocytes CD11b
+
 Gr-1
Hi
 SCC
Hi 172
 
 CD11b
+
 Gr-1
+
 F4/80
VAR 
In a mouse model of 
intraperitoneal foreign body 
inflammation
173
 
 CD11b
+
 Ly6C
+
 F4/80
-
 
173
 
Macrophages CD11b
+
 F4/80
+
 Ly6C
-
 
173
 
 CD11b
Hi
 F4/80
Hi
 CD11c
Lo
 SCC
Med 172
 
 CD11c
+
 F4/80
+
 
174
 
 CD11c
Hi
 F4/80
Hi
 I-Ab
Hi 175
 
Conventional DCs CD11c
+
 MHCII
+
 
160
 
 CD11c
Hi
 F4/80
Hi
 I-Ab
Hi
 
175
 
Plasmacytoid DCs CD11c
+
 MHCII
+
 Ly6C
+
 
164
 
Myeloid-derived 
suppressor cells 
CD11b
+
 Gr-1
+
 (F4/80
VAR
 Ly6C
VAR
) Mixture of immature monocytes 
and granulocytes but also 
including mature neutrophils and 
inflammatory monocytes)
173, 176, 177
 
Monocytes  CD11b
+
 F4/80
INT 178
 
 CD11b
Hi
 SCC
Lo
 Gr-1
-
 
172
 
Monocytes  CCR2
+
; 
classical 
‘inflammatory’ 
CD11b
+
 F4/80
INT
 CD11c
-
 Ly6C
+ 178
 
 CD11b
+
 F4/80
+
 Gr-1
+
 Ly6C
+ 90
 
 CD11b
Hi
 Gr-1
Lo
 Ly6C
Hi 175
 
 CD11b
+
 Gr-1
-
 Ly6C
Hi 179
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Monocytes  CCR2
-
; 
non-classical 
‘resident’ 
CD11b
+
 F4/80
INT
 CD11c
INT/+
 
Ly6C
Lo
 
178
 
 CD11b
+
 F4/80
+
 Gr-1
-
 Ly6C
-
 
90
 
 CD11b
Hi
 Gr-1
Lo
 Ly6C
Lo
 Equivalent subset in tumour 
models is Tie-2 expressing 
monocytes (TEMs)
175, 180
 
 CD11b
+
 Gr-1
-
 Ly6C
Lo
 
179
 
Microglia CD11c
+
 CD45
Lo
 F4/80
Lo
 
181
 
 
 
Table 4 The key innate immune cell subsets and various definitions for them based on 
surface marker expression in mice 
Table summarising the key myeloid cell populations as defined by mainly using the cell surface 
markers CD11b, F4/80, Gr-1 and Ly6C (VAR=variable; INT=intermediate; MED=medium; 
Hi=high; Lo=Low; SCC=side scatter). Additional markers described in the publications referred 
to may have been omitted for clarity. Overlap of marker expression between different 
populations reflects the high levels of heterogeneity and plasticity in innate immune cell 
populations – this is at least partly dependent on a variation in activation states that is 
dependent on the local inflammatory environment and the tissue being analysed. Variations in 
marker expression within the same population may reflect differences between experimental 
models, protocols and gate definitions, and occasionally differences of opinion on the exact 
nature of a cell population (dendritic cells for example). 
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3.2 Establishing the phenotype of innate immune cell 
populations in young wild-type retina and choroid 
 
3.2.1 Innate immune cell populations in young wild-type retina 
 
Using directly conjugated antibodies for CD11b, F4/80, Gr-1, Ly6C and CD11c, 
compensations for flow cytometry were set using single-stained splenocyte 
suspensions and gates set using fluorescence-minus-one controls for each 
tissue as a guide (Figure 23 and Figure 15).  
 
Despite use of the brightest fluorochrome, the signal from F4/80+ cells was 
relatively low indicating that F4/80 is expressed at low levels in microglia -  a 
finding confirmed on immunohistochemistry of CCL2-/- mouse eye sections 
where signal amplification was necessary to enable visual detection (Figure 16). 
Retinal microglia were identified as being largely CD11b+ F4/80+ Gr-1- in young 
(<4m) wild-types. An example of the gating strategy employed in the 
identification of the CD11b+ F4/80+ Gr-1- population is shown (Figure 17). 
Microglia constituted approximately 0.07% (mean; n=9) of live cells in a retinal 
suspension and are henceforth referred to as Gr-1- macrophages.  CD11b+ 
F4/80+ Gr-1+ cells (henceforth referred to as Gr-1+ macrophages) were by 
comparison very few in number in uninflamed tissue and staining may represent 
non-specific antibody binding (Figure 18). 
 
The granulocyte population in the retina was identified as CD11b+ Gr-1+ F4/80- 
(Figure 18, main plot ungated cells). Previous studies153 have identified 
neutrophils (which constitute the majority of granulocytes) as CD45+ Gr-1+ or 
CD11b+ Gr-1+. Given that Gr-1 is expressed on a number of other myeloid cell 
types (including F4/80+ monocyte/macrophage subsets and NK cells)  
granulocytes were further distinguished as being F4/80-. It was not possible to 
separate eosinophils and basophils from the neutrophil population using the 
panel of markers available so the population was collectively referred to as the 
granulocyte population. As a general rule the levels of expression of Gr-1 in this 
population mirrored those of Ly6C. Gating for double-positive or negative 
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populations for these markers was performed but more consistent results were 
obtained if either Gr-1 or Ly6C was used (probably because a further reduction 
in numbers in the final gate was avoided). Granulocytes constituted 0.13% of 
live cells in the retina (mean; n=9). 
 
Dendritic cells were defined as CD11b+ CD11c+ Gr-1- (Figure 19). It was noted 
that whilst most CD11b+ CD11c+ cells were Gr-1- a small number were Gr-1+ 
(most likely plasmacytoid DCs). CD11b+ CD11c+ Gr-1- cells were largely 
negative for F4/80. DCs exhibited the most consistent changes in response to 
ageing or laser-induction of CNV and constituted 0.05% of live cells (mean; 
n=9). 
 
A total of 42 permutations of marker expression on CD11b+ cells were analysed 
across experiments with the aim of identifying any small but significant shifts in 
sub-populations. CD11b+ cells constituted 1.2% of live cells in the retina (mean; 
n=9), in keeping with the findings of other groups168, interestingly however most 
retinal CD11b+ cells were completely negative for all other markers in the panel 
(Figure 20), that is they were CD11b+ F4/80- Gr-1- Ly6C- CD11c-. The reasons 
for this are unclear since this was not found in choroidal tissue or spleen and 
cannot be explained by the inadvertent inclusion of CD11b- cells in a CD11b+ 
gate alone. It is possible that F4/80 is expressed at such low levels in retina that 
a significant number of microglia are excluded when gating for F4/80+ cells, 
alternatively other populations such as NK cells and pericytes may be CD11b+ 
yet negative for the other markers. 
 
Of the four principle populations identified, granulocytes formed the largest 
group followed by roughly equal proportions of Gr-1- macrophages and DCs, 
Gr-1+ macrophages formed the smallest subset. 
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Figure 14 Single-stain controls for fluorophore compensations 
For the purposes of compensation, individual splenocyte 
suspensions derived from a young adult wild-type mouse were 
stained for each conjugated antibody (x-axes) and comparisons 
made with levels of fluorescence in the other channels that would be 
employed when using the full panel (y-axes). Voltages applied 
during acquisition of data using the BD LSRII were adjusted for 
optimum separation of the stained population. 
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Figure 15 Fluorescence-minus-one controls for retinal and RPE-choroidal cell 
suspensions 
Fluorescence minus one controls for retinal (first column) and RPE-choroidal (third column from 
the left) cell suspensions. Representative plots obtained by staining for all markers in tissue 3 
days post-induction of CNV by diode laser are shown in adjacent columns for comparison. DAPI 
was used to stain for and exclude dead cells from the analyses and data is fully compensated. 
Plots show gating for the marker excluded from panel as part of FMO (x-axis) against side-
scatter area (y-axis) for clarity – other gating strategies (see following Figures for examples) 
based on FMO controls were employed to identify specific cell populations.  
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Figure 16 The macrophage-specific marker F4/80 is expressed at low levels in the retina 
and choroid of CCL2
-/-
 mice 
Immunohistochemistry staining for the microglia/macrophage marker F4/80 in sections taken 
from >18m CCL2
-/-
 mouse eyes (40x magnification using fluorescent microscopy). A protocol 
involving signal amplification was required to demonstrate F4/80
+
 cells in mouse retina and 
RPE-choroid (wild-type and CCL2
-/-
 mice). No primary control - 1/250 streptavidin-Alexa546 
conjugated secondary following signal amplification (top panels); 1/500 anti-F4/80 with no signal 
amplification (middle panels), arrows indicate location of autofluorescent material in the 
subretinal space; 1/500 anti-F4/80 staining with signal amplification (bottom panels), 
arrowheads indicate position of F4/80
+
 ramified microglia in the inner and outer plexiform layers 
of the retina, F4/80
+
 cells were also seen throughout the choroid where levels of expression 
were considerably higher. IPL=inner plexiform layer; INL=inner nuclear layer; OPL=outer 
plexiform layer; ONL=outer nuclear layer; PR=photoreceptor layer; RPE=retinal pigment 
epithelium;CH=choroid.  
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Figure 17. Representative flow cytometry scatter plot of a Gr-1
-
 F4/80
+
 macrophage 
population derived from the pooled retinae of a young (<4m) wild-type mouse 
Smaller plots illustrate the ancestry of the F4/80
+
 population. Gates (from left to right) show: all 
events; live cells (dead cells DAPI positive); CD11b
+
 cells; CD11b
+
 Gr-1
-
 cells; with main plot 
demonstrating the final live CD11b
+
 Gr-1
-
 F4/80
+
 population. F4/80 was expressed at low levels 
in the retina (confirmed by immunohistochemistry analysis, fluorescence minus one controls and 
analysis of splenocyte suspensions). The number of cells in each gate expressed as a 
percentage of all events on the plot is shown in black with the total number of events plotted 
shown in red. Fluorophores conjugated to antibodies against the respective markers are listed 
in the Methods section. Gates were set according to fluorescence-minus-one controls 
performed on retinal cell suspensions. Side scatter area (SSC-A); forward scatter area (FSC-A); 
numbers in gates indicate gated cells as a percentage of all events on plot.  
0 50K 100K 150K 200K 250K
FSC-A
0
50K
100K
150K
200K
250K
S
S
C
-A
78
0 50K 100K 150K 200K 250K
FSC-A
0
10
2
10
3
10
4
10
5
D
A
P
I
5.05
0 102 103 104 105
CD11b
0
10
2
10
3
10
4
10
5
L
y
6
c
1.31
0 50K 100K 150K 200K 250K
SSC-A
0
10
2
10
3
10
4
10
5
G
r-
1
88.9
0 102 103 104 105
CD11b
0
10
2
103
10
4
105
F
4
/8
0
14.2
625
Chapter 3  The effects of ageing 
118 
 
 
Figure 18. Representative flow cytometry scatter plot of a Gr-1
+
 F4/80
+
 macrophage 
population derived from the pooled retinae of a young (<4m) wild-type mouse 
Smaller plots illustrate the ancestry of the F4/80
+
 population. Gates (from left to right) show: all 
events; live cells (dead cells DAPI positive); CD11b
+
 cells; CD11b
+
 Gr-1
+
 cells; with main plot 
demonstrating the final live CD11b
+
 Gr-1
+
 F4/80
+
 population. Numbers of Gr-1
+
 macrophages in 
retina from unprocedured eyes were extremely low and most likely the result of non-specific 
staining or gated granulocytes. F4/80
-
 population in the main plot constitutes a Gr-1
+
 subset of 
high scatter these were considered to be granulocytes (predominantly neutrophils). The number 
of cells in each gate expressed as a percentage of all events on the plot is shown in black with 
the total number of events plotted shown in red. Fluorophores conjugated to antibodies against 
the respective markers are listed in the Methods section. Gates were set according to 
fluorescence-minus-one controls performed on retinal cell suspensions. Side scatter area (SSC-
A); forward scatter area (FSC-A). 
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Figure 19 Representative flow cytometry scatter plot of a CD11c
+
 innate immune cell 
population (DCs) derived from the pooled retinae of a young (<4m) wild-type mouse 
Smaller plots illustrate the ancestry of the CD11c
+
 population. Gates (from left to right) show: all 
events; live cells (dead cells DAPI positive); CD11b
+
 cells; CD11b
+
 CD11c
+
 cells; with main plot 
demonstrating the final live CD11b
+
 Gr-1
-
 CD11c
+
 population. CD11c
+
 cells were consistently 
Gr-1
-
 but expressed varying levels of F4/80 (data not shown). The number of cells in each gate 
expressed as a percentage of all events on the plot is shown in black with the total number of 
events plotted shown in red. Fluorophores conjugated to antibodies against the respective 
markers are listed in the Methods section. Gates were set according to fluorescence-minus-one 
controls performed on retinal cell suspensions. Side scatter area (SSC-A); forward scatter area 
(FSC-A). 
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Figure 20.  Permutations of marker expression on retinal cells from young (<4 month old) wild-type mice. 
A total of 42 permutations of marker expression on CD11b
+
 cells were analysed in order to establish populations of interest. Some of these 
permutations are shown above. Four permutations were useful in identifying distinct CD11b
+
 populations that might change with age or in 
pathological neovascularisation (n=9; mean number of live cells=73996; error bars=SEM; all populations are CD11b
+
). Gating strategies for 
these key subsets are shown in Figure 17,Figure 18 and Figure 19. Most cells gated for CD11b were negative for CD11c, Gr-1, Ly6C and 
F4/80 (see final column) and may include pericytes, natural killer cells and a number of CD11b
-
 cells. 
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3.2.2 Innate immune cell populations in young wild-type 
choroid 
 
 
Using fluorescence-minus-one controls as a guide it was possible to establish 
that gates drawn for retinal cell suspensions could also be used for RPE-
choroid - thereby allowing direct comparison of the two tissues. 
 
CD11b+ cells constituted 16.6% of live cells in young (<4m) wild-type RPE-
choroid (mean; n=6), a finding that gives some indication as to the highly 
immunologically active nature of this tissue. The gating strategies employed 
were as for retinal cell suspensions (Figure 21, Figure 22 and Figure 23), as 
were the permutations of marker expression examined (Figure 24). Key 
populations were as defined for retina,  with Gr-1- macrophages consitituting 
1.4% of live cells; Gr-1+ macrophages 0.29%; granulocytes 5.4% and DCs 3.5% 
of live cells (mean; n=6). 
 
Of the 4 principle populations identified, relative proportions were as in young 
wild-type retina except for DCs which constituted a larger population than Gr-1- 
macrophages (Figure 25).  
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Figure 21. Representative flow cytometry scatter plot of a Gr-1
-
 F4/80
+
 innate immune cell 
population (Gr-1
-
 macrophages) derived from the pooled RPE-choroids of a young (<4m) 
wild-type mouse. 
Smaller plots illustrate the ancestry of the F4/80
+
 population. Gates (from left to right) show: all 
events; live cells (dead cells DAPI positive); CD11b
+
 cells; CD11b
+
 Gr-1
-
 cells; with main plot 
demonstrating the final live CD11b
+
 Gr-1
-
 F4/80
+
 population. As in the retina, F4/80 was 
expressed at low levels in the choroid (confirmed by immunohistochemistry analysis, 
fluorescence minus one controls and analysis of splenocyte suspensions). The number of cells 
in each gate expressed as a percentage of all events on the plot is shown in black with the total 
number of events plotted shown in red. Fluorophores conjugated to antibodies against the 
respective markers are listed in the Methods section. Gates were set according to fluorescence-
minus-one controls performed on retinal cell suspensions. Side scatter area (SSC-A); forward 
scatter area (FSC-A). 
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Figure 22. Representative flow cytometry scatter plot of a Gr-1
+
 F4/80
+
 innate immune cell 
population (Gr-1
+
 macrophages) derived from the pooled RPE-choroids of a young (<4m) 
wild-type mouse. 
Smaller plots illustrate the ancestry of the F4/80
+
 population. Gates (from left to right) show: all 
events; live cells (dead cells DAPI positive); CD11b
+
 cells; CD11b
+
 Gr-1
+
 cells; with main plot 
demonstrating the final live CD11b
+
 Gr-1
+
 F4/80
+
 population. Gr-1
+
 macrophages constituted a 
small proportion of total macrophages in the RPE-choroid. F4/80
-
 population in the main plot 
constitutes a Gr-1
+
 subset of high scatter that were considered to be granulocytes 
(predominantly neutrophils). The number of cells in each gate expressed as a percentage of all 
events on the plot is shown in black with the total number of events plotted shown in red. 
Fluorophores conjugated to antibodies against the respective markers are listed in the Methods 
section. Gates were set according to fluorescence-minus-one controls performed on retinal cell 
suspensions. Side scatter area (SSC-A); forward scatter area (FSC-A). 
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Figure 23 Representative flow cytometry scatter plot of a CD11c
+
 innate immune cell 
population (DCs) derived from the pooled RPE-choroids of a young (<4m) wild-type 
mouse 
Smaller plots illustrate the ancestry of the CD11c
+
 population. Gates (from left to right) show: all 
events; live cells (dead cells DAPI positive); CD11b
+
 cells; CD11b
+
 CD11c
+
 cells; with main plot 
demonstrating the final live CD11b
+
 Gr-1
-
 CD11c
+
.
 
Fluorophores conjugated to antibodies 
against the respective markers are listed in the Methods section. Gates were set according to 
fluorescence-minus-one controls performed on retinal cell suspensions. 
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Figure 24. Permutations of marker expression on RPE-choroid cells from young (<4 month old) wild-type mice  
As with retina, a total of 42 permutations of marker expression on CD11b
+
 cells were analysed in order to establish populations of interest and four 
permutations were useful in identifying distinct CD11b
+
 populations that might change with age or in pathological neovascularisation (n=6; mean 
number of live cells=3348; error bars=SEM; all populations are CD11b
+
). Gating strategies for these key subsets are shown in Figure 21, Figure 22 and 
Figure 23. Overall, CD11b
+
 cells were found to constitute a much higher proportion of the cell population in the RPE-choroid (over 16% of live cells 
compared to 1.2% in retina). In contrast to retina, CD11c
-
 Gr-1
-
 Ly6C
-
 F4/80
-
 cells formed a smaller proportion of total CD11b
+
 cells.
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3.3 The effects of ageing on innate immune cell 
populations in the retina and choroid 
 
Having determined the proportions of innate immune cell populations in the 
retinae and RPE-choroids of young wild-type mice, the effects of ageing on the 
same populations were established by analysing tissue obtained from 12 month 
old and >18 month old wild-type animals (Figure 25).  
 
A significant increase in the proportion of DCs was observed in both retina and 
RPE-choroid between <4 and 12 months of age (mean % live cells; t-test 
p<0.01 for both tissues) with no significant increase thereafter. Comparison of 
>18m old and <4m old tissues revealed that the proportion DCs was almost 4 
times greater in aged retina (t-test p<0.01) and more than double in aged RPE-
choroid (t-test p<0.05). 
 
An increase in the proportion of Gr-1- macrophages was also seen in the retina 
with age – mainly in >18m animals where, as a percentage of live cells, the 
proportion of Gr-1- macrophages was more than double that observed in <4m 
mice (t-test p<0.05). 
 
No significant difference between young and old age groups was observed in 
any of the other key populations. 
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Figure 25. Age-related changes in the innate immune cell populations of wild-type retina 
(A) and RPE-choroid (B) 
Graphic representations of changes in key innate immune cell populations (CD11b
+
) in 
unprocedured wild-type retina and RPE-choroid expressed as a proportion of total live cells. 
Tissue pooled from each animal and mean % of live cells calculated for each population (n=9, 5 
and 9 for retina and n=6, 5 and 9 for choroid - for age groups <4, 12 months and >18 months 
respectively; error bars=SEM). Dendritic cells (CD11c
+
 Gr-1
-
) and Gr-1
-
 macrophages (F4/80
+
 
Gr-1
-
) accumulate with age in the retinae of wild-type mice with a significant increase in the 
proportion of DCs as early as 12 months of age (A). DCs also accumulate with age as early as 
12 months in the RPE-choroid, there were no significant changes in any other RPE-choroidal 
innate immune cell populations with age (B). 
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3.4 Peripheral effects of ageing on innate immune cell 
populations 
 
To determine whether changes observed with ageing in innate immune cell 
populations were restricted to the eye or associated with changes in the 
periphery, splenocyte suspensions from wild-types aged <4m and >18m were 
analysed. 
 
Fluorescence-minus-one controls used as a guide for gating are shown (Figure 
26). Gating for DCs, Gr-1- macrophages, Gr-1+ macrophages and granulocytes 
in spleen revealed significant changes in the proportions of DC and Gr-1- 
macrophage populations with age with an approximately 3-fold increase in their 
sizes (Figure 27A). These findings correlated with data obtained from the 
retinae and RPE-choroids of wild-type mice (Figure 25).  
 
The greater cell numbers in this tissue permitted an additional strategy for 
identifying CCR2+ and CCR2- monocytes. This involved gating CD11b+ F4/80Low 
cells (monocytes) for Ly6CHigh (CCR2+), Ly6CMid and Ly6CLow (CCR2- 
monocytes) populations (Figure 28B and Figure 28). Comparison of these 
populations between <4m and >18m animals revealed a significant increase in 
the proportion of the Ly6CLow (CCR2-) monocyte population with age. Again this 
finding was in keeping with changes in the CCR2- monocyte populations as 
determined using the Gr-1 marker and suggests that, in spleen, F4/80+ Gr-1- 
cells may equate to F4/80+ Ly6CLow populations.  
 
Analysis of other subgroups revealed a significantly higher proportion of 
CD11b+ CD11c- F4/80- Gr-1- Ly6C- cells in aged spleen compared to young 
(Figure 27B). It was noted that, as in RPE-choroid and retinal tissue, 
monocyte/macrophages in wild-type spleen were largely CCR2- (as defined 
using Gr-1 or Ly6C). 
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Figure 26 Fluorescence-minus-one controls for splenocyte suspensions 
Fluorescence-minus-one controls for splenocyte suspensions derived from young wild-type 
mice. DAPI was used to stain for and exclude dead cells from the analyses and data fully 
compensated. Plots show gatin for the excluded marker as part of the FMO (x axis) against 
side-scatter (y axis). Gating strategies based on FMO controls were used as the basis for 
identifying specific cell populations. 
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Figure 27. Changes with age in spleen innate immune cell populations of wild-type mice 
Key innate immune cell populations derived from wild-type spleen. Mean % of live cells 
calculated for each population (n=12 for <4m group and n=7 for >18 month group; error 
bars=SEM). Dendritic cells and Gr-1
-
 macrophages accumulate with age in the retinae and 
RPE-choroids of wild-type mice – this was also found to be the case in the spleen where an 
approximately 3-fold increase in these populations was observed (A). In addition, the 
identification of subpopulations of CD11b
+
 F4/80
Low
 Ly6C
High
, Ly6C
Mid
 and Ly6C
Low
 cells was 
also possible in spleen and a significant increase in the proportion of Ly6C
Low
 (CCR2
-
) 
monocytes was observed with age (B). A significant increase in the proportion of CD11b
+
 
CD11c
-
 F4/80
-
 Gr-1
-
 Ly6C
-
 cells (possibly NK cells) was also observed. 
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Figure 28. F4/80
Low
 population in the spleen may divided into Ly6C
High
, Ly6C
Mid
 and 
Ly6C
Low
 subgroups 
Whereas the limited number of cells derived from retina and RPE-choroid did not permit 
analysis of F4/80
+
 Gr-1
+
 or F4/80
+
 Ly6C
+
 subpopulations in these tissues it was possible to 
determine such groups with more confidence, particularly using Ly6C, in splenocyte 
suspensions. Smaller plots illustrate the ancestry of CD11b
+
 F480
Low
 Ly6C
+
 populations derived 
from young (<4 month old) wild-type spleen. Gates (from left to right) show: all events; live cells 
(dead cells DAPI positive); CD11b
+
 cells; CD11b
+
 F4/80
+
 cells and CD11b
+
 F4/80
+
 Ly6C
+
 cells; 
with main plot demonstrating the final live CD11b
+
 F4/80
Low
 Ly6C
High
, Ly6C
Mid 
and
 
Ly6C
Low
 
subsets. Gating strategies were otherwise as applied to retinal and RPE-choroid cell 
suspensions. F4/80
Low
 population represents monocytes whilst F4/80
High
 cells (outside gates in 
main plot) represent mature macrophages. 
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3.5 Effects of CCL2 deficiency on the profile of innate 
immune cells in retina and choroid 
 
Deficiencies in certain chemokines, such as CCL2, and their receptors have 
been demonstrated to result in the accelerated accumulation of subretinal 
macrophages with age120, 169. Levels of the chemokine CCL2 are significantly 
elevated in the retinae and RPE-choroids of aged wild-type mice and the 
receptor for CCL2 (CCR2) is expressed on a range of innate immune cells 
including CCR2+ monocytes124. It was hypothesised that CCL2 deficiency 
results in the subretinal accumulation of macrophages through altered 
trafficking or maturation of specific innate immune cell populations and that it 
might be possible to confirm such effects by identifying changes in the 
proportions of these cells in the retinae and RPE-choroids of CCL2-/- mice over 
time. 
 
In comparison with age-matched wild-type retina, the proportion of DCs was 
found to be significantly higher in <4m CCL2-/- mouse retina by a factor of more 
than 4 (t-test p<0.02) – making it the dominant innate immune cell population in 
the retinae of CCL2-deficient mice (Figure 29). There was a trend, though not 
significant, towards a slight increase in the proportion of DCs in the retinae of 
CCL2-/- mice with ageing (<4m CCL2-/- mice vs. >18m CCL2-/- mice) suggesting 
a ceiling was reached earlier in these animals. A concomitant rise in the 
proportion of DCs in the retinae of wild-type mice with age meant there was 
ultimately no significant difference in the levels of DCs between aged CCL2-/- 
mice and aged wild-types. Gr-1+ macrophages were also found to be 4 times 
higher in the retinae of CCL2-/- mice (t-test p<0.02), though again no change 
was observed with ageing. 
 
Most striking, aside from the elevated levels of DCs, was the rapid increase in 
the proportion of Gr-1- macrophages observed around 12 months of age in 
CCL2-/- mouse retina. Similar changes were observed in wild-types (in which 
numbers almost doubled), however in CCL2-/- mice the proportion of Gr-1- 
macrophages more than doubled after 12 months of age (t test 12m CCL2-/- 
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Figure 29. The effect of CCL2 deficiency on innate immune cell populations in the retina 
and how they change with age 
Proportions of innate immune cell populations in the retina of CCL2
-/-
 mice (B) with analysis for 
wild-type mice provided above for comparison (A – as for Figure 25A). The proportion of DCs in 
young (<4m) CCL2
-/-
 retina is higher than age-matched wild-type retina by a factor of more than 
4 (p=0.02). The proportion of Gr-1
+
 macrophages is also significantly higher in young CCL2
-/-
 
retinae (p=0.02). With increasing age it can be seen that the proportion of DCs plateaus such 
that there is no significant difference between wild-type and CCL2
-/-
 retina at >18m; however the 
proportion of Gr-1
-
 macrophages rises rapidly after 12m in CCL2
-/-
 retina such that levels are 
equivalent to those of DCs and more than double that seen in age-matched wild-types (p=0.01). 
The rise in the proportion of Gr-1
-
 macrophages coincides with a decline in granulocytes in 
CCL2
-/-
 retina. Tissue pooled from each animal and mean % of live cells calculated for each 
population; n=8, 4 and 7 for age groups <4, 12 months and >18 months respectively (B); error 
bars=SEM.
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mice vs. >18m CCL2-/- mice;  p=0.03) ultimately matching levels of DCs in the 
retinae of >18m. The rise in Gr-1-macrophages coincided with a decline in the 
proportion of granulocytes in CCL2-/- mouse retina with levels significantly lower 
in >18m animals compared with <4m mice (t-test; p=0.02), no such decline was 
observed in wild-type mice. 
 
In contrast to findings in the retina, no significant difference in the proportion of 
DCs in CCL2-/- RPE-choroid was observed at any timepoint compared with age-
matched wild-type tissue (Figure 30). Even so, the DC population in CCL2-/- 
RPE-choroid appeared to behave in a similar manner to that in CCL2-/- retina, 
with a suggestion of higher numbers in younger animals that approached a 
ceiling by 12 months of age. 
3.6 Effects of CCL2 deficiency on the profile of innate 
immune cells in the spleen 
 
It was hypothesised that changes in the balance of CCR2+ and CCR2- 
monocyte populations in the periphery might explain the effects of CCL2 
deficiency on local innate immune cell populations in retina and RPE-choroid. 
Certain DC subsets are derived from CCR2+ monocyte populations and resident 
microglia are thought originate from CCR2- monocyte populations. Having 
previously established that the proportions of DCs and CCR2- monocytes 
appeared significantly elevated in aged wild-type spleen - with a trend towards 
decreased Ly6CHigh (CCR2+) monocytes - the spleens of CCL2-/- mice were 
analysed.  
 
Splenocyte suspensions from <4m and >18m CCL-/- mice were analysed and 
compared with those obtained from age-matched wild-type animals (Figure 31). 
Proportions of Gr-1- macrophages and DCs were significantly lower in young 
CCL2-/- spleen compared with young wild-types (t-test; p=0.02 for both 
populations). The proportion of granulocytes and Gr-1+ macrophages was not 
significantly different in young CCL2-/- spleen compared with age-matched wild-
type tissue.  
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Figure 30. The effect of CCL2 deficiency on innate immune cell populations in the RPE-
choroid and how they change with age 
Proportions of innate immune cell populations in the choroid of CCL2
-/-
 mice (B) with analysis for 
wild-type mice provided above for comparison (A – as for Figure 25B). In contrast to findings in 
retina, there was no significant difference in the proportion of DCs in CCL2
-/-
 choroid at any 
timepoint compared with age-matched wild-type choroid, although the trend was for this 
population to be higher at the extremes of age in CCL2
-/-
 mice and DCs appeared to increase 
with age without quite achieving significance. There was no significant change in the 
proportions of any other innate immune cell population with age in CCL2
-/-
 mouse choroid 
although there was a trend towards a decrease in the levels of granulocytes (as in wild-types). 
Tissue pooled from each animal and mean % of live cells calculated for each population; n=7, 4 
and 6 for age groups <4, 12 months and >18 months respectively (B); error bars=SEM. 
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Figure 31. The effect of CCL2 deficiency on innate immune cell populations in the spleen 
and how they change with age 
Proportions of innate immune cell populations in the spleen of CCL2
-/-
 mice (B) with analysis for 
wild-type mice provided above for comparison (A - as for Figure 27A). The proportion of Gr-1
-
 
macrophages was 3 times smaller, and that of DCs 2 times smaller, in young (<4m) CCL2
-/-
 
spleen compared with age-matched wild-type spleen (t-test; p=0.02 for both populations). The 
proportion of granulocytes and Gr-1
+
 macrophages was not significantly different in young 
CCL2
-/-
 spleen compared with age-matched wild-type tissue. Increasing age was associated 
with significant increases in the proportions of Gr-1
-
 macrophages and DCs in CCL2
-/-
 spleen 
(approximately 3-fold – as in wild-types). Levels of these populations appeared to still be below 
those seen in >18m wild-types (t-test; p=0.06 for Gr-1
-
 macrophages and p=0.05 for DCs). 
Comparison of the other populations in aged CCL2
-/-
 mice with those in age-matched wild-types 
revealed no significant difference between them. Tissue pooled from each animal and mean % 
of live cells calculated for each population; n=9 and 6 for CCL2
-/- 
age groups <4 and >18 months 
respectively (B); error bars=SEM. 
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Significant increases in the proportions of Gr-1- macrophages and DCs were 
observed in spleens of >18m CCL2-/- mice compared with <4m animals (t-test; 
p=0.06 for Gr-1- macrophages and p=0.05 for DCs). Levels of DCs were seen 
to double with age (t-test; p<0.01) and Gr-1- macrophages seen to treble (t-test; 
p<0.02), although levels of these populations appeared to remain below those 
seen in >18m wild-type spleen (t-test; p=0.06 for Gr-1- macrophages and 
p=0.05 for DCs). Comparison of the other populations in aged CCL2-/- mice with 
those in age-matched wild-types revealed no significant difference between 
them. 
 
Application of the gating strategy designed to establish monocyte subsets 
according to levels of Ly6C expression revealed changes consistent with those 
obtained using the Gr-1 marker. Ly6CLow (CCR2-) monocytes were found to be 
significantly lower in young CCL2-/- mice, however the size of this group was 
seen to increase 5-fold with age (t-test <4m CCL2-/- vs. >18m CCL2-/- mice; 
p=0.02) and levels at >18m were observed to be the equivalent of those seen in 
>18m wild-types. No significant change was observed with age in the other 
monocyte populations of CCL2-/- mice though in general the trend was for the 
Ly6CHigh (CCR2+) population to be smaller. Unlike wild-types, no increase in the 
proportion of CD11b+ CD11c- F4/80- Gr-1- Ly6C- cells was seen with age in 
CCL2-/- mice (Figure 32). 
 
Overall, results suggest that ageing is associated with increased levels of 
CCR2- monocytes and DCs in the spleens of wild-type animals. The effect of 
CCL2 deficiency is to significantly reduce the levels of these populations in the 
spleens of young CC2L-/- mice. The effects of ageing on spleen 
monocyte/macrophage populations and DCs appeared broadly similar in wild-
type and CCL2-/- mice though the trend was for levels of these populations to be 
lower in CCL2-deficient animals. 
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Figure 32. The effect of CCL2 deficiency on CD11b
+
 F4/80
Low
 Ly6C
+
 subpopulations and CD11b
+
 CD11c
-
 F4/80
-
 Gr-1
-
 Ly6C
-
 cells in the spleen. 
Proportions of Ly6C
High
, Ly6C
Mid
 and Ly6C
Low
 monocyte subpopulations and CD11b
+
 F4/80
-
 Gr-1
-
 Ly6C
-
 populations in the spleen of wild-type and 
CCL2
-/-
 mice aged <4m (A) and >18m (B). Data for wild-type spleens as for Figure 27B – shown here for comparison. The proportion of Ly6C
Low
 (CCR2
-
) monocytes in the spleens of <4m CCL2
-/-
 mice was less than half that in age-matched wild-types (t-test; p<0.01). The proportion of Ly6C
High
 (CCR2
+
) 
monocytes also appeared lower in young CCL2
-/-
 mice however this was of borderline significance. With ageing, levels of Ly6C
Low
 monocytes were seen 
to increase 5-fold in CCL2
-/-
 mice (t-test <4m CCL2
-/-
 vs. >18m CCL2
-/-
 mice; p=0.02) with no significant difference in this population between >18m 
CCL2
-/-
 animals and age-matched wild-types. Unlike wild-type mice, CCL2
-/-
 mice showed no significant increase in the proportion of CD11b
+
 F4/80
-
 Gr-
1
-
 Ly6C
-
 cells in the spleen with age. For CCL2
-/-
 mice, n=9 and 6 for age groups <4 and >18 months respectively; for wild-type mice, n=12 and n=7 for 
each of age groups <4 and >18 months respectively; error bars=SEM. 
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3.7 Discussion 
 
 
Ageing results in changes in innate immune cell populations in the retina, RPE-
choroid and spleen.  
 
The proportions of CCR2+ and CCR2- monocytes have been demonstrated 
previously to be the same in the spleen as in peripheral blood, consequently it 
may be inferred that changes in the spleen, in wild type animals at least, reflect 
those in circulating innate immune cell populations95. Evidence suggests a role 
for Ly6CLow (CCR2-) monocytes in the maintenance of tissue resident 
macrophage populations7. In support of this, flow cytometric analysis of 
splenocyte populations revealed an increase in the proportion of CCR2- 
monocytes with age that correlates with a significant age-related increase in the 
levels of Gr-1- macrophages (most likely microglia) in wild-type retina. Similarly, 
a significant increase in the DC population of wild-type spleen with age was 
associated with significant increases in the DC populations of both retina and 
RPE-choroid. Levels of Gr-1- macrophages remained unchanged in the RPE-
choroid with age. 
 
Proportions of CCR2- monocytes and DCs were significantly lower in the 
spleens of young CCL2-deficient mice compared with young wild-types and this 
difference was largely preserved with ageing. Given the above findings one 
might have expected to observe lower levels of these populations in the retinae 
of young CCL2-/- mice compared with young wild-types (and possibly even in 
the older age-groups). In the case of DCs the opposite was the case, with four 
times as many observed in the retinae of young CCL2-/- mice. In contrast, there 
was no significant difference in the proportions of the Gr-1- macrophage 
population in the retinae between the two genotypes before 12m of age. These 
findings suggest, not surprisingly, that recruitment of CCR2- monocyte 
populations for the purpose of forming resident microglial populations is not 
CCL2 dependent. They also suggest that CCL2 is in some way important for 
either the maturation or trafficking of DCs in the retina and that a failure of the 
appropriate signalling leads to an accumulation of these cells locally with a 
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diminution of their numbers in the periphery (where migration to lymph nodes 
and spleen would normally occur).  
 
The changes with age in the spleens and retinae of CCL2-/- mice appear to 
support a role for CCL2 in DC trafficking. Increases in DC populations with age 
in wild-type retina were matched by similar increases in the proportions of this 
population in the wild-type spleen. In contrast, the increase in the proportion of 
DCs in the spleens of CCL2-/- mice with age was much smaller compared with 
the highly elevated levels in the retina - this raises the possibility that a system-
wide failure of DC trafficking from the tissues might be responsible for reduced 
numbers of these cells in the spleen. Evidence of increased numbers of DCs in 
other non-lymphoid tissues from CCL2-/- mice would be needed to confirm this. 
 
DC levels, though greatly elevated, were seen to plateau in the retinae of CCL2-
/- mice after 12 months of age. This was associated with a sharp rise in the 
proportion of Gr-1- macrophages in the retina – much higher than that observed 
in wild-types. Given that levels of CCR2- monocytes in the spleens of aged 
CCL2-/- mice are certainly not higher than those in age-matched wild-types it is 
interesting to speculate on the mechanism behind the increased levels of Gr-1- 
macrophages in the retinae of CCL2-deficient animals. Their accumulation 
appears to be a reaction to chronic failure of DC maturation/trafficking and not 
driven by age-related changes in ‘resident’ phenotype monocyte populations in 
the periphery. 
 
No subretinal macrophages have been demonstrated on histological sections 
before the age of 18 months in either wild-type or CCL2-/- mice120. Since the DC 
population is elevated in the retinae of CCL2-/- mice at an early age it is the 
behaviour of Gr-1- macrophage populations that fits better with the histological 
data (data that also suggest subretinal macrophages accumulate more rapidly 
in the CCL2-/- mouse retina than the wild-type). The differential behaviour of DC 
populations in these models has not been noted previously - it is possible that a 
focus on subretinal cells and the use of microglial - rather than DC-specific 
markers has led to DCs escaping inclusion in any counts of innate immune cells 
in histological sections. 
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CCL2 deficiency (unlike CCR2 deficiency) has been demonstrated not to affect 
directly the egress of monocytes and other innate immune cells from the bone 
marrow170. This suggests that the changes observed in the spleens of CCL2-/- 
mice arise from altered maturation pathways for monocytes in the peripheral 
blood – unless, that is, CCL2 somehow plays a role in the recruitment of 
monocytes that do not express its receptor.  The changes in monocyte 
subpopulations and DCs observed with age were not significantly different 
between wild-types and CCL2-/- mice suggesting that CCL2 does not have a 
direct role in innate immunosenescence in this tissue. An exception to this was 
the observation that an undefined population of CD11b+ CD11c- F4/80- Gr-1- 
Ly6C- cells (possibly NK cells) increased with age in wild-type but not CCL2-
deficient mice (no such change was observed in retinal or RPE-choroidal 
tissue). 
 
Findings in the RPE-choroid were broadly similar to those in the retina, though 
not statistically significant – this may be because the yield of live cells from two 
pooled RPE-choroids was approximately 20 times smaller than from retinae. 
Nevertheless, DCs appeared to constitute a larger population in young CCL2-/- 
RPE-choroid compared with age-matched wild-type tissue and, similarly to the 
retina, the size of the DC population appeared to increase in the first 12 months 
of life. Whereas significant increases in Gr-1- macrophage populations were 
observed in the retina with age in both wild-type and CCL2-/- mice, this was not 
the case in the choroid where macrophage populations remained low relative to 
DCs and granulocytes. 
 
It could be argued that the observed effects of ageing in wild-type and CCL2-/- 
mice arise from selection for animals of advanced age with a specific immune 
phenotype (potentially certain phenotypes may be associated with a higher risk 
of death at younger age thereby skewing the cohort of aged animals). It would 
be difficult to control for this. In this study there was a natural loss of animals 
from both CCL2-/- and wild-type cohorts as the animals aged but this was not 
felt to be at levels which might bias results.  Regardless, the use of inbred 
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strains, which are more-or-less genetically identical, greatly minimises the risk 
of selection for animals with a specific immunophenotype. 
 
Overall these results suggest that age-related changes in the peripheral innate 
immune cell compartment may modulate inflammatory effects at a local level in 
the retina and RPE-choroid of the eye in wild type mice. CCL2 appears not to 
play a direct role in changes observed with age systemically but deficiency of 
this chemokine does result in a shift towards lower levels of CCR2- monocytes 
and DCs in the spleen for the lifespan of the animal.  Normal maturation and/or 
trafficking of DCs appears to be CCL2-dependent and a failure of normal 
signalling results in increased levels of DCs, and subsequently microglia, in the 
retina - an effect that may explain some of the changes in innate immune cell 
populations in the spleens of CCL2-/- mice. 
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Chapter 4: The characterisation of innate immune 
cell populations involved in CNV 
 
4.1 Introduction 
 
This chapter documents work aimed at identifying whether the changes 
observed in innate immune cell populations in the retina, RPE-choroid and 
spleen might explain the increase in CNV severity observed with ageing, and 
the role of the chemokine CCL2 in this process.  
 
AMD is associated with CNV in approximately 10% of cases. CNV is also a 
feature of eye diseases other than AMD. The extent of CNV and its sequelae 
appear strongly related to the nature of the eye disorder and the age of an 
affected individual. For example, the type of CNV that most commonly affects 
young subjects (CNV associated with myopia or presumed ocular 
histoplasmosis) tends to be smaller, leaks and haemorrhages less, and tends 
not to result in the disciform scar so frequently seen in long-standing AMD150. 
 
It has been demonstrated previously that age is an independent risk factor for 
the severity of CNV induced by laser-mediated rupture of Bruch’s membrane in 
wild-type mice162. CNV in older mice are larger, thicker, more cellular and 
probably more vascularised than in younger animals. Increased neovascular 
responses have been found in older animals using other models of vascular 
injury and a number of mechanisms have been proposed for this including the 
loss of soluble growth factor inhibitors from the blood, increased soluble growth 
stimulants, changes in immune function and changes in vascular progenitor 
cells. However, the picture is further complicated by the finding of impaired 
angiogenesis in aged animals in other models such as those for hind limb 
ischaemia and wound healing models182.  
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There is contradictory evidence for the role of macrophages in laser-induced 
CNV that might be explained by a bias towards the recruitment of one type of 
F4/80+ cell over another96, 154, 156.  Apte et al. suggested a role for macrophages 
in the inhibition of laser-induced CNV after demonstrating that increased 
macrophage recruitment is associated with smaller CNV size in IL-10-/- mice 
and anti-CD11b and anti-F4/80 antibody-mediated depletion of 
monocyte/macrophage populations is associated with increased lesion size. 
Espinosa-Heidmann et al. used clodronate liposomes to deplete circulating and 
choroidal monocyte/macrophage populations and demonstrated a correlation 
with reduced lesion size96, 152. Pro-angiogenic properties have been ascribed to 
CCR2- monocytes and their counterparts in tumour biology, the tie-2 expressing 
monocytes (TEMS). In contrast, CCR2+ monocytes have been described as 
having a more ‘inflammatory’ phenotype95. It was therefore hypothesised that 
the observed changes in innate immune cell populations locally and in the 
periphery with age might explain the increased severity of CNV seen in aged 
wild-type mice. This was tested by subjecting young (<4m), 12m and >18m 
wild-type and CCL2-/- mice to laser-induction of CNV. The size of the CNV and 
the local innate immune cell reponse to laser induction to CNV were both 
determined. Analysis of the CNV response in CCL2-/- mice was considered to 
be of particular interest given the increase in the CCR2- (Gr-1-/ Ly6CLow) 
monocyte population in the periphery with age.  
 
To determine whether findings might be conserved across models of choroidal 
neovascularisation, the innate immune cell populations in the retinae, RPE-
choroids and spleens of a strain of mouse in which CNV occurs spontaneously 
were examined (Figure 33). The JR5558 mouse develops multiple areas of 
CNV in the posterior fundus around 10-12 days post-natally before developing a 
lethal leukaemia at 3 months of age. CNV in the JR5558 mouse has been 
demonstrated to be associated with an infiltration of F4/80+ cells on 
immunohistochemistry. Whilst the genotype corresponding with the above 
phenotype is unknown, this model was felt to be more in keeping with the 
pathological neovascularisation seen in AMD than alternatives such as the 
oxygen-induced retinopathy model where retinal neovascularisation arises 
primarily as a result of dysregulated vasculogenesis.
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Figure 33 F4/80 and Ly6C immunostaining of a retinal and RPE-choroidal section taken 
from a 6 week old JR5558 mouse 
Fundus fluorescein angiographic images demonstrating multiple areas of choroidal 
neovascularisation in the posterior pole of a 6wk old JR5558 mouse eye with leakage evident in 
the late phase of the angiogram (a); confocal microscopic images of 16μm sagittal sections 
stained for the monocyte/macrophage marker F4/80 and Ly6C - a marker expressed on 
a
Merged + DAPI
F4/80
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granulocytes, CCR2
+
 monocyte subsets and retinal/choroidal vascular endothelium (b); merged 
images show F4/80
+
 cells associated with neovascular changes in the subretinal space at x20 
magnification (arrow; c) and x40 magnification (d). 
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4.2 Effects of ageing and CCL2 deficiency on the 
severity of laser-induced CNV 
 
Three separate experiments were conducted with the aim of better 
understanding the effects of ageing and CCL2 deficiency on the extent of CNV. 
Each experiment involved the induction of CNV by diode laser in wild-type and 
CCL2-/- mice aged <4 months, 12 months and >18months with comparison of 
the mean size of CNV between the two genotypes in each age group (as 
determined by analysis of the early phase of fundus fluorescein angiography 
performed at 2 weeks post-laser). 
 
The mean size of CNV lesions in <4m CCL2-/- mice was found to be 42% 
smaller (t-test; p<0.01) than in age-matched wild-type mice (Figure 34). This 
difference in lesion size between the two genotypes remained consistent and 
statistically significant with ageing.  
 
Lesion size was seen to increase significantly with age in both wild-type and 
CCL2-/- mice. Lesions in >18m wild-type mice were larger, on average, by a 
factor of 2.6 compared with <4m wild-type mice (p<0.01) and, in the case of 
>18m CCL2-/-, 2.7 times larger compared with <4m CCL2-/- animals (p<0.01). 
Findings in wild-type mice were in keeping with those published in the 
literature162. 
 
Linear regression analysis indicated that CCL2 deficiency reduces the effects of 
ageing on CNV size. These results suggest a role for CCL2 in modulating the 
neovascular response in CNV and that CCL2 may play a role in the age-
dependent increase in CNV severity. They also suggest that the subretinal 
microglia, observed to accumulate more rapidly with age in CCL2-/- mice, do not 
exert a significant pro-angiogenic effect – if they did then the effect of CCL2 
deficiency on lesion size would be attenuated with age compared with wild-type 
mice. 
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Figure 34. The effects of ageing and CCL2 deficiency on laser-induced choroidal neovascularisation 
Mean lesion size following laser-induced CNV in WT and Ccl2
-/-
 mice and the changes with age. Results are shown from the early phase of fluorescein 
angiograms at 2 weeks post-laser (mean area of hyperfluorescence +/- SEM; N refers to number of lesions) with representative images from 
angiograms shown below. Significant differences between age-matched groups are indicated with an asterisk (student t-test; p<0.05).Mean lesion size 
was significantly reduced in young Ccl2
-/-
 mice compared to age–matched wild-types with the effect preserved in 12m and >18m mice. Both wild-type 
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and Ccl2
-/-
 mice exhibited significant linear increases in lesion size with age however the trend lines suggest that the effects of ageing on CNV severity 
were attenuated in CCL2 deficient mice (linear regression; p=0.059). 
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4.4 Titration of a dose response to laser-induced CNV 
 
Laser-induced CNV has been used in conjunction with flow cytometric assays to 
establish a role for macrophages, DCs and neutrophils in CNV and to determine 
the kinetics of cell recruitment153, 156, 160. The protocols adopted by these studies 
have employed standardised laser settings to induce CNV in multiple locations 
in the mouse fundus using observation of a cavitation bubble as evidence of 
successful Bruch’s membrane rupture – the most critical aspect of laser delivery 
in this model.  
 
It is highly unlikely that the cell infiltrate associated with 3-4 lesions (the 
numbers used in the assessment of effects on CNV size) would be sufficient to 
allow for the analysis of small populations, or even be detectable using flow 
cytometry. Consequently, previous studies have delivered as many as 30-50 
burns per fundus before harvesting tissue153, 156, 160. Given the size of mature 
CNV lesions relative to the mouse fundus, the dimensions of the mouse eye 
and the degree of acute inflammation associated with CNV induction, these 
numbers were considered excessive – even after taking into account variations 
in equipment and laser settings. The number of CNV lesions per fundus was 
therefore optimised for the purpose of accurately determining the pro-
angiogenic inflammatory response in the retinae and RPE-choroids of young 
and old mice of different genotypes. The decision was made to harvest tissue at 
3 days post-CNV induction for the following reasons: previous studies have 
indicated that peak macrophage infiltration at the site of CNV takes place 2-3 
days post-induction of CNV153, 155; the start of RPE and endothelial cell 
proliferation is a feature of the day 3 timepoint and this immediately precedes 
the exponential growth of CNV. The 3 day post-induction timepoint was 
considered sufficiently removed from the initial phase of inflammation (which 
would most likely be directed at removal of apoptotic cells and necrotic tissue) 
for any pro-angiogenic infiltrate to be identified.  
 
Having decided on the timepoint of interest, two cohorts of young (<4m) wild-
type mice were subjected to laser-induction of CNV – one group receiving 10 
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burns per fundus and the other 20 burns per fundus. Retinae and RPE-choroids 
were harvested at 3 days post-laser and tissue pooled for flow cytometric 
analysis. Induction of 10 CNV lesions per fundus was found to result in a 
significant increase in the proportion of CD11b+ cells in retinal tissue without the 
significant reduction in live cell numbers observed following the induction of 20 
lesions per fundus (Figure 35). CNV induction resulted in significant increases 
in the proportion of CD11b+ cells in the RPE-choroid but without a significant 
difference between groups receiving either 10 burns or 20 burns and with no 
significant reduction in the live cell population (Figure 36). 
 
4.5 The innate immune response to laser-induced CNV 
 
Induction of CNV by laser is a well-established animal model that has proved a 
reliable method for investigating the pathology of human CNV and developing 
therapeutic modalities183. The model was therefore employed to determine 
whether the effects of CCL2 deficiency in reducing CNV size and attenuating 
the effects of ageing on CNV severity were modulated by specific innate 
immune cell populations. It was hypothesised that a failure to recruit CCR2+ 
monocytes to CNV lesions might be responsible for these effects. 
 
To determine the effects of CCL2 deficiency and age on the innate immune 
response to CNV, cohorts of wild-type and CCL2-/- mice were divided into 3 age 
groups (<4m, 12m and >18m - as for unlasered animals) and CNV induced at 
10 locations in each fundus of each animal. Retinal and RPE-choroidal tissue 
was then harvested 3 days after CNV-induction for flow cytometric analysis and 
the results compared across age groups and between age-matched lasered 
and unlasered animals.  
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Figure 35. Induction of CNV by diode laser at 10 separate locations in each fundus 
results in significant inflammatory infiltrate without excessive tissue destruction in the 
retina of <4m wild-type mice 
The percentage of CD11b
+
 cells in the retina increased at 3 days post-induction of CNV 
following delivery of either 10 or 20 burns to the fundi compared with unlasered tissue. There 
was no significant difference between groups receiving 10 or 20 burns in terms of CD11b
+
 cell 
infiltrate although data acquired following delivery of 20 burns was more variable (A). Delivery of 
20 burns to each fundus resulted in significant tissue loss in the retina with half the number of 
live cells acquired for analysis compared with fundi receiving 20 burns each. There was no 
significant difference in live cell counts between the unlasered group and that receiving 10 
burns per fundus. Retinae pooled for each animal and mean % of live cells calculated for 
CD11b
+
 population (n=9, 8 and 7 for unlasered, 10 and 20 lesions per fundus groups 
respectively); error bars=SEM. 
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Figure 36 Induction of CNV by diode laser at 10 separate locations in each fundus results 
in significant inflammatory infiltrate without excessive tissue destruction in the choroid 
of <4m wild-type mice 
The percentage of CD11b
+
 cells in the choroid increased at 3 days post-induction of CNV 
following delivery of either 10 or 20 burns to the fundi compared with unlasered tissue. There 
was no significant difference between groups receiving 10 or 20 burns in terms of CD11b
+
 cell 
infiltrate (A). Delivery of 20 burns to each fundus resulted in significant tissue loss in the choroid 
with less than half the number of live cells acquired for analysis compared with fundi receiving 
10 burns each. There was no significant difference in live cell counts between the unlasered 
group and that receiving 10 burns per fundus. Delivery of 10 or 20 burns per fundus resulted in 
significant increases in the proportion of CD11b
+
 cells in the choroid. Choroids pooled for each 
animal and mean % of live cells calculated for CD11b
+
 population (n=9, 8 and 7 for unlasered, 
10 and 20 lesions per fundus groups respectively); error bars=SEM. 
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4.5.1 The innate immune response to laser-induced CNV in 
wild-type mice 
4.5.1.1 The innate immune response to laser-induced CNV in wild-type 
mouse retina 
 
Laser-induction of CNV at 10 separate locations in the fundi of <4m wild-type 
mice resulted in significant increases in the key innate immune cell populations 
compared to age-matched unlasered tissue (t-test; p<0.05). As a proportion of 
live cells, CD11b+ cells increased significantly, suggesting recruitment of cells 
from the periphery. The sub-population found to undergo the greatest rise were 
DCs which increased more than 10-fold, with granulocytes increasing more than 
4-fold. A 3-fold increase in Gr-1- macrophages and 7-fold increase in Gr-1+ 
macrophages was also noted – these constituted a much smaller proportion of 
live cells in lasered retina.  
 
Comparison of lasered >18m wild-types with age-matched unlasered wild-type 
tissue suggested that only an increase in DC and granulocyte populations was 
reproduced post-laser in aged animals (p<0.01). Comparison of lasered and 
unlasered age-matched tissue should be viewed in the context of significant 
increases in the proportion of Gr-1- macrophages and DCs in unlasered tissue 
with age – this may account for significant increases post-laser in young groups 
for macrophage subpopulations but not in older animals. Subtraction of values 
obtained for age-matched unlasered tissue from those obtained for lasered 
tissue suggested no difference in the proportions of cells recruited to lasered 
retina between young and old wild-type animals. Statistical analysis of results 
obtained for young lasered and old lasered tissue revealed no significant 
difference in the proportions of any of the key populations with age (Figure 
37A).  
 
The data obtained from young and old lasered wild-type retina suggest the 
increase in CNV severity with age, in wild-types, is not due to differences in 
innate immune cell recruitment in the retina. 
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4.5.1.2 The innate immune response to laser-induced CNV in wild-type 
mouse RPE-choroid 
 
Significant increases in the proportion of granulocytes and DCs were seen post-
laser in <4m wild-type choroid (t-test unlasered vs lasered age-matched tissue; 
p<0.01) with a small, borderline significant increase in the Gr-1+ macrophage 
population. The granulocyte population increased 4-fold in young animals after 
lasering (Figure 38A). 
 
Only the proportion of granulocytes was significantly elevated in >18m wild-type 
RPE-choroid post-CNV induction with a 9-fold increase observed (p<0.01. 
Comparison of <4m, 12m and >18m lasered groups suggested a trend (of 
borderline significance) towards an increase in granulocyte recruitment to the 
lasered RPE-choroid (t-test <4m vs >18m lasered wild-types; p=0.06).  
 
Values obtained for age-matched unlasered tissue were subtracted from those 
obtained for lasered tissue. Findings supported the evidence for enhanced 
granulocyte recruitment to choroidal CNV with age. DC recruitment appeared 
primarily to be a characteristic of young animals with recruitment appearing to 
decline with age. 
 
The increase in granulocyte recruitment to lasered RPE-choroid may explain 
the observed increase in CNV lesion size with age in wild-types. 
 
4.5.2 The innate immune response to laser-induced CNV in 
CCL2-/- mice 
 
4.5.2.1 The innate immune response to laser-induced CNV in CCL2-/- 
mouse retina 
 
Comparisons were made between genotypes and as well as within genotypes. 
Comparisons were also made between lasered and unlasered tissue within 
these two groups (Figure 37B). 
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Laser-induction of CNV at 10 separate locations in the fundi of <4m CCL2-/- 
mice resulted only in a significant increase in the granulocyte population in the 
retina (t-test unlasered vs lasered <4m wild-type tissue; p<0.01). This was in 
contrast to wild-type retina where all populations – in particular the DC 
population – were observed to increase significantly. This suggests that CCL2 is 
not as important for the recruitment of granulocytes (most likely neutrophils) as 
it is for other innate immune cell populations in the laser CNV model. 
 
However, comparison of data obtained from lasered >18m CCL2-/- retinae with 
those obtained from unlasered >18m CCL2-/-  mice revealed a borderline 
significant increase in the proportion of DCs in lasered CCL2-/- retina with age (t-
test; p<0.06). Comparison across age groups in lasered CCL2-/- animals 
suggested that suppression of DC recruitment to lasered retinae was limited to 
animals <4m old with some recovery of recruitment by 12 months of age. As 
with wild-type animals, however, comparison of data obtained from lasered and 
unlasered age-matched tissue should be viewed in the context of significant 
increases in the proportion of Gr-1- macrophages and DCs in unlasered tissue 
with age. Compensating for these changes, however, did not alter the trend for 
an increase in DC recruitment to lasered CCL2-/- retina with age. 
 
The proportion of Gr-1- macrophages was significantly reduced in the lasered 
<4m CCL2-/- mice in comparisons made between both unlasered and lasered 
tissue in young CCL2-/- mice and comparison of young lasered tissue between 
genotypes, and was seen to increase with age whilst remaining significantly 
lower than that in >18m unlasered tissue (t-test >18m unlasered vs >18m 
lasered tissue; p=0.05). Compensating for the increase observed in unlasered 
tissue with age suggested a possible emigration of Gr-1- macrophages from the 
retina following laser in aged mice.  
 
The granulocyte response to laser-induced CNV in the retina of CCL2-/- mice 
was maintained in >18m animals but found not to be significantly different to 
that seen in the <4m age group – reinforcing the conclusion that CCL2 is not 
vital to the recruitment of granulocytes to retina in this model. 
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4.5.2.2 The innate immune response to laser-induced CNV in CCL2-/- 
mouse RPE-choroid 
 
 
Comparisons were made between genotypes and as well as within genotypes. 
Comparisons were also made between lasered and unlasered tissue within 
these two groups (Figure 38B). 
 
DC and macrophage recruitment recruitment in lasered <4m CCL2-/- RPE-
choroid was impaired (t-test <4m unlasered tissue vs. <4m lasered tissue). 
There was a doubling of the granulocyte population after lasering young 
animals that was of borderline significance (t-test <4m unlasered tissue vs. <4m 
lasered tissue; p=0.08). This pattern was largely maintained in aged animals - 
comparison of >18m unlasered mice with >18m lasered mice revealed that DC 
and macrophage recruitment remained impaired whilst a 5-fold rise in the 
proportion of granulocytes was observed (t-test >18m unlasered tissue vs. 
>18m lasered tissue; p<0.01). 
 
As in retina, proportions of Gr-1+ and Gr-1- macrophages were seen to increase 
significantly in lasered RPE-choroid with age (t-test <4m lasered vs. >18m 
lasered tissue; p<0.01 for both populations). Numbers were small, however, 
and taking into account populations in unlasered tissue revealed that 
recruitment remained unaltered with age. 
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Figure 37 Gr-1
-
 monocyte/macrophages and DC recruitment to the retina following laser-induced CNV is impaired in young CCL2
-/-
 mice but 
DC recruitment appears to increase with ageing 
Charts illustrating the key innate immune cell populations in wild-type (A) and CCL2
-/-
 mouse retina (B). Changes with age in unprocedured eyes are 
shown on the left and the changes with age in eyes 3 days after induction of 10 CNV lesions by diode laser are shown in the middle panels. Charts with 
corrections for the levels of innate immune cell populations present in the retina prior to lasering are shown on the right (percentages of cells in age-
matched unlasered tissue subtracted from percentages of cells in lasered tissue). Comparison of age-matched unlasered and lasered tissue revealed a 
significant increase in all populations in young wild-type retina post-laser but only granulocytes and DCs in aged animals. Only the proportion of 
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granulocytes was increased post-laser in young CCL2
-/-
 mice suggesting that granulocyte recruitment is not as dependent on CCL2 as other innate 
immune cell populations. Some recovery of DC recruitment to 12m and >18m lasered retina in CCL2
-/-
 animals was noted in comparisons with age-
matched unlasered tissue. Significant increases in Gr-1
-
 macrophage populations with age in lasered CCL2
-/-
 retina (t-test <4m vs >18m) most likely 
reflect underlying increases in these populations with age in unlasered tissue – correction for this suggested that laser induction of CNV resulted in net 
emigration of this population from the retina in the aged mice. Tissue pooled from each animal and mean % of live cells calculated for each population. 
N numbers for unlasered tissue as for Figure 29A and B. For lasered tissue: n=8, 4 and 7 for wild-type mice aged <4, 12m and >18m respectively and 
n=10, 5 and 6 for CCL2
-/-
 mice aged <4m, 12m and >18m respectively. P values to the right of each plot are for t-tests comparing data obtained for <4m 
and >18m tissue. Error bars=SEM. 
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Figure 38. DC recruitment/maturation in the RPE-choroid following laser-induced CNV is impaired in young CCL2
-/-
 mice and enhanced 
granulocyte recruitment may account for increased lesion size with age in both wild-type and CCL2-deficient animals. 
Charts illustrating the key innate immune cell populations in wild-type (A) and CCL2
-/-
 mouse RPE-choroid (B). Changes with age in unprocedured eyes 
are shown on the left and the changes with age in eyes 3 days after induction of 10 CNV lesions by diode laser are shown in the middle panels. Charts 
with corrections for the levels of innate immune cell populations present in the RPE-choroid prior to lasering are shown on the right (percentages of cells 
in age-matched unlasered tissue subtracted from percentages of cells in lasered tissue). Comparison of age-matched unlasered and lasered tissue 
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revealed a significant increase in granulocytes and DCs in young wild-type RPE-choroid post-laser (p<0.01) but only granulocytes in aged animals 
(p<0.01).The granulocyte population was seen to increase 4-fold in young WT mice and to increase 9-fold in aged WT mice post-laser. No significant 
difference in DC and macrophage/monocyte populations was observed post-laser in young CCL2
-/-
 mice in comparison with age-matched unlasered 
tissue; a borderline significant doubling of the granulocyte population was observed, however (p=0.08). A significant increase in the proportion of 
granulocytes only was observed in aged CCL2
-/-
 mice post-laser (5-fold increase; p<0.01). Tissue pooled from each animal and mean % of live cells 
calculated for each population. N numbers for unlasered tissue as for Figure 30A and B. For lasered tissue: n=9, 4 and 6 for wild-type mice aged <4, 
12m and >18m respectively and n=8, 5 and 6 for CCL2
-/-
 mice aged <4m, 12m and >18m respectively. P values to the right of each plot are for t-tests 
comparing data obtained for <4m and >18m tissue. Error bars=SEM. 
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4.6 The immunophenotype of a model of spontaneous 
choroidal neovascularisation 
 
Confirmation of the involvement of specific immune cell populations in choroidal 
neovascularisation was sought through analysis of the innate immune cell 
populations present in the spleen, retina and RPE-choroid of <4m JR5558 mice. 
These animals develop CNV at multiple locations in the posterior fundus at p10-
12 before expiring from leukaemia at approximately 3 months of age184. Retinal 
neovascularisation, though not choroidal neovascularisation, has been 
described in cases of acute myeloid leukaemia (in the absence of radiotherapy), 
chronic myelocytic leukaemia and acute lymphocytic leukaemia185. The 
underlying genetic defect in JR5558 mice is unknown. Given the significant 
increases in DCs and granulocytes associated with CNV at the 3 day timepoint 
in the laser model it was hypothesised that these cells might be implicated in 
CNV in JR5558 mice.  
 
Flow cytometric analysis of splenocytes obtained from 2m old JR5558 mice 
revealed significant increases in the proportions of Gr-1+ and Ly6CHigh (CCR2+) 
F4/80+ cells compared with young adult wild-type mice – these populations 
were increased by as much as 14-fold (t-test p<0.01). A small, borderline 
significant increase in the proportion of Gr-1- macrophages was also observed 
but aside from this no other changes in the patterns of innate immune cell 
distribution in JR5558 mouse spleen were found.  
 
In keeping with the above findings in the periphery, the levels of Gr-1+ 
macrophages in JR5558 RPE-choroid were double that in young wild-types (t-
test; p<0.01), however no changes were observed in any of the other key 
populations in this tissue. In JR5558 mouse retina, the granulocyte population 
was found to be significantly reduced whilst the proportion of DCs was more 
than double that observed in wild-type tissue (t-test; p<0.01). 
Macrophage/monocyte populations in retina were unchanged. 
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The above findings support evidence derived from application of the laser 
model in young wild-type and CCL2-/- animals for a role for DCs in pathological 
neovascularisation in the eye. The absence of any increase in this population in 
the RPE-choroid was unexpected, however, and it is possible that the Gr-1+ 
macrophage population in the RPE-choroid, which is greatly elevated, is the 
main driver of choroidal neovascularisation in this model. 
  
The dominance of the Ly6CHigh (CCR2+) monocyte population in JR5558 spleen 
(quite the reverse of findings in wild-type tissue) may explain the increase in Gr-
1+ macrophages in the RPE-choroid in these mice. The high levels of Ly6CHigh 
(CCR2+) monocytes in JR5558 spleen may also explain the increased levels of 
DCs in their retinae. Given that CCR2+ monocytes are known precursors of 
inflammatory DCs one might hypothesise that a higher ratio of CCR2+ 
monocytes to CCR2- monocytes in the periphery (as occurs in younger wild-
type and CCL2-/- mice as well as JR5558 mice) favours higher levels of DCs in 
the tissues. An alternative explanation for the elevated proportion of DCs in the 
retinae of these mice is that this is a reactive phenomenon to choroidal 
neovascularisation and inflammation in much the same way that levels of DCs 
in the retina rise with age. In any case it is unlikely that retinal DCs play a minor 
role in the neovascular response in this model – whether a pro- or anti-
angiogenic one remains to be confirmed. 
 
The nature of the choroidal neovascularisation observed in JR5558 mice and 
that following laser-induced rupture of Bruch’s membrane are clearly not directly 
comparable – the acute inflammation associated with neovascularisation in the 
laser model is typified by an increase in granulocytes in the retina whereas the 
opposite is seen in JR5558 mice. Equally, higher levels of DCs are seen in the 
retinae of aged wild-type and CCL2-/- mice yet this is not associated with the 
spontaneous neovascularisation observed in the JR5558 model. This suggests 
that the DCs recruited following laser-induction of CNV have a markedly 
different phenotype to those seen to accumulate with age in the retina and 
RPE-choroids of wild-type and CCL2-/- animals. Analysis of the innate immune 
cell populations in JR5558 mice is nevertheless relevant since the results 
support the involvement of DCs and Gr-1+ macrophages in pathological 
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neovascularisation and indicate a role for changes in peripheral innate immune 
cell populations in driving this process. 
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Figure 39 The pattern of innate immune cell distribution in the spleen, retina and RPE-choroid of JR5558 mice 
The proportion of CD11b
+
cells in young JR5558 spleen was significantly increased (A). Most of these cells were Gr-1
+
 macrophages/monocytes. 
Separation of monocyte subsets based on levels of Ly6C expression revealed a predominance of Ly6C
High 
(CCR2
+
) cells - whilst increases in all 
monocyte populations were observed, the Ly6C
High
 (CCR2
+
) population was found to be 9-fold greater in size than in young wild-type spleen (t-test; 
p<0.01). The pattern of monocyte distribution in the spleen was associated with changes in innate immune cell populations in both the RPE-choroids 
and retinae of JR5558 mice compared to wild-type age-matched animals. The proportion of DCs in JR5558 retina was more than double that in wild-
type tissue (t-test; p<0.01) and the granulocyte population significantly reduced (B). In RPE-choroid levels of Gr-1
+
 macrophages were more than 
double in JR5558 mice, in keeping with findings in the spleen (t-test; p<0.01). Asterisks indicate significance of p<0.01. 
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4.7 Discussion 
 
The purpose of the work described in this chapter was to identify whether 
changes in innate immune cell populations associated with CNV lesions, or in 
the periphery, might explain the increased severity of CNV with age and 
whether CCL2 has a role in this process. 
 
To identify the key innate immune cell populations recruited to choroidal 
neovascular lesions in the mouse eye, CNV was induced in young adult wild-
type eyes and the innate immune cell populations in retina and RPE-choroid 
analysed 3 days later (at the time of peak recruitment of these populations). All 
populations in the retina were seen to increase significantly after CNV induction 
– in particular those of granulocytes and DCs (Figure 37). Granulocytes and DC 
populations were also increased in the choroid post-laser (Figure 38). 
Interpreting these data required that age-related changes in unlasered tissue be 
taken into account. Findings were in keeping with published work suggesting 
that DCs and granulocytes have a role in pathological neovascularisation in the 
eye. It has previously been demonstrated that immature DCs (CD11c+ MHC 
class IILow cells) expressing VEGFR2 peak between 2 and 4 days post-induction 
of CNV by laser. Immature DCs have been shown to be closely involved with 
the developing neovascular complex and when transplanted intravenously are 
capable of augmenting CNV growth160. Other work has demonstrated that 
neutrophil recruitment peaks at 48 hours post-laser-induction, with neutrophils 
the predominant cell type at this timepoint153. In this thesis, granulocytes were 
found to be recruited in equal numbers to DCs at the 3 day timepoint, a finding 
which would be in keeping with the expected kinetics of innate immune cell 
recruitment.  
 
The chemokine CCL2 is upregulated in the aged retina and choroid and is 
central to innate immune cell recruitment124. It was hypothesised that a 
deficiency in CCL2 might impair recruitment of innate immune cell populations 
expressing CCR2 and attenuate the neovascular response in young mice. It 
was also hypothesised that CCL2 deficiency would limit the increase in CNV 
lesion size observed with ageing in wild-types. To test the first of these 
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hypotheses, young adult wild-type and CCL2-/- mice were subjected to induction 
of CNV by laser and the mean lesion size in each group determined by 
fluorescein angiography 2 weeks later. The mean CNV lesion in <4m CCL2-/- 
mice was found to be 42% smaller (t-test; p<0.01) than that in age-matched 
wild-type mice (Figure 34). The innate immune cell populations recruited to 
lesions in <4m CCL2-/- mice were then determined as they had been for young 
adult wild-type mice using flow cytometry. The smaller mean CNV lesion size in 
CCL2-deficient mice was found to be associated with an impaired recruitment of 
DCs and macrophages to both retina and RPE-choroid. A two-fold increase in 
the granulocyte population in the RPE-choroids <4m CCL2-/- mice post-
induction of CNV was identified - this was of borderline significance (unlasered 
vs. lasered tissue; p=0.08). The preservation of granuloctyte recruitment in 
CCL2-/- mice suggests that CCL2 is important for the recruitment of DCs and 
monocyte/macrophages to CNV lesions. It also suggests that the level of 
granulocyte recruitment in CCL2-deficient mice, though half that seen in wild-
types, is still sufficient to drive a reduced neovascular response and that these 
cells are important in CNV development. The maintenance of granulocyte 
recruitment in the absence of CCL2 has also been demonstrated in CCR2-/- 
mice70, 72. 
 
The possibility that CCL2 deficiency in CCL2-/- mice would result in a failure to 
recruit CCR2+ monocytes – thereby confirming the pro-angiogenic or anti-
angiogenic nature of this population - was investigated. Neither the CCR2+ nor 
the CCR2- monocyte populations (as determined using the Gr-1 marker) was 
increased in lasered RPE-choroids derived from either wild-type or CCL2-
deficient mice. This suggests that these monocyte populations do not have an 
important role in CNV development, at least at the 3 day timepoint.  However, a 
failure to increase the proportion of not only Gr-1+ macrophages but also Gr-1- 
macrophages did appear to be a feature of the retinal microenvironment 3 days 
post-laser induction of CNV in young CCL2-/- mice (reductions in the former 
population did not quite achieve significance however; t-test of lasered wild-type 
vs lasered CCL2-/- mouse retinae; p=0.065). On this evidence, CCL2 deficiency 
would in some way appear to affect not only the recruitment of CCR2+ 
monocytes but also, rather unexpectedly, CCR2- monocytes to the retina and 
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consequently it cannot be said with confidence whether one subset is more pro-
angiogenic than the other. One possible explanation for this is that monocyte 
subpopulations were sequentially recruited, as has been described in other 
models. In the healing mouse myocardium post-infarction, for example, 
recruitment of CCR2+ monocytes with phagocytic, pro-inflammatory capacities 
precedes the arrival of CCR2- monocytes with more pro-angiogenic, ‘healing’ 
properties95. It is therefore possible that failure to recruit CCR2+ monocytes in 
young CCL2-/- mice at 1 or 2 days post-laser resulted in a subsequent failure of 
CCR2- monocyte recruitment at 3 days post-laser – analysis of these 
populations at these timepoints would be necessary to confirm this. It should be 
noted that use of the F4/80 marker did not allow for a distinction between 
proliferating microglia and recruited monocytes. Microglial proliferation and 
migration in response to CNV induction by laser has been demonstrated in a 
number of studies previously but the extent to which this behaviour influences 
CNV development has yet to be determined186. A further caveat to those data 
derived from use of the laser model was the observation that raised levels of 
CCR2+ monocytes (Gr-1+ or Ly6CHigh F4/80+ cells) in the spleens of JR5558 
mice, together with raised levels of CCR2+ monocytes in the choroid and DCs in 
the retina, were associated with spontaneous CNV. The model is not directly 
comparable with the laser-induced CNV model, however, and the cell 
populations involved in acute and chronic neovascular responses are likely to 
be very different. Nevertheless, results from analysis of JR5558 tissue do 
suggest an important role for CCR2+ monocytes in the development of CNV. 
 
To determine whether CCL2 deficiency attenuates the effects of ageing on CNV 
lesion size, wild-type and CCL2-/- mice aged 12 months and >18 months were 
subjected to laser induction of CNV and lesion sizes determined at 2 weeks 
post-laser. Results were compared with those obtained from <4 month old 
animals. A linear increase in mean lesion sizes in both groups was observed 
with age. Lesion sizes in aged animals were more than double those observed 
in young animals, regardless of genotype. The effect of CCL2 deficiency in 
attenuating CNV was preserved with ageing and linear regression analysis 
indicated that the protective effect of CCL2 deficiency was increased with age. 
Flow cytometry of retinal and RPE-choroidal cell suspensions derived from 
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lasered 12m and >18m mice was performed to determine whether changes in 
recruited innate immune cell populations might account for the differences in 
lesion sizes. Recruitment of key populations to lasered retina appeared to be 
unchanged in wild-type mice with age. DC recruitment to lasered CCL2-/- retinae 
increased with age whilst an emigration of Gr-1- macrophages also appeared to 
occur in older animals. Analysis of RPE-choroid, perhaps of more relevance 
given the inclusion of CNV lesions, suggested that recruitment of granulocytes 
to lasered choroid more than doubled with age in both wild-type and CCL2-/- 
mice. The possibility that enhanced granulocyte recruitment with age might 
explain the increases in lesion size with age for each genotype was considered, 
however flow cytometry results obtained from 12m wild-type mice were not 
entirely in keeping with the linear changes in lesion size. Granulocyte 
recruitment to wild-type choroid was seen to increase 4-fold in young wild-types, 
3-fold in 12m mice, and 9-fold in >18m mice. Granulocyte recruitment to the 
choroids of CCL2-/- mice increased by 2-fold in young animals post-laser, over 
3-fold in 12m mice and 5-fold in aged mice. The numbers of circulating 
neutrophils and their precursors are not thought to be affected by ageing in 
humans (this would fit with unchanged numbers found in the spleens of wild-
type and CCL2-/- mice). However, evidence suggests that neutrophils derived 
from aged humans exhibit impaired chemotactic capacities - this would appear 
not be the case in mice in the laser-induced CNV model. Infiltrated neutrophils 
from patients with chronic inflammatory lung diseases and rheumatoid arthritis 
highly express chemokine receptors such as CCR2 on their surfaces that are 
absent or only marginally expressed on circulating neutrophils85. Similarly in 
vivo work in models of vasculitis has demonstrated that neutrophils express 
CCR2 in adjuvant-immunised but not naive rats and constitute the dominant 
population recruited by CCL2. This raises the possibility that neutrophil 
recruitment to aged or chronically inflamed retina and choroid may also be 
enhanced. Neutrophils in the elderly also adopt a low-grade inflammatory status 
in the absence of stimulation and release more elastase on activation. The 
release of more elastase by neutrophils recruited to Bruch’s membrane could 
potentiate a choroidal neovascular response in the aged126. 
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The possibility that increased DC populations observed in unlasered tissue with 
age might correlate with increased CNV lesion size was considered. This theory 
is not supported by the observation that the size of DC populations in the retina 
and RPE-choroid of young CCL2-/- mice is significantly higher than in young 
wild-types yet CNV size is significantly smaller. However, overall, innate 
immune cell numbers are increased in the unlasered tissue of both genotypes 
with age and this suggests underlying damage that renders the eye more 
susceptible to laser-induction of CNV. An untested observation was that 
cavitation bubbles arising from delivery of diode laser in older animals were 
consistently much larger than in younger ones suggesting that Bruch’s 
membrane is more susceptible to rupture and that CNV might spread in the 
subretinal plane with more ease in aged eyes. This may be because the 
accumulation of subretinal microglia with age disrupts the interaction between 
RPE and neuroretina. It is likely that the DCs which accumulate with age in 
retina and RPE-choroid exhibit a more ‘migratory’ phenotype than the 
population recruited to CNV lesions which are most likely to be ‘inflammatory’ 
DCs. A more detailed phenotypic characterisation would be necessary to 
confirm this but these two DC subsets probably have very different pro-
angiogenic capacities. Having demonstrated the infiltration of DCs into laser-
induced CNV lesions in CX3CR1GFP/+, Eter et al. concluded that these were of a 
‘conventional’ (cDC) phenotype based on their expression of CD11b, however a 
high level of CD11b expression is also a feature of inflammatory DCs and 
consequently the marker cannot be used to distinguish the two populations164, 
186. 
 
Finally, the possibility that the 3-fold increase in CNV lesion size with age in 
both genotypes might be explained by similar 3-fold increases in Gr-1- 
monocyte/macrophage and DC populations in the spleens of CCL2-/- and wild-
type mice was considered (Figure 31). The finding that DC populations in the 
spleens of CCL2-/- mice were smaller by a factor of 2 and those of Gr-1- 
macrophages smaller by a factor of 3 compared with age-matched wild-types, 
correlated with the consistently smaller CNV lesion sizes observed in CCL2-
deficient animals. It has also recently been established that post-ischaemic 
neovascularisation is highly dependent on monocyte levels in the bloodstream 
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and that CCL2/CCR2 signalling is important in regulating circulating levels of 
both CCR2+ and CCR2- monocytes (it is postulated that the impact of disrupted 
CCL2/CCR2 signalling on CCR2- cells is a downstream consequence of a 
primary effect on CCR2+ cells) 187, 188.  However, the age-related changes in 
systemic innate immune cell populations were not reflected in changes to the 
same populations recruited to CNV lesions post-laser. DC recruitment to 
lasered choroid, if anything, declined with age in wild-type and CCL2 deficient 
mice and Gr-1- macrophage recruitment appeared largely unchanged. So whilst 
changes in innate immune cell populations in the spleens of wild-type and 
CCL2-/- mice underwent consistent changes with age it was not possible to infer 
a causative effect where increases in CNV lesion size were concerned. 
Interestingly, whilst granulocyte recruitment to lasered choroids was increased 
with age, no significant increase in granulocyte populations in spleens was 
seen. 
 
In summary, granulocytes and DCs were identified as the main innate immune 
cell populations associated with laser-induced choroidal neovascularisation at 
the 3 day timepoint in mice. The almost 3-fold increase in CNV size with age 
observed in wild-type and CCL2-/- mice might be explained by an increased 
propensity to recruit granulocytes to RPE-choroidal tissue with age, but these 
two factors could not be claimed to correlate closely. A 3-fold increase in Gr-1- 
macrophage and DC populations with age in unprocedured wild-type and CCL2-
/- mice spleens did correlate closely with increased CNV size but this was not 
reflected in changes in populations recruited to CNV lesions. Increased severity 
of CNV with age may therefore be a function of local anatomical changes (or a 
combination of factors including cytokine expression). CCL2 deficiency in young 
mice resulted in a significantly reduced proportion of Gr-1- 
monocyte/macrophages in retina in the acute phase following rupture of Bruch’s 
membrane and this correlated with smaller CNV.  CCL2 deficiency also results 
in the build-up of a Gr-1- resident macrophage population with age - were this 
population to exert a protective effect it might explain the slower increase in 
CNV size with age in CCL2-/- mice. Finally, analysis of innate immune cell 
populations in the JR5558 model of spontaneous CNV indicates a particular 
role for CCR2+ monocytes in pathological neovascularisation in association with 
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DCs in this model and provides further evidence to support the hypothesis that 
shifts in innate immune populations in the periphery are capable of influencing 
the pattern of innate immune cell distribution in the eye.
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Chapter 5: Manipulation of innate immune cell 
populations as a means of attenuating 
pathological neovascularisation 
 
The work in this chapter explores the effects of inhibition of tyrosine kinase 
receptors on innate immune cell populations in the context of experimental 
treatments for CNV. It also explores the effects of direct manipulation of innate 
immune cell activation on CNV growth through activation of the CD200R 
signalling pathway and the relationship to cell phenotype. 
 
VEGF-A antagonists such as ranibizumab and bevacizumab improve vision in 
wet AMD by reducing the excessive vascular permeability of choroidal 
neovascular membranes. They do not, however, cause existing CNV to regress 
and the reduction of treatment below a critical level results in resumption of 
CNV growth and leakage17. It is possible that other VEGF family members and 
growth factors, such as platelet-derived growth factor B (PDGF-B) – known to 
promote pericyte survival - have a role in sustaining neovascular membranes. 
Manipulation of these other pathways may therefore prove useful in the 
development of more effective therapies for both wet AMD and 
neovascularisation in tumours. Consequently, a number of compounds have 
been developed which target the kinase activity of tyrosine kinase-containing 
receptors – of which VEGF receptors (VEGFR) and PDGF receptor (PDGFR) 
are closely related examples. Members of the VEGF family bind to three 
tyrosine kinase receptors: VEGFR-1, VEGFR-2 and VEGFR-3. Both VEGFR-1 
and VEGFR-2 are expressed on vascular endothelial cells, monocytes, 
macrophages and haemopoietic stem cells. Receptor tyrosine kinase inhibitors 
(RTKIs) may therefore have intended or unintended effects on innate immune 
cell populations when employed in the treatment of wet AMD or other conditions 
where neovascularisation plays a prominent role189. 
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The potential for receptor kinase inhibition in the treatment of CNV was 
explored using pazopanib, a small-molecule kinase inhibitor that blocks 
VEGFR1, VEGFR2 and VEGFR3 with 50% inhibitory concentration of 10nM, 
30nM and 47nM respectively. It is also active, at higher concentrations, against 
PDGFR-B and c-Kit (a cytokine receptor expressed on the surface of 
haemopoietic stem cells), fibroblast growth factor receptor 1 (FGFR1), FGFR3 
and c-fms (another tyrosine kinase receptor the ligand for which is macrophage 
colony stimulating factor, also known as M-CSF or CSF-1)190.  
 
Pazopanib has been demonstrated previously to be effective in inhibiting the 
development of CNV, causing the regression of established neovascular 
membranes following oral delivery and suppressing the development of CNV by 
as much as 93%190. An initial experiment was therefore performed to confirm 
the suppressive effect of pazopanib delivered by oral gavage in the mouse 
model of laser-induced CNV. Flow cytometric analysis of retinal and RPE-
choroidal tissue harvested at 3 days post-laser induction of CNV in pazopanib-
treated mice was undertaken in order to determine whether local innate immune 
cell populations might be affected by tyrosine kinase receptor inhibition and 
whether any changes might correlate with the effect of the drug on lesion size. 
Evidence is emerging to support a role for myeloid-derived innate immune cells 
in the regulation of tumour angiogenesis, growth and metastasis – in particular, 
research has focused on M1- and M2-polarised macrophages, Tie-2 expressing 
monocytes, myeloid-derived suppressor cells (defined as CD11b+ Gr-1+) and 
tumour-associated neutrophils. Other research has indicated the potential for 
RTKIs to promote tumour metastasis through their inhibition of pericyte 
recruitment to tumour vasculature. Further work was therefore undertaken to 
determine the effects of pazopanib on peripheral innate immune cell 
populations and provide information regarding its mechanism of action. 
Therapeutic doses of pazopanib were administered by oral gavage over a 17 
day period to determine the response to laser-induced CNV and spleens from 
these animals were then harvested for flow cytometric analysis189.  
 
Pazopanib has been observed to remain associated with the uveal tract in 
rodents after quantitative whole body autoradiography experiments which may 
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be due to melanin binding (Figure 49; personal communication: Peter Adamson, 
GlaxoSmithKline). Experiments were therefore conducted to determine whether 
bound pazopanib in the uveal tract might have biological activity in the absence 
of detectable concentrations in the plasma. Were pazopanib bound within the 
uveal tract demonstrated to have therapeutic effects on CNV, this might allow 
for the development of reduced dosing regimens of the drug.  
 
The potential to treat choroidal neovascularisation through the induction of 
specific regulatory pathways was investigated. Given the effect of CCL2-
deficiency on lesion size in CCL2-/- mice subjected to laser-induction of CNV, it 
was hypothesised that therapeutic manipulation of monocyte/macrophage 
activation might have a beneficial effect on the neovascular response. The 
membrane glycoprotein CD200 receptor (CD200R) is expressed on myeloid 
cells and T and B cell subsets, its ligand CD200 is a also a membrane 
glycoprotein that is expressed on a wide variety of cell types including lymphoid 
cells, neurones (such as those in the CNS and retina) and endothelial cells. 
Ligation of CD200R by CD200 has been demonstrated to inhibit classical 
monocyte/macrophage activation and suppress inflammation in a number of 
models (such as the experimental autoimmune uveitis and experimental 
autoimmune encephalomyelitis models) and CD200R signalling is down-
regulated in lesions associated with multiple sclerosis, Parkinson’s and 
Alzheimer’s disease110, 191-194. Use of a rat monoclonal antibody that was 
agonistic for mouse CD200R allowed the effects of myeloid cell manipulation on 
CNV to be studied without the potentially confounding effects associated with 
use of more broad spectrum drugs such as pazopanib (especially given that 
monocyte/macrophages express VEGF receptors). The effect of an agonist for 
CD200R on CNV lesion size, following both intraperitoneal and intravitreal 
delivery of CD200R agonist was established. Changes in the proportions of 
innate immune cell populations in the retina and choroid were then determined 
using flow cytometry and immunohistochemistry. 
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Figure 40 Pazopanib is retained in the uveal tract of rodents in the absence of detectable 
concentrations in the plasma 
Whole body radiography of a rat following a single dose (100mg/kg) of pazopanib by oral 
gavage. Pazopanib radioactivity was observed in melanin-containing tissues including the uveal 
tract up to 35 days after delivery (A). Plasma concentrations following a single oral 
administration of pazopanib (10mg/kg or 300mg/kg) to 10wk old C57Bl/6NCrl mice (n=15/dose 
group). Levels of drug in the 300mg dose group approached limits of detection at 102 hours and 
were undetectable in the 10mg dose group at >72 hours post-delivery (B). Data reproduced by 
kind permission GSK Plc. 
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In summary, confirmation of the effect of receptor tyrosine kinase inhibition on 
laser-induced CNV was sought – therapeutics targeting multiple pathways 
simultaneously may prove the most effective way of controlling CNV in patients 
not only via their direct effects on endothelial cell proliferation but also on the 
recruitment and activation of innate immune cells. Such an approach may come 
with an increased risk of unwanted side effects, particularly on innate immune 
cell populations. Experiments were therefore designed to identify the effects of 
receptor tyrosine kinase inhibition on innate immune cell populations both in the 
eye and in the periphery. The possibility of using pazopanib’s property of 
retention in the uveal tract to minimise dose was also explored. Finally, the 
potential for modulating monocyte/macrophage activation directly as a means of 
suppressing CNV was explored using an agonist for the CD200 receptor 
delivered both systemically and locally. The effect of such an approach on the 
local innate immunophenotype was also determined. 
 
 
5.1 The effect of multi-target kinase inhibition in the 
laser-induced CNV model 
 
Based on published data on the pharmacokinetics of orally administered 
pazopanib190, young adult wild-type mice were divided into two cohorts with one 
group receiving vehicle only and the other a dose of 10mg/kg pazopanib twice 
daily by oral gavage for a total of 22 days, beginning 5 days before induction of 
CNV. Fundus fluorescein angiography was performed at 1 week and 2 weeks 
post-induction of CNV by diode laser and the results of the early phase of the 
angiograms analysed to determine the mean CNV lesion size in each cohort. 
 
The results of early phase angiographic analysis revealed significant reductions 
in mean lesion size of 54% at 1 week post-induction of CNV in animals 
receiving pazopanib compared to vehicle only, and 60% at 2 weeks post-
induction of CNV (t-test; p<0.01 at both timepoints; Figure 41). This effect 
compared favourably with published data indicating a 93% reduction in mean 
area of CNV at 2 weeks post-laser in wild-type mice receiving a dose of 10  
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Figure 41 Pazopanib delivered by oral gavage results in a significant reduction in mean 
lesion size at 1 and 2 weeks post-induction of CNV by diode laser 
Results of early phase angiographic analysis in animals receiving either pazopanib (20mg/kg) or 
vehicle only by oral gavage for a period before and after induction of CNV by diode laser. Figure 
shows experimental timeline (A) and mean lesion size in each experimental group at 1 week 
and 2 weeks post-induction of CNV with representative angiographic images below (B). 
Significant reductions in mean lesion size of 54% at 1 week post-induction of CNV and 60% at 2 
weeks post-induction of CNV were observed in animals receiving pazopanib compared to 
vehicle only, (t-test; p<0.01 at both timepoints; error bars=SEM). 
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times higher (100mg/kg twice daily by oral gavage). The experimental protocol 
also differed from published work in that lesion size was determined by fundus 
fluorescein angiography as opposed to the analysis of choroidal flat-mounts 
obtained from fluorescein-labelled dextran-perfused animals190. 
5.2 Systemic delivery of pazopanib results in altered 
proportions of peripheral innate immune cell 
populations 
 
To determine the effect of pazopanib on peripheral innate immune cell 
populations, spleens were harvested from young adult mice that had received 
either vehicle only or 10mg/kg pazopanib twice daily for a total period of 22 
days. These mice underwent laser induction of CNV at three locations in each 
fundus at 5 days and fundus fluorescein angiography at 1 and 2 weeks post-
laser. A washout period of three days following the last set of angiograms was 
included in the protocol to allow time for residual fluorescein (which is highly 
water soluble) to make its way out of system so that this did not interfere with 
flow cytometric analysis. 
 
Splenocyte suspensions were stained for dead cells, CD11b, F4/80, Gr-1, Ly6C 
and CD11c as previously described. A significant reduction in the proportion of 
CD11b+ Gr-1+ cells was noted in the spleens of animals receiving pazopanib (t-
test; vehicle only vs. pazopanib; p<0.05), based on their lack of F4/80 
expression these cells appeared to be granulocytes. No significant differences 
were observed in any other populations though trends towards reductions in 
levels of Gr-1+ macrophages and Ly6CLow monocytes were seen. 
 
The reduction in Cd11b+ Gr-1+ cells in the spleens of pazopanib-treated animals 
is suggestive of an effect on myeloid-derived suppressor cells (MDSCs). 
MDSCs may be isolated from spleen, bone marrow and tumour infiltrate and are 
of interest in tumour biology because of their ability to promote tumour 
progression by rendering tumours refractive to anti-VEGF treatments176. 
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Figure 42 Prolonged systemic delivery of pazopanib is associated with a significant reduction in the proportion of granulocytes in the spleen 
The proportions of innate immune cell subpopulations were determined in splenocyte suspensions obtained from young adult wild-type mice receiving 
either 10mg/kg pazopanib bd or vehicle only by oral gavage for a total of 22 days; mice were subjected to laser induction of CNV in three locations in 
the fundus after 5 days of oral gavage and underwent fundus fluorescein angiography subsequently (see Figure 41A). No significant differences were 
observed between any of the key populations except granulocytes which were significantly lower in animals receiving pazopanib (mean % live cells +/- 
SEM). N=5 for pazopanib-administered animals and N=5 for vehicle-administered animals. 
0.00
1.00
2.00
3.00
4.00
5.00
6.00
7.00
8.00
9.00
CD11b+ 
only
GR1+ 
F4/80-
GR1+ 
F4/80+
GR1-
F4/80+
CD11c+ 
GR1-
F4/80 Low 
Ly6C High
F4/80 Low 
Ly6C Mid
F4/80 Low 
Ly6C Low
CD11c-
F4/80- Gr1-
Ly6C-
%
 L
iv
e
 c
e
ll
s
 (
m
e
a
n
)
CD11b+ sub-population 
p=0.04
NS NS NS
Pazopanib-administeredVehicle-administered
Chapter 5  Manipulating innate immune cells 
183 
 
5.3 The effect of multi-target kinase inhibition on innate 
immune cell populations in the retina and choroid 
 
 
Previous work had demonstrated that all key innate immune populations were 
increased post-induction of CNV in wild-type mouse retina with similar 
increases observed in RPE-choroid (Gr-1- macrophages excepted in the case of 
lasered RPE-choroid). Laser-induction of CNV in the CCL2-/- mouse had 
revealed that a failure of DC and Gr-1- monocyte/macrophage recruitment might 
be an important factor in the reduced levels of CNV in this model (Figure 37 and 
Figure 38). To determine the effect of pazopanib on innate immune cell 
populations in retina and RPE-choroid post-induction of CNV, young wild-type 
mice were divided into two cohorts with one group receiving 10mg/kg pazopanib 
bd from 1 day pre-laser and the other receiving vehicle only. Tissue was 
harvested 3 days post-induction of CNV by diode laser, when macrophage 
infiltration is at its peak, and cell suspensions were subjected to flow cytometric 
analysis. CNV was induced at 10 separate locations in each fundus. 
 
Analysis of cell populations derived from pazopanib-treated animals revealed 
that the proportion of Gr-1+ monocyte/macrophages in the retinae of these mice 
was more than double that observed in those receiving vehicle only (t-test; 
p<0.05). There was also a trend towards an increase in the fraction of 
granulocytes and a more subtle reduction in the proportion of Gr-1- 
monocyte/macrophages in the retinae of pazopanib-treated animals. Analysis of 
RPE-choroidal cell suspensions revealed no significant differences between 
pazopanib and vehicle-treated animals although there was a trend towards 
increased levels of Gr-1+ monocyte/macrophages and a reduction in levels of 
DCs in the pazopanib-treated group (Figure 43). 
 
These results suggest a role for pazopanib in modulating 
monocyte/macrophage responses to laser-induced CNV, particularly in the 
retina. These data also provide additional evidence in support of a pro-
angiogenic role for Gr-1- (CCR2-) monocytes in the acute phase of pathological 
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neovascularisation in the eye that may be countered by measures favouring 
recruitment of Gr-1+ (CCR2+) monocytes. 
 
5.4 Retention of pazopanib in the uveal tract may be 
exploited to minimise systemic exposure to drug 
 
Pazopanib, administered by oral gavage or by periocular injection, accumulates 
in the uveal tract which is hypothesised to occur through an ability to bind ocular 
melanin (personal communication; Peter Adamson, GSK). Flow cytometric 
analysis of innate immune cell populations derived from the pazopanib-treated 
animals indicated that the drug appeared to have an effect on the proportions of 
innate immune cells in the retina and RPE-choroid following induction of CNV 
and also on myeloid-derived cell populations in the spleen following a protracted 
course of administration. It was hypothesised that melanosomes in the retinal 
pigment epithelium might act as a slow-release depot for pazopanib. An 
experiment was designed with the aim of establishing the longevity of action of 
retained pazopanib in the uveal tract. Were retained pazopanib demonstrated to 
be biologically active this would have implications for the optimisation of 
therapeutic dosing regimens (potentially limiting systemic exposure to the drug). 
It would also suggest that pazopanib’s effect is derived from modulation of cell 
behaviour at a local rather than peripheral level provided no other tissues in the 
body exhibit a depot effect (this does not appear to be the case based on whole 
body quantitative autoradiography in rodents – personal communication; Peter 
Adamson, GSK). 
 
Previous work had indicated that pazopanib has a predicted half-life in the 
mouse of <4 hours190. It was calculated that dosing 3 days prior to induction of 
CNV would result in only 0.0001% of the original oral dose remaining at the time 
of the lasering. Young adult wild-type mice were administered single doses of 
pazopanib, ranging from 3 – 300mg/kg, or vehicle only and then subjected to 
induction of CNV by diode laser at three separate fundus locations 3 days later. 
Peripheral blood samples were collected from three animals receiving the 
highest dose of pazopanib at the day 3 timepoint to confirm undetectable  
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Figure 43 Pazopanib increases levels of Gr-1
+
 monocyte/macrophages in the retina at the 
3 day post-laser timepoint 
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Timeline summarising the experiment is shown (A). The proportions of key innate immune cell 
populations in the retinae (B) and RPE-choroids (C) of  young adult wild-type mice 3 days post-
induction of CNV following administration of pazopanib 10mg/kg twice daily by oral gavage (-1 
to 3 days post-laser). The proportion of Gr-1
+
 monocyte/macrophages in the retinae of 
pazopanib-treated mice was more than double that observed in animals receiving vehicle only 
with a trend towards a reduction in the Gr-1
-
 fraction. Trends towards an increase in the fraction 
of Gr-1
+
 monocyte/macrophages in RPE-choroids of pazopanib-treated animals and a decrease 
in the fraction of DCs were also observed. Mean % live cells calculated from retinal cell 
suspensions obtained by pooling tissue from both eyes of each animal. CNV induced at 10 
separate locations per fundus. N=7 for pazopanib-treated mice and n=5 for vehicle-treated 
mice. 
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levels of pazopanib in the plasma at the time of CNV induction. Fluorescein 
angiography was then performed at 7 and 14 days post-laser. 
 
Initial results indicated that pazopanib delivered at a dose of 10mg/kg and 
above 3 days prior to induction of CNV was capable of significantly reducing 
CNV lesion size two weeks post-induction of CNV (Figure 44) – that is with the 
exception of the group receiving a dose of 30mg/kg in which a reduction was 
observed that did not achieve significance (p=0.09), the reasons for this were 
unclear. However, analysis of plasma samples revealed detectable levels of 
pazopanib well above those expected (GSK; data not shown) and therefore the 
possibility that circulating pazopanib may have had an effect on CNV 
development could not be excluded. 
 
The experiment was repeated with a 5 day lag time after dosage of animals with 
30mg/kg pazopanib, 3mg/kg pazopanib or vehicle only (Figure 45). Levels of 
pazopanib were found to be undetectable (analysis by GSK – data not shown) 
at the day 0 timepoint, when CNV was induced. Since oral pazopanib had been 
demonstrated to have an effect on peripheral innate immune cell populations 
following multiple administrations over a prolonged period (Figure 42), 
splenocyte suspensions derived from animals dosed either with pazopanib or 
vehicle 5 days previously were analysed for changes to proportions of innate 
immune cell sub-populations – no changes were observed. Results indicated 
that a 30mg/kg dose of pazopanib was sufficient to have an effect on CNV 
induced 5 days later when fundus fluorescein angiography was performed at 
the 1 week post-laser timepoint but not at 2 weeks (t-test vehicle vs. pazopanib-
dosed groups; p=0.05 for group receiving pazopanib 30mg/kg and p=0.08 for 
3mg/kg group). Results for animals receiving 3 mg/kg pazopanib suggested a 
non-significant intermediate effect supportive of a dose-dependent response. 
These data indicate that retained pazopanib is pharmacologically active and 
has a potential therapeutic effect in CNV for up to a week after induction, with 
lesion size remaining reduced (if not quite significantly) at 2 weeks post-
induction when levels of the drug are presumably insufficient to prevent the 
further increase in lesion size that is observed in vehicle-administered animals.  
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Figure 44 The effect on lesion size of pazopanib delivered by oral gavage 3 days prior to 
induction of CNV by laser 
Multiple dosages of pazopanib or vehicle delivered by oral gavage 3 days prior to induction of 
CNV. Timeline for experiment shown (A). Mean lesion size in each group following fundus 
fluorescein angiography at 1 and 2 weeks (B) and N numbers (C). Initial results indicated that 
pazopanib delivered at a dose of 10mg/kg and above, 3 days prior to induction of CNV, was 
capable of significantly reducing CNV lesion size two weeks post-induction of CNV. However, 
analysis of plasma samples revealed detectable levels of pazopanib well above those expected 
(GSK; data not shown) it could therefore not be concluded that melanosome-bound pazopanib 
was responsible for the observed effects on CNV. Error bars = SEM. 
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Figure 45 Pazopanib retained in the uvea exhibits a depot-effect and is biologically active 
Young adult wild-type mice were administered a single dose of either 30mg/kg pazopanib, 
3mg/kg pazopanib or vehicle only by oral gavage 5 days prior to induction of CNV by diode 
laser. Timeline for experiment is shown (A). Levels of pazopanib in the 30mg/kg group were 
found to be undetectable at the day 0 timepoint, when CNV was induced (n=4; plasma 
concentrations as determined by GSK using HPLC/MS). A 30mg/kg dose of pazopanib resulted 
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in sufficient levels of bioavailable, melanosome-bound drug to significantly reduce lesion size by 
a third at 1 week post-induction of CNV and possibly beyond, though results did not quite 
achieve significance at 2 weeks (B; t-test vehicle vs pazopanib 30mg/kg; p=0.05 at 1 week and 
p=0.08 at 2 weeks). Representative images taken from vehicle-administered and 30mg/kg 
pazopanib-dosed animals. 
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Figure 46 Pazopanib delivered by oral gavage (30mg/kg) has no effect on peripheral innate immune cell populations at 5 days post-delivery 
Pazopanib had previously been demonstrated to have an effect on innate immune cell populations in the spleen following prolonged administration by oral 
gavage. Innate immune cell populations in spleens harvested from young adult wild-type mice 5 days after delivery of either 30mg/kg pazopanib or vehicle 
were analysed to exclude the possibility that changes in peripheral innate immune cell populations might account for the depot-effect observed with 
pazopanib retained in the uvea. Results demonstrated no significant effect on any peripheral innate immune cell populations that might account for the effect 
on CNV lesion size observed in pazopanib-treated animals at this timepoint. 
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5.5 The effect of CD200R agonist on laser-induced 
choroidal neovascularisation 
 
Induction of CD200R signalling on monocyte/macrophages has been 
demonstrated to significantly attenuate inflammatory responses in models of 
autoimmune uveitis and autoimmune encephalitis and down-regulation of 
signalling has been linked with multiple sclerosis, Parkinson’s and Alzheimer’s 
disease107, 109, 110, 191, 192. Evidence suggests that CD200-CD200R interactions 
exert their effect through alternative macrophage activation193. 
 
To establish whether alternative activation of monocyte/macrophages has an 
effect on the development of CNV, young adult mice were subjected to 
induction of CNV by diode laser and injected intravitreally with either 10μg of an 
agonist rat IgG1-anti-mouse CD200R mAb (courtesy of Andrew Dick/DNAX 
Schering-Plough) or isotype control 3 days later109. Animals were injected at the 
3 day timepoint because this was known to be the peak time for macrophage 
recruitment to CNV lesions153, 155. Lesion sizes were assessed by fundus 
fluorescein angiography at 7 and 14 days post-laser. 
 
Results indicated that induction of CD200R signalling by intravitreal injection of 
an agonist antibody 3 days post-laser significantly reduced mean lesion size in 
young adult wild-type mice at the 2 week timepoint by as much as 43% (Figure 
47; t-test isotype control vs. CD200R agonist-injected eyes). This suggests that 
innate immune cell controlled CNV remodelling takes place over a relatively 
prolonged period even though lesion size is almost maximal at 1 week post-
induction. Consequently, there may be a wide window of opportunity for 
intervention by way of driving alternative macrophage activation. The effects of 
a once-only injection of the more specific CD200R agonist into the eye also 
compared favourably with those of daily delivery of pazopanib by oral gavage 
(Figure 41). 
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Figure 47 CD200R agonist delivered at the time of peak monocyte/macrophage 
recruitment results in significantly reduced mean lesion size on fundus fluorescein 
angiography performed 2 weeks after laser-induction of choroidal neovascularisation 
Mean lesion size following laser-induced CNV in young adult WT mice following injection of 
either CD200R agonist or isotype control antibody at 3 days post-laser ( timeline of experiment - 
A). Results are shown from the early phase of fluorescein angiograms at 1 and 2 weeks post-
laser (B - mean area of hyperfluorescence +/- SEM; N refers to number of lesions) with 
representative images from angiograms shown below. Mean lesion size in mice receiving 10μg 
CD200R agonist compared with isotype control antibody was significantly reduced by 43% at 
the 2 week post-laser timepoint (t-test; p<0.01). 
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5.6 Effect of CD200R agonist on CNV correlates with 
changes in innate immune cell populations in the retina 
and choroid 
 
Having established that delivery of a CD200R agonist 3 days post-induction of 
CNV resulted in a significant reduction in lesion size, confirmation of an effect 
on innate immune cell populations was sought by assessing the phenotype of 
myeloid-derived cells present in the retinae and RPE-choroids of CD200R 
agonist- or isotype control-injected young adult wild-type mice at the 1 and 2 
week post-laser timepoints (Figure 48).  
 
To drive detectable levels of cell recruitment/proliferation, CNV was induced at 
10 separate locations in each fundus. Intravitreal delivery of 10μg CD200R 
agonist at 3 days post-laser resulted in a significant increase in the proportion of 
Gr-1- monocyte/macrophages in the retina at 1 week and granulocytes in the 
RPE-choroid at the 2 week timepoint (Figure 48A and Figure 49B; t-tests of 
pooled tissue from CD200R-injected eyes vs. isotype control-injected eyes; 
p<0.05 for Gr-1- macrophages in retina at 1 week and p<0.05 for granulocytes 
in RPE-choroid at 2 weeks). No significant differences were observed in any 
other innate immune cell populations. 
 
Induction of CD200R signalling therefore resulted in an increase in the 
proportion of Gr-1- monocyte/macrophages in the retina that preceded 
breakdown of the neovascular complex, with a subsequent increase in the 
recruitment of granulocytes (most likely neutrophils) to the RPE-choroid. The 
recruitment of neutrophils to the RPE-choroid at two weeks may be explained 
by an increase in CNV-derived cellular debris requiring clearance.  
 
Immunohistochemical confirmation of the innate immune cell phenotypes 
present in the CNV lesions of CD200R agonist-injected or isotype control-
injected eyes at the 1 week timepoint was sought. A total of 3 CD200R-injected 
eyes and 3 isotype control-injected eyes were harvested for 
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immunohistochemistry at 1 week post-induction of CNV. Saggital sections were 
stained for F4/80 and Ly6C (the Ly6C- macrophage population was found to 
behave identically to the Gr-1- macrophage population on flow cytometric 
analysis – data not shown). In keeping with the results of flow cytometric 
analysis smaller lesion size was associated with higher numbers of Ly6C- 
F4/80+ cells in the retina (Figure 50). Accurate quantification of macrophage 
numbers in sections was not possible given the close proximity of cells to one 
another in the retina, CNV lesions and RPE-choroid. Consequently only 
representative images are shown. 
 
Ly6C and Gr-1 were found to be expressed in a similar pattern to that obtained 
from immunostaining of the retinal vasculature and choroid. Confirmation of co-
localisation of Gr-1 expression with the vascular marker collagen IV was 
therefore obtained (Figure 51). Constitutive expression of Ly6C on a 
subpopulation of small vessel endothelium has been described previously, 
though not in the retina/choroid195-197. Gr-1 has not been described as being 
expressed on vascular endothelium before. Confirmation that 
monocyte/macrophages expressing the CD200R were present in the periphery 
and in the eye was also sought. Immunostaining for the markers F4/80, Ly6C 
and CD200R revealed the presence of large numbers of CD200R positive, 
Ly6C- monocyte/macrophages clustered around large, multinucleated F4/80- 
Ly6CHigh cells in young adult wild-type spleen follicles (Figure 52A).  
 
Immunostaining of saggital sections taken from young adult wild-type mouse 
eyes 1 week after induction of CNV in 10 locations revealed the presence of 
Ly6C- CD200R+ macrophages in close proximity to retina overlying CNV. 
CD200R is known to be expressed on a range of myeloid cell types, whether it 
is preferentially expressed on Ly6CHigh (CCR2+) or Ly6CLow (CCR2-) monocytes 
is not known though these results would suggest that levels are higher on 
Ly6CLow populations. The possibility that those cells staining positive for 
CD200R in the spleen might be DCs could not be excluded – CD200R has 
been demonstrated to be most highly expressed on DCs194. In keeping with  
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Figure 48. CD200R agonist delivered at the time of peak monocyte/macrophage 
recruitment following laser-induction of CNV results in a significant increase in the 
proportion of Gr-1
-
 macrophages at 1 week post-laser in the retina 
The proportion Gr-1
-
 (and Ly6C
-
 macrophages – data not shown) in the retinae of  young adult 
wild-type mice following intravitreal delivery of  CD200R agonist 3 days post-induction of CNV 
was found to be significantly increased compared with isotype antibody injected controls at 1 
week post-laser (A). The difference was not maintained at 2 weeks post-laser (B). Mean % live 
cells calculated from retinal cell suspensions obtained by pooling tissue from both eyes of each 
animal. CNV induced at 10 separate locations per fundus. For isotype control-injected mice, n=5 
and 9 for the 1 week and 2 week timepoints respectively; for CD200R agonist-injected mice, 
n=6 and 8 for 1 week and 2 week timepoints respectively; error bars=SEM.  
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Figure 49 CD200R agonist delivered at the time of peak monocyte/macrophage 
recruitment following laser-induction of CNV results in a significant increase in the 
proportion of granulocytes at 2 weeks post-laser in the RPE-choroid 
The proportion granulocytes (CD11b
+
 Gr-1
+
 F4/80
-
) cells in the choroids of  young adult wild-
type mice following intravitreal delivery of  CD200R agonist 3 days post-induction of CNV was 
found to be unchanged at 1 week post-laser (A) but increased compared with isotype antibody 
injected controls at the 2 week timepoint (B). Mean % live cells calculated from RPE-choroidal 
0
10
20
30
40
50
60
CD11b+ GR1+ F4/80- GR1+ F4/80+ GR1- F4/80+ CD11c+ GR1-
%
 L
iv
e
 c
e
ll
s
 (
m
e
a
n
)
CD11b+ subpopulation
A RPE-choroid - 7 days post-laser
Isotype control-injected
CD200R agonist-injected
0
10
20
30
40
50
60
CD11b+ GR1+ F4/80- GR1+ F4/80+ GR1- F4/80+ CD11c+ GR1-
%
 L
iv
e
 c
e
ll
s
 (
m
e
a
n
)
CD11b+ subpopulation
B RPE-choroid - 14 days post-laser
p<0.05
p<0.05
Chapter 5   Manipulating innate immune cells 
198 
 
cell suspensions obtained by pooling tissue from both eyes of each animal. CNV induced at 10 
separate locations per fundus. For isotype control-injected mice, n=5 and 8 for the 1 week and 2 
week timepoints respectively; for CD200R agonist-injected mice, n=6 and 12 for 1 week and 2 
week timepoints respectively; error bars=SEM. 
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Figure 50 Immunohistochemistry demonstrating smaller lesions and more Ly6C
-
 F4/80
+
 cells in CD200R agonist-injected eyes at 1 week 
Representative confocal photomicrograph projections (x20) of sections taken from the centre of CNV lesions in isotype control- and CD200R agonist-
injected eyes (A and B respectively). 10μg of either isotype control or CD200R agonist were injected intravitreally at 3 days post-induction of CNV by 
laser. Increased numbers of Ly6C
-
 F4/80
+
 macrophages with a ramified microglial appearance are clearly visible in CD200R agonist-injected eyes in 
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association with smaller lesion size (as indicated by arrows). Retinal and choroidal vascular endothelium was Ly6C
+
 (confirmed by collagen IV staining -    
). Site of CNV is marked by asterisks. 
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Figure 51 Gr-1 is expressed in the retinal vasculature 
Immunohistochemistry staining demonstrating co-localisation of the vascular marker collagen IV 
(red) with Gr-1 (green) in a section taken from a young adult wild-type mouse 3 days post-
induction of CNV by diode laser. A similar pattern was seen using the Ly6C marker (Figure 50). 
Fluorescence micrographs at x60 magnification. 
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Figure 52 Ly6C
Low
 monocyte/macrophages in the spleen and Ly6C
-
 macrophages in the 
retina express CD200R 
Representative confocal micrograph projections showing small numbers of CD200R positive 
(Ly6C
Low
) monocyte/macrophages clustered around a large, multinucleated F4/80
-
 Ly6C
+
 cell 
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(arrow) in young wild-type spleen. Arrowheads indicate the position of cells where F4/80 and 
CD200R staining colocalise (A). Confocal microscopy images demonstrating the presence of 
weakly CD200R
+
 Ly6C
-
 microglia in the retina 1 week after laser-induction of CNV; vessels in 
retinal tissue and choroid stain positive for Ly6C (B). 20x merged images (left); 40x panels 
(right). 
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the immunohistochemistry data indicating lower levels of expression of CD200R 
on retinal macrophages compared with those in the spleen, other work has 
confirmed that microglia in human brain express lower levels of CD200R than 
peripheral blood-derived macrophages110. 
5.7 Anti-angiogenic effect of CD200R agonist is 
accelerated when administered prior to induction of 
CNV 
 
The potential for early delivery of CD200R agonist antibody to attenuate the 
neovascular response in the laser-induced CNV model was explored. This 
would have implications for manipulation of the CD200R-CD200 pathway in 
acute cases of wet AMD and also further understanding of the importance of 
CD200R signalling in the initial stages of the neovascular response. 
 
The possibility of injecting CD200R agonist antibody intravitreally immediately 
pre- or post-laser induction of CNV was considered. This would reduce the 
number of anaesthetic treatments to which animals were subjected from two to 
one. The advantages of this would be to minimise harm to the mice and also to 
reduce the risk of keratopathy associated with general anaesthesia that 
otherwise reduces the quality of angiographic imaging. A pilot experiment, 
however, revealed that injection immediately prior to lasering resulted in a 
temporary cataract that significantly reduced levels of energy delivered to 
Bruch’s membrane in attempts to rupture it. Injection immediately after lasering 
precipitated haemorrhage at sites of CNV induction. Consequently, two cohorts 
of young adult mice were injected intravitreally with either 10μg CD200R agonist 
antibody or 10μg isotype control 1 day pre-induction of CNV at three locations in 
each fundus and subjected to fundus fluorescein angiography at 1 and 2 weeks 
post-laser (Figure 53A). 
 
Results indicated that delivery of CD200R agonist antibody 1 day prior to 
induction of CNV by diode laser resulted in reduced lesion size at 2 weeks (t-
test; p<0.05). Levels were comparable with those achieved following injection at 
3 days post-laser (39% compared with 43% in animals injected at 3 days post-
laser. However, injection 1 day prior to laser had the additional effect of 
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significantly reducing lesion size at 1 week post-laser, by 30% compared with 
isotype control-injected eyes, suggesting an effect on cells recruited before 
maximal infiltration of monocyte/macrophages at 3 days – most likely 
neutrophils (Figure 53B). 
5.8 Systemic delivery of CD200R agonist 3 days post-
induction of CNV does not reduce lesion size in the 
laser model 
 
Systemic delivery of CD200R agonist antibody has been demonstrated to 
attenuate the inflammatory response in the experimental autoimmune uveitis 
model109. An experiment was undertaken to determine whether intraperitoneal 
delivery of CD200R antibody agonist results in significant suppression of the 
neovascular response in the laser-induced CNV model. If systemic delivery of  
CD200R agonist antibody were found to  reduce CNV lesion size, this would 
have implications for the role of the CD200R-CD200 axis in modulating the 
behaviour of peripheral innate immune cells in pathological neovascularisation 
and give some indication as to the potential for systemic toxicity, or even 
benefit, in other tissues. It would also permit greater flexibility in terms of when 
the drug might be delivered in relation to the timing of CNV induction and avoid 
the increased variability associated with undertaking intravitreal injections. 
 
CD200R agonist antibody, at a dose found to be effective in the EAU model 
(120μg), or isotype control antibody were delivered by intraperitoneal injection in 
young adult wild-type mice 3 days post-induction of CNV by diode laser (at 3 
locations in each fundus). Animals were subjected to fundus fluorescein 
angiography at 1 and 2 weeks post-laser. No significant effect on lesion size 
was observed in the CD200R agonist-treated group at either the 1 or 2 week 
timepoints. These data suggest that either insufficient quantities of 
therapeutically active antibody were available to the intravascular compartment 
or that concentrations achieved had no significant effect on either peripheral or 
local innate immune cell populations (Figure 54). 
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Figure 53. Delivery of CD200R agonist before induction of CNV results in an earlier effect 
on the neovascular response. 
10μg CD200R agonist delivered by intravitreal injection 1 day pre-induction of CNV results in 
significantly reduced mean lesion size on fundus fluorescein angiography performed 1 and 2 
weeks after laser-induction of choroidal neovascularisation. Summary of experimental timeline 
shown (A).Chart shows mean lesion sizes following laser-induced CNV in young adult WT mice 
after injection of either CD200R agonist or isotype control antibody at 1 day pre-laser (B). 
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Results are shown from the early phase of fluorescein angiograms at 1 and 2 weeks post-laser 
(mean area of hyperfluorescence +/- SEM; N refers to number of lesions) with representative 
images from angiograms shown below. Mean lesion size in mice receiving 10μg CD200R 
agonist compared with isotype control antibody was significantly reduced by 30% at the 1 week 
and 39% at the 2 week post-laser timepoints (t-test; p<0.05). 
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Figure 54 120μg CD200R agonist delivered by intraperitoneal injection 3 days post-
induction of CNV has no effect on neovascular response 
Mean lesion size as assessed by fundus fluorescein angiography performed 1 and 2 weeks 
after laser-induction of choroidal neovascularisation in young adult wild-type mice. Mice 
received either 120μg isotype control antibody or CD200R agonist intraperitoneally at 3 days 
post-induction of CNV. Timeline summarising experiment shown (A). Results are shown from 
the early phase of fluorescein angiograms at 1 and 2 weeks post-laser (B) - mean area of 
hyperfluorescence +/- SEM; N refers to number of lesions. 
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5.9 Discussion 
 
This chapter documents two approaches to the treatment of CNV: one where a 
more conventional treatment directed at inhibition of tyrosine kinase receptors, 
such as VEGF receptors, was demonstrated to have an effect on both local and 
systemic innate immune cell populations; and one in which innate immune cells 
were targeted directly using an agonist for the CD200 receptor. The purpose of 
the work on tyrosine kinase receptor inhibition was to establish whether an 
approach primarily targeting the VEGFR signalling pathway, hitherto the most 
successful method of treating wet AMD, might have effects on innate immune 
cell populations also known to express VEGF receptors.  The purpose of the 
work focusing on CD200R signalling was to explore the effect of targeting 
innate immune cell alternative activation pathways directly – such an approach 
might have additional benefits beyond those derived from VEGFR inhibition 
which, on their own, appear only to reduce leakage in established CNV23. 
 
VEGFR-1 and VEGFR-2 are expressed in vascular endothelial cells, 
monocytes, macrophages and hematopoietic stem cells. These cells have been 
demonstrated to modulate tumour growth and angiogenesis in a VEGF-
dependent manner and the effect of anti-VEGF treatment on myeloid cells has 
therefore been widely studied. It is noteworthy that VEGFR-1 blocking 
antibodies inhibit the formation of bone marrow –derived progenitor cells that 
form pre-metastatic clusters in tumour models. VEGF has been implicated in 
the defective maturation of DCs from immature precursors and blocking this 
effect improves the efficacy of anti-tumour immunotherapy in cancer patients. 
Decreases in levels of VEGF following anti-VEGF treatment have been 
demonstrated to enhance the antigen-presenting capacity of DCs by reducing 
numbers of immature myeloid cells, such as MDSCs, that are known to inhibit 
DC function. For example, the delivery of the anti-VEGF antibody bevacizumab 
in metatstatic renal cancer has been shown to reduce the size of the CD11b+ 
VEGFR+ population of MDSCs in peripheral blood. Studies aimed at identifying 
VEGF-independent mediators of tumour angiogenesis have identified the G-
CSF-mediated upregulation of a protein known as Bv8 in CD11b+ Gr-1+ cells 
associated with tumours that are resistant to treatment – blocking these 
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pathways has been demonstrated reduce the growth of refractory tumours. The 
results of these studies suggest a possible role for such cell types in the 
propagation of CNV in the aged eye and new avenues to explore in the delivery 
of more effective treatments for CNV, both responsive and unresponsive to 
current therapies189. 
 
The multi-target tyrosine kinase inhibitor pazopanib has been demonstrated to 
be capable of both suppressing the development of CNV and inducing the 
regression of established neovascular membranes in the laser model190. In 
causing the regression of established CNV, pazopanib exerts additional effects 
beyond those expected from blockade of VEGFR signalling alone. The 
mechanism for these effects remains a source of speculation but candidates 
include the blockade of PDGF-B signalling (known to promote the recruitment, 
proliferation and survival of pericytes) and blockade of c-Kit (a receptor for stem 
cell factor that contributes to angiogenesis by increasing nuclear localisation of 
hypoxia inducible factor 1α). However, pazopanib is also active to a lesser 
extent on a number of other tyrosine kinase receptors including FGFR1, FGFR3 
and c-fms (also known as CSF-1 receptor). CSF-1 regulates macrophage 
differentiation, survival and function – making it an attractive therapeutic target 
in a number of chronic inflammatory and neoplastic diseases198. 
 
In a series of experiments, the antiangiogenic effect of pazopanib was 
confirmed and it was determined that multi-target tyrosine kinase inhibition is 
associated with changes in innate immune cell phenotypes both in the spleen 
and the eye. Specifically, it was established that prolonged administration (over 
a 3 week period) of therapeutic doses of pazopanib resulted in a significant 
reduction in the proportion of granulocytes (or even the more loosely defined 
CD11b+ Gr-1+ ‘myeloid-derived suppressor cell’ population of cancer biology), in 
the wild-type mouse spleen (Figure 42). It was also established that delivery of 
pazopanib in the context of laser-induced CNV resulted in a significant increase 
in the proportion of Gr-1+ (CCR2+) monocyte/macrophages in the retinae of 
treated mice at the 3 day post-laser timepoint, when levels of 
monocyte/macrophage recruitment to CNV are at their highest (Figure 43). 
Preferential recruitment of Gr-1+ (CCR2+) monocyte/macrophages to the retina 
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at 3 days post-induction of CNV would be in keeping with evidence suggesting 
that Gr-1- (CCR2-) monocyte/macrophages constitute the key pro-angiogenic 
subpopulation at this timepoint. Therapies designed to affect the balance of 
monocyte subpopulations at critical points in the neovascular process may 
therefore have beneficial effects in the context of CNV. Such effects may partly 
explain the additional anti-angiogenic effects of pazopanib. 
 
The possibility that pazopanib exerted some of its anti-angiogenic effects 
through suppression of circulating granulocytes or myeloid-derived suppressor 
cells (effects found to be in evidence following prolonged administration of the 
drug) could not be excluded entirely. The heterogeneous myeloid-derived 
suppressor cell populations of the spleen, bone marrow and tumour infiltrate are 
thought to exert pro-angiogenic effects that render tumours refractive to anti-
VEGF therapies189. Granulocytes, which are also CD11b+ Gr-1+ (but F4/80-), 
remain the largest innate immune cell population in retina and RPE-choroid at 
the 3 day post-laser time point, they are most likely the principal effectors of 
angiogenesis in the context of CCL2 deficiency where normal 
monocyte/macrophage recruitment is inhibited (Figure 37) and their role in 
pathological neovascularisation has been described previously153. It is certainly 
conceivable that suppression of granulocytes in the periphery might have 
beneficial effects for CNV but the potential side effects, particularly in leaving a 
subject open to acute infection, are highly significant. Consequently an 
experiment was designed to determine whether the uveal tract retention 
properties of pazopanib might be exploited in such a way that exposure of the 
drug was limited to its site of action in the eye. Such an approach would 
minimise systemic exposure to pazopanib (whether delivered orally or topically), 
reduce the therapeutically effective dose in the eye and give some indication as 
to whether pazopanib retains significant biological activity in the absence of any 
systemic effects. Initial work identified that the pharmacokinetics of pazopanib 
were such that 3 days after a single dose by oral gavage, significant amounts of 
the drug were still present in plasma samples obtained from young adult wild-
type mice. A further experiment was conducted where pazopanib was delivered 
in a single dose 5 days prior to induction of CNV by diode laser. In this 
experiment no significant levels of pazopanib were detectable in plasma 
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samples obtained at the time of lasering. Lesion size at 1 week post-laser was 
significantly reduced by as much as 33% in animals pre-treated with pazopanib 
and it was therefore concluded that pazopanib retained in the uveal tract is 
therapeutically active. The absence of a significant effect on lesion size at the 2 
week timepoint indicated that levels of retained drug were either insufficient or 
not in a pharmacologically active form for an effect on neovascularisation much 
beyond 11 days after delivery. Further work would be needed to determine the 
long-term effects of bound and non-bound pazopanib on the innate immune cell 
populations of the eye. Potentially toxic effects on the neuroretina and choroidal 
vaculature have been attributed to VEGFR blockade and the additional effects 
of targeting other tyrosine kinase receptors in the eye cannot be 
underestimated: it has been demonstrated, for example, that CSF-1 is important 
for migratory DC development and the effects of prolonged CSF-1 receptor 
blockade are therefore of particular importance given the striking effects that 
chemokine deficiencies appear to have on DC trafficking in the retina and 
choroid20, 21, 164. 
 
To determine whether targeting innate immune cell activation pathways directly 
might be of benefit in CNV, the effect of intravitreal delivery of a CD200R 
agonist on lesion size was investigated. To maximise any potential therapeutic 
effect, CD200R agonist antibody was delivered at the peak time of 
monocyte/macrophage recruitment, 3 days after induction of CNV by diode 
laser.  CD200R agonist-injected eyes exhibited significantly reduced CNV, 
compared with those injected with isotype control antibody, by as much as 43% 
at the 2 week timepoint. Interestingly, CD200R induction appeared to result in 
the breakdown of CNV that was otherwise almost fully formed at the 1 week 
time point. The precipitation of CNV regression was preceded by a significant 
increase in the proportion of Gr-1- (CCR2-) monocyte/macrophages in the 
retinae of CD200R agonist-injected mice at 1 week post-laser and an increase 
in granulocytes in the RPE-choroid (presumably triggered by the release of 
material from the degenerating neovascular membrane) at 2 weeks post-laser. 
 
The finding that an in increase in the proportion of Gr-1- 
monocyte/macrophages in the retinae of CD200R agonist-injected eyes was 
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associated with a subsequent reduction in CNV lesion size in some ways runs 
contrary to evidence obtained following use of pazopanib suggesting that these 
cells constitute a more pro-angiogenic subset. However, a direct comparison of 
the data is not possible since tissue was harvested at the 3 day post-laser 
timepoint in the case of pazopanib-treated animals and at the 1 and 2 week 
post laser time points in the case of CD200R agonist-treated animals. 
Differences between these datasets most likely reflect the sequential 
recruitment of monocyte/macrophages described in other disorders159. That is 
to say that whilst a balance favouring recruitment or proliferation of Gr-1+ 
monocyte/macrophages at 3 days post-laser results in a suppression of CNV, a 
similar effect may potentially result from the recruitment/proliferation of the Gr-1- 
subset at 1 week post-laser. Since differentiation between microglia and Gr-1- 
monocytes was not possible, any changes in the proportion of retinal CD11b+ 
Gr-1- F4/80+ cells may be due to either proliferation of the microglial population 
or recruitment of the monocytic subset – further work would be needed to 
establish this. The process of pathological neovascularisation, at least in the 
early stages, is highly dynamic with cells exhibiting the same surface markers 
appearing to have different functions at different time points. Therapies 
targeting a specific population of innate immune cells may therefore be 
extremely effective if delivered in the first week of onset but achieve little, or 
even be counterproductive, at other time points. There is at least circumstantial 
evidence to support this given that a significant increase in the proportion of 
granulocytes in the RPE-choroid precedes a rapid increase in lesion size at 3 
days post-laser but a further increase (compared to isotype control-injected 
eyes) is also associated with a reduction in lesion size at 2 weeks post-laser in 
CD200R agonist-injected eyes. 
 
Intravitreal injection of CD200R agonist or isotype control antibody immediately 
after induction of CNV resulted in significant subretinal and intravitreal 
haemorrhage at the site of Bruch’s membrane rupture and this precluded flow 
cytometric analysis of innate immune cell populations post-treatment at the 3 
day post-laser timepoints. However, intravitreal delivery of CD200R agonist 1 
day prior to induction of CNV was found to be effective in suppressing the 
neovascular response at both 1 and 2 weeks post-laser and consequently it 
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may be possible to examine the effect of CD200R signalling on innate immune 
cell populations at the 3 day timepoint using this approach (Figure 53).  
 
Systemic delivery of CD200R agonist by intraperitoneal injection was found not 
to be effective in suppressing laser-induced CNV, although intravenous delivery 
of the same antibody has previously been shown to significantly reduce CD45+ 
inflammatory infiltrate and structural damage in the EAU model109. These 
results suggest that the induction of CD200R signalling on cells in the periphery 
fails to significantly alter the progression of CNV in the eye. Fundamental 
differences between the EAU and laser-induced CNV models may explain why 
systemic delivery is effective in the former but not the latter. The EAU model 
relies on the systemic delivery of an antigen (interphotoreceptor retinoid binding 
protein in wild-type animals) in combination with an adjuvant that is taken up by 
antigen presenting cells which drive a T cell-mediated immune response in the 
eye. The process of systemic antigen uptake and presentation is very likely to 
be attenuated following systemic delivery of CD200R agonist, resulting in less 
uveitis. In contrast, the laser-induced CNV model relies on the combined activity 
of recruited myeloid cells and resident microglia to generate pathology that is 
heavily dependent on the nature of the local inflammatory microenvironment. 
Consequently the effects of systemically delivered CD200R agonist in the 
context of laser-induced CNV are more limited. 
 
In summary, two experimental approaches to the treatment of CNV were 
investigated using the laser model of CNV induction. In both cases it was 
possible to associate effects on innate immune cell populations in the eye with 
an effect on the degree of neovascularisation. Systemic delivery of the multi-
target tyrosine kinase inhibitor pazopanib was demonstrated to suppress the 
development of CNV in association with an increase in the proportion of Gr-1+ 
monocyte/macrophages in the retina at 3 days post-laser. Prolonged systemic 
exposure to pazopanib was also associated with a significant reduction in the 
proportion of granulocytes in the spleens of treated animals. It was 
hypothesised that pazopanib retained in the uveal tract might confer a depot 
effect and the drug was found to be active in suppressing CNV in the absence 
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of detectable levels in the plasma of treated animals. Certain innate immune cell 
populations, such as macrophages, express VEGF receptors but it is also 
possible that pazopanib exerts its effect on innate immune cells by acting on the 
CSF-1 receptor.  
 
Induction of CD200R signalling was also found to suppress CNV development 
(when administered intravitreally before CNV induction). In addition, CD200R 
agonist antibody delivered intravitreally 3 days after CNV induction appeared to 
accelerate the breakdown of neovascular membrane in association with raised 
levels of Gr-1- monocyte/macrophages in the retina at 1 week and granulocytes 
in the RPE-choroid at 2 weeks. A rise in Gr-1- macrophages in the retinae of 
aged CCL2-/- was also associated with a reduction in the neovascular response 
in these animals and, overall, these results in combination with those obtained 
from therapeutic intervention suggest that manipulation of macrophage 
populations in the retina, rather than the choroid or periphery, may have 
greatest impact on the development and/or regression of CNV. Further work 
would be required to confirm that peripheral innate immune cell populations are 
unaffected following a once-only delivery of pazopanib and to identify the 
functional changes associated with particular patterns of surface marker 
expression in the relevant populations. 
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Chapter 6: Discussion 
 
6.1 Analysis of the innate immune system of the retina 
and RPE-choroid 
 
This thesis describes a body of work aimed at developing a greater 
understanding of the role played by innate immune cells in ageing of the retina 
and RPE-choroid. It explores how changes in the various innate immune cell 
sub-populations might contribute to the pathogenesis of age-related macular 
degeneration and how they might be manipulated to improve its management. 
 
The first chapter documents experiments designed to determine the phenotypes 
of innate immune cells  in the retina and RPE-choroid of wild-type mice and the 
changes in these populations with age, before going on to identify how a 
deficiency of the chemokine CCL2 in CCL2-/- mice affects the proportions of the 
various populations in young and aged animals. The second chapter details the 
effects of age and CCL2 deficiency on laser-induced CNV lesion size and 
investigates the role played by innate immune cells in this process. The innate 
immune cell populations recruited following laser-induction of CNV are 
compared with those found in a model of spontaneous CNV with the aim of 
identifying common pro-angiogenic cell types. The final chapter explores the 
effects of tyrosine kinase receptor inhibition on local and peripheral innate 
immune cell populations in the context of laser-induced CNV and the potential 
for inducing alternative activation, through CD200R signalling, as a means of 
inhibiting the neovascular response. 
 
There has been a revival of interest in the role played by innate immune cells in 
the pathology of AMD (and many other age-related disorders) in recent years 
following the discovery that polymorphisms in complement genes, such as 
those for CFH and C3 are associated with the condition30-32, 41, 64. This thesis 
demonstrates that it is possible to detect small but significant changes in innate 
immune cell populations, as defined by their levels of surface marker 
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expression in response to ageing, chemokine deficiency, induction of CNV and 
therapeutic intervention. Given the difficulties of identifying individual myeloid 
cells in the retina and RPE-choroid for the purpose of cell counts (particularly in 
eyes subjected to laser induction of CNV), the inherent variability associated 
with immunohistochemical staining of fixed tissue and the variability associated 
with the laser model and intravitreal injections, it might not have been possible 
to detect these changes using any method other than flow cytometry. The initial 
attempts of others to identify DCs in the retina using immunohistochemical 
staining were negative for example111. Having said that, immunohistochemistry 
does have one important advantage over flow cytometry in providing more 
information about the location of cell types and their morphology. A 
considerable amount of data, based largely on immunohistochemistrical 
analysis, already exists in the literature regarding the trafficking and behaviour 
of innate immune cells in the retina and RPE-choroid (as defined by their 
expression of CD11b, F4/80, the microglial marker Iba-1 or expression of 
CX3CR1GFP), however comparatively little was known about the specific 
phenotypes of these broadly defined populations and hence this became a 
focus for further investigation102, 111, 112, 153, 171.  
 
 
There exists a degree of variation in the literature relating to how innate immune 
cell populations may be defined using surface markers. CCR2+ monocytes in 
particular are variously described as being F4/80Low cells that are Gr-1+, Ly6C+ 
or Ly6CHigh – in some cases these markers are referred to interchangeably, 
despite evidence that they are epitopically distinct93. In the case of DCs there is 
some debate as to whether they exist as a separate population from the 
mononuclear phagocyte system at all, though most authors would agree that 
these cells, regarded as highly important in bridging the innate and adaptive 
immune responses, may be defined by their high levels of expression of the 
integrin CD11c111, 174. F4/80, a marker thought to have a role in the induction of 
regulatory T cell responses89, has been consistently used to identify 
monocyte/macrophages since its discovery over 25 years ago, however recent 
evidence suggests that even neutrophils are capable of acquiring this marker 
and transdifferentiating to macrophages under certain conditions88, 173. These 
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points are made by way of stressing the plasticity of the immune system and not 
with the intention of undermining the approach taken to defining cell populations 
in this thesis or any other work. By analysing changes in cell populations, as 
defined using surface markers, it was the aim of this study to establish, even if 
only in snapshot, an association between specific cell populations and the 
changes observed with age or pathological neovascularisation in the eye. 
Similar approaches have yielded extremely valuable data in other areas of 
immunology and permitted a more focused exploration of associated functional 
changes166, 170, 199. 
 
The role played by innate immune cells, in particular microglia, in ocular ageing 
and choroidal neovascularisation is unclear – perhaps because macrophages in 
the retina and RPE-choroid have been defined very broadly in the past. Using 
antibodies against innate immune cell surface markers in combination with flow 
cytometry it was possible to determine that innate immune cells constitute 
approximately 1.2% of live cells in the retinae and 16.6% of live cells in the 
choroids of young adult wild-type mice. Interestingly, of the definable sub-
populations, CD11b+ Gr-1+ F4/80- cells (most likely granulocytes) appear to 
comprise the largest fraction both in the retina and RPE-choroid at a young age.  
The possibility that such a high proportion of granulocytes might simply reflect 
the composition of the intravascular compartment was considered. However, 
the effect of perfusing animals with a buffered salt solution prior to harvesting 
tissue - thereby removing cells from the lumens of the retinal and choroidal 
vasculature - has been found to be insignificant186. This leaves open the 
possibility that CD11b+ Gr-1+ F4/80- cells, in this context, are in fact pericytes. 
Pericytes have been demonstrated to express the myeloid lineage marker 
CD11b and macrophage marker ED-2 in culture and microvessels isolated from 
rat brain. Future work that makes use of other markers for pericytes, such as 
the chondroitin sulphate proteoglycan NG2, in conjunction with 
immunohistopathological techniques may enable the exact nature of this 
population to be determined. 
 
As wild-type mice age the DC populations in both retina and RPE-choroid 
rapidly overtake granulocytes to become the predominant innate immune cell 
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population in these tissues. The increase in DCs appears greatest in the first 
year of life in both tissues and is the only feature of ageing, at least where the 
relative proportions of innate immune cells are concerned, in the RPE-choroid. 
In the retina, rapid expansion of the DC population in the first year of life is 
followed by an equally rapid expansion in the Gr-1- macrophage population after 
12 months of age. 
 
How do these results square with what is known about innate immune cells in 
the retina and RPE-choroid and the way they change with age? In the retina, 
microglial cells are generally thought of as the main resident immune cells in 
young adult wild-type mice, and DCs and resident macrophages as the key 
populations in the choroid. These findings do contrast slightly with those 
described in Chapter 3 where granulocytes appeared the main innate immune 
cell population in young adult wild-type retina. Xu et al. have described an 
increase in the number of MHC-IILow TLR3+ TLR4+ 33D1+ cells derived from the 
CD11b+ CD45Low population in aged mouse retinae and concluded that this 
change arose from an age-dependent activation of retinal microglia (Figure 55). 
They also described an accumulation of CD11c+ cells with age although, 
interestingly, additional work has identified subretinal microglia as expressing 
both the microglial marker Iba-1 and the phagocytic marker CD68, but not 
MHCII or CD11c antigens9.  
 
Xu et al. arrived at their conclusions regarding subretinal microglia through the 
immunohistochemical analysis of RPE-choroidal flat mounts, however a flow 
cytometric analysis of the CD11b+ F4/80+ subpopulations described in this 
thesis revealed no significant difference in their levels in the RPE-choroid with 
age. The reasons for this are unclear: one possibility is that autofluorescent 
cells such as lipofuscin-laden subretinal microglia were excluded from the 
analysis as a by-product of exercising the standard controls, another is that 
large bloated subretinal macrophages are incapable of withstanding the rigours 
of the flow cytometric protocol and rupture easily. A further possibility is that the 
flow cytometric protocol, whilst allowing enormous flexibility in terms of the cell 
populations analysed, was simply not sensitive enough to detect a population of 
cells that probably numbers no more than 100 in an aged wild-type RPE- 
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Figure 55 Microglial changes in the aged mouse retina.  
(A) Phenotype of CD11b
+
CD45
low
 (insert) retinal microglia in different ages of mice. *, p<0.05 
compared to 6-month old mice (n = 4; student t test). (B), Subretinal Iba-1
+
 microglia in a 22-
month old mouse. (C), Normal CX3CR1
gfp/gfp
 retinal microglia in the inner plexiform layer of a 3-
month old mouse. (D, E), Atrophic Cx3cr1
gfp/gfp
 retinal microglia in the inner plexiform of a 22-
month old mouse. Atrophic cells have fragmented, tortuous processes with bulbous swellings 
(arrowheads). From Xu et al. 2008 
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choroidal flatmount (this may explain why it was possible to detect an increase 
in Gr-1- macrophages with age in the RPE-choroids of CCL2-/- mice but not wild-
types). In any case, it is not possible to conclude with any certainty which of the 
two populations seen to increase in the retina with age (DCs and Gr-1- 
macrophages), if either, equates to the subretinal microglial population. The 
timing of the responses and the markers identified on subretinal microglia 
suggest that these are (or are derived from) the Gr-1- macrophages and that the 
increase in DCs, though very likely to be related to the accumulation of 
subretinal microglia, occurs independently. This is important because the timing 
of these responses suggests that a failure of DC trafficking/maturation precedes 
active or reactive changes in the microglial population. 
 
Ageing is thought to affect every innate immune cell in the body, whether by 
changes in numbers or function or both. Such changes may be related to 
intrinsic or extrinsic factors – that is altered function may either occur 
independently of a cell’s microenvironment or as a direct result of age-related 
cues from the tissues. The effect of ageing on innate immune cell function also 
varies according to the method of study (in vitro or in vivo), the species studied 
and the subpopulation. Some subpopulations are more heavily studied than 
others in this context - there are almost no studies on morphological and 
functional changes in neutrophil granulocytes, for example, and those in mice 
date back more than two decades. In mice the evidence available suggests that 
the concentration of neutrophils in the peripheral blood increases with age but 
that their functional capacity remains unchanged. In contrast, neutrophils in 
humans exhibit impaired function and altered signal transduction that may serve 
to explain the susceptibility of the elderly to bacterial and fungal sepsis – these 
differences have led some to conclude that mice may not be ideal models for 
studying neutrophil immunosenescence200. 
 
The evidence for immunosenescence in the mononuclear phagocyte system is 
more consistent: macrophages isolated from aged subjects have been 
demonstrated to have decreased chemotactic activity and defective 
phagocytosis (Table 5)201. An impaired ability either to phagocytose or process 
phagocytosed debris may account for the lipofuscin-laden appearance of 
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dystrophic microglia in the subretinal space and brains of aged mice129. 
Cytokine production also appears to be reduced in aged mice compared with 
young in vitro though the importance of the microenvironment is underlined by a 
more pro-inflammatory cytokine output of the same cells in vivo following LPS 
exposure. In the brain, aged microglia are thought to be ‘primed’ to produce 
higher levels of pro-inflammatory cytokines. This increase has been noted to be 
in proportion to higher basal levels of cytokine secretion, and therefore suggests 
intact acute inflammatory mechanisms. Nevertheless, exposure to high levels of 
pro-inflammatory cytokines may directly enhance neurodegeneration regardless 
of whether the response is ‘proportional’ and therefore contribute to the death of 
photoreceptors and supporting cells in a condition such as AMD129.  
 
An age-related increase in circulating levels of inflammatory cytokines such as 
TNF-α and Il-6 has been attributed to both cells of the monocytic lineage and 
aged stromal cells such as fibroblasts. The observed in vivo effects of ageing on 
macrophage function also correlate with reduced efficiency of TLR-dependent 
pathways which may be of particular relevance in AMD given a putative 
association between geographic atrophy and TLR3 signalling202. Dendritic cell 
populations also undergo age-related changes with descriptions of a decline in 
cell numbers, impaired antigen presentation and reduced migration to 
peripheral lymph nodes all featuring in the literature. It appears that the 
migration of mature antigen-carrying DCs from the peripheries to secondary 
lymphoid organs is highly dependent on chemokine signalling. Levels of the 
chemokine receptor CCR7 on DCs and chemokines in the tissues, such as 
CCL19 and CCL21 are similar in young and aged mice but the capacity for their 
upregulation is impaired in the latter. These features of ageing are thought to 
account for the reduced accumulation of DCs in the draining lymph nodes of 
aged mice200. Subretinal macrophages have previously been shown to originate 
from the retinal microglial population9. The work in this thesis suggests that a 
failure of DC maturation/migration or saturation of this pathway may precede 
the accumulation of subretinal macrophages with age and that normal 
functioning of the DC population is CCL2-dependent. Levels of the cytokine  
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Table 5 Age-related changes in the human innate immune system 
Macrophages isolated from aged subjects have been demonstrated to have decreased 
chemotactic activity and defective phagocytosis. An impaired ability either to phagocytose or 
process phagocytosed debris may account for the lipofuscin-laden appearance of dystrophic 
microglia in the subretinal space and brains of aged mice. Immunosenescence affecting 
dendritic cells, NK cells and neutrophils may also have role in the pathogenesis of AMD. 
Adapted from Panda et al. 2009. 
  
NK cells ↑ Numbers
↓ Cytotoxicity
Intact antibody-dependent cell cytotoxicity
Il-2-dependent IFN-γ and Il-2 and Il-12-induced chemokine production (MIP-1α, RANTES and Il-8)
Monocytes ↑, ↓ or unchanged LPS-induced cytokine production
↓ TLR1/2-induced Il-6 and TNF-α production
↓ TLR1 and TLR4 surface expression
↓ TLR-induced CD80 upregulation
↓ DC-SIGN signalling in macrophages (to West Nile virus)
↓ Phagocytosis
↓ Percentage of CD68-positive macrophages in the bone marrow
Dendritic cells ↑ Or unchanged number or percentage of mDCs
↓ Or unchanged number or percentage of pDCs
↓ Langerhans cell density in skin
Unchanged transendothelial migration, preserved ability of antigen-pulsed DCs to stimulate T-cell proliferation
↓ Pinocytosis or endocytosis and impaired chemokine-induced migration
↓ LPS-induced Il-12 production in mDCs
↓ IFN-α production in PBMCs
↑ TLR4- and TLR-8-induced Il-6 and TNF-α production in MDDCs
↑ Self-DNA-induced production of IFN-α and Il-6 in MDCCs
↓ Akt-phosphorylation, ↑ p38 phosphorylation (MDCCs)
                              Effect
NK cells, natural killer; Il, interleukin; IFN, interferon; MIP, macrophage inflammatory protein; RANTES, regulated upon activation,
normal T-cell expressed and lipopolysaccharide; TLR, Toll-like receptor; TNF, tumour necrosis factor; DC-SIGN, dendritic cell-specific
ICAM-3 grabbing non-lectin; mDC, myeloid dendritic cell; pDC, plasmacytoid dendritic cell; PBMC, peripheral blood mononuclear cell;
MDDC, monocyte-derived dendritic cell
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TNF-α and chemokines CCL2, CCL3, CCL8 and CCL12 have been found to be 
increased in the retinae of aged mice114, 124. Similarly chemokines and signalling 
pathways involved in leukocyte migration and extravasation, such as CCL2, 
have been found to be upregulated in the aged RPE-choroid. This would appear 
to be a part of the parainflammatory response associated with ageing - the 
question is: what role do DCs and subretinal macrophages play in the 
pathogenesis or prevention of AMD?  
 
Given that an increase in CCL2 is a feature of normal ageing, it was 
hypothesised that failure of its expression might result in an exaggerated ageing 
phenotype detectable before the appearance of subretinal macrophages. The 
relative proportions of innate immune cells in the retinae and RPE-choroids of 
CCL2-/- mice were therefore established, as in wild-type mice, in three different 
age groups. The proportion of DCs in the retinae of CCL2-/- mice was found to 
be four times higher in <4 month old mice than in age-matched wild-types with 
levels appearing to plateau after 12 months of age, after which time a much 
greater rise in the proportion of Gr-1- macrophages (most likely subretinal) was 
noted. These findings suggest that a failure of DCs to traffic out of the retina, or 
saturation of this pathway, results in the activation of microglia and their 
migration to the subretinal space. It was thought that such an effect might not 
be confined to the retina and that a system-wide failure of DC maturation might 
result in depleted numbers in the lymph nodes and spleen to which they would 
normally traffic to. To confirm this, proportions of innate immune cells in the 
spleens of wild-type and CCL2-/- mice were analysed. Age-related increases in 
DCs and Gr-1- monocyte/macrophages were identified in both genotypes; 
however CCL2-deficient animals exhibited consistently lower levels of these 
subpopulations compared to wild-types suggesting that it might be possible to 
detect the effects of defective DC trafficking in peripheral tissues other than the 
eye. In support of this, studies on Langerhans’ cells (the DC population in the 
skin) have revealed that cells lacking the receptor for CCL2 (CCR2) exhibit 
defective trafficking from the dermis to draining lymph nodes and have lower 
numbers of DCs in their spleens203. A role for CCR2 ligands in local DC 
activation has also been in established in the lung with CCR2-/- mouse DCs 
exhibiting an intrinsic activation/maturation defect and an associated diminution 
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of Th1 responses204. A system-wide failure of DC trafficking raises the intriguing 
possibility that lipofuscin-laden macrophages may be a feature of other tissues 
with age in the CCL2-/- mouse – increased skin autofluorescence, for example, 
is a feature of normal ageing in both humans and mice and has also been 
associated with wet AMD205.  
 
Another possible explanation for the findings in CCL2-/- mice is that a failure of 
monocyte recruitment to the retina in some way resulted in the ‘exhaustion’ of 
resident macrophage populations that were not replenished, resulting in a 
compensatory increase in DCs – however the increase in the proportion of DCs 
in the retina precedes the time taken for microglia to turn over (6 months), so 
this is unlikely206. Furthermore, the absence of either CCL2 or CCR2 individually 
has not been found to affect the turnover of monocyte-derived microglia in the 
mouse brain although double knockout of both ligand and receptor does result 
in a significant reduction in turnover137. Of particular interest where monocyte 
recruitment is concerned is the increase in the Gr-1- monocyte/macrophage 
population of the spleen that was observed with ageing in both wild-type and 
CCL2-/- mice. An increase in the equivalent CCR2- population in humans 
(CD14+ CD16+ monocytes) has also been found. CD14+ CD16+ monocytes from 
aged humans display reduced levels of the activation molecule HLA-DR and the 
chemokine receptor CX3CR1 which may have functional relevance given the 
potential effect on their migratory capacity, most especially in AMD where 
polymorphisms of the CX3CR1 receptor have already been linked with an 
increased risk of developing the disease169, 207. 
 
6.2 The role of the innate immune system in choroidal 
neovascularisation 
 
Having established a role for CCL2 in modulating the retinal response to 
ageing, further work was undertaken to determine the effect of CCL2 deficiency 
on choroidal neovascularisation following laser-induced rupture of Bruch’s 
membrane. Three principle questions were addressed, the first being which 
innate immune cell populations were involved in the neovascular response at 3 
days post-induction of CNV when monocyte/macrophage recruitment is at its 
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peak, the second being the extent to which CCL2 deficiency affects lesion size 
and the recruitment of particular cell populations, and the third being whether 
the increases in CNV lesion size with age might be explained either by 
increased numbers of subretinal macrophages.or by changes in innate immune 
cell recruitment. 
 
The development of CNV and pathological neovascularisation in general 
depends largely on patterns of cell recruitment and cytokine expression typically 
associated with acute inflammation (as opposed to the chronic inflammation 
associated with ageing). The laser-induced model of CNV was used to 
determine whether recently identified, monocyte subpopulations – classified as 
Gr-1+ Ly6CHigh CCR2+ and Gr-1- Ly6CLow CCR2- - might have particular roles to 
play in choroidal neovascularisation. It was hypothesised that changes in CNV 
lesion size with age might be explained by differences in the level of recruitment 
of these populations and that their manipulation might prove therapeutically 
beneficial. The phenotypes of the two principal monocyte populations have 
been characterised in disease models as diverse as those for myocardial 
infarction (Error! Reference source not found.), urinary tract infection and 
foreign body responses in the peritoneum165, 166, 173. CCR2+ monocytes have 
been broadly defined as having ‘pro-inflammatory’ properties and CCR2- 
monocytes ‘wound healing’ properties that include pro-angiogenic potential. In 
addition CCR2- monocytes are thought to be the principal population involved in 
the replenishment of resident macrophage populations and, in keeping with the 
analysis of innate immune cell populations in murine spleen described 
previously, a significant age-related shift in monocyte populations from CCR2+ 
to CCR2- has been established in humans 7. 
 
Analysis of retinal and RPE-choroidal cell suspensions from young adult wild-
type mice revealed an increase in the proportions of all of the key innate 
immune cell populations at 3 days post-induction of CNV by diode laser in the 
retina (in particular DCs and granulocytes) and increases in the proportion of 
DCs and granulocytes only in the RPE-choroid. These findings are largely in 
keeping with those of Nakai et al. who identified recruitment of VEGR2-
expressing DCs to newly formed blood vessels following induction of CNV, with 
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levels peaking between 2 and 4 days post-laser160. It is also in keeping with the 
results of others, including Tsutsumi et al. and Eter et al. whose work, using 
CCR2-/- and CX3CR1GFP/+ mice respectively, suggests roles for macrophages 
(both recruited and resident), granulocytes and DCs in the propagation of CNV 
at similar timepoints in its pathogenesis153, 186. However, the results do run 
contrary to the findings of Apte et al. who advocate a role for macrophages in 
the inhibition of laser-induced CNV after demonstrating that increased 
macrophage recruitment is associated with smaller CNV size in Il-10-/- mice and 
that anti-CD11b and anti-F4/80 antibody-mediated depletion of systemic 
monocyte/macrophage populations is associated with increased lesion size. 
The findings of Apte et al. are in direct contradiction, in fact, to those of 
Espinosa-Heidmann et al. who, using clodronate liposomes to deplete 
circulating and choroidal monocyte/macrophage populations, demonstrated a 
correlation with reduced lesion size96, 152.  
 
It was hypothesised that conflicting reports of the effects of 
monocyte/macrophage depletion (or inhibition) on CNV lesion size in the 
literature might be explained by the preferential effects of the various 
experimental techniques on particular monocyte subpopulations – interventions 
favouring a reduction in CCR2- Gr-1- monocyte populations might result in 
reduced CNV whereas a reduction in CCR2+ Gr-1+ monocyte populations might 
have the opposite effect. CCL2-/- mice were used to determine whether absence 
of the ligand for CCR2+ cells might result in an increase in lesion size. In fact, a 
reduction in laser-induced CNV lesion size, as well as lesion size in a model of 
alkali-induced corneal neovascularisation, has previously been demonstrated in 
CCR2-/- mice - suggesting that, in these models at least, CCR2+ cells might be 
important effectors in the neovascular process150, 189.  The validity of the 
observations in CCR2-/- mice is open to question, however, since absence of 
CCR2, though not CCL2, has been shown to inhibit the emigration of 
monocytes from the bone marrow136, 156, 208. Equally, the results of experiments 
employing chimeric GFP+ animals to distinguish resident from recruited cells are 
in dispute since the total body irradiation required in the development of  
 
  
Chapter 6  Discussion 
228 
 
chimeric mice triggers enhanced recruitment of blood monocytes to the 
retina209. 
 
Comparison of innate immune cells isolated from the eyes of young adult CCL2-
/- mice at 3 days post-laser with both unlasered CCL2-/- tissue and lasered wild-
type tissue revealed a significant reduction in the proportions of all innate 
immune cell populations, except granulocytes, in both the retina and RPE-
choroid. This was associated with a significant reduction in lesion size (Figure 
34). The effect of CCL2 knockout suggested an important role for recruited cells 
in the development of CNV. It also suggested that granulocytes might be 
capable of making a limited, though significant, contribution to pathological 
neovascularisation in the absence of other innate immune cell populations – 
something also found in the CCR2-/- mouse153.  
 
The percentage of Gr-1+ monocytes in the retina and RPE-choroid, even post-
laser, was found to be much lower than expected (a finding supported by 
immunohistochemistry analysis) and recruitment of both monocyte 
subpopulations appeared to be suppressed in CCL2-/- mice. It was perhaps 
surprising to observe such a marked effect of CCL2 deficiency on the 
recruitment of Gr-1- monocytes given they do not express CCR2. This effect 
was attributed to the sequential recruitment of monocyte subsets observed 
elsewhere in the body – failure to recruit even small numbers of CCR2+ 
monocytes in the initial stages of a response may have knock-on effects on the 
recruitment of the CCR2- subset159. One reason why levels of Gr-1+ monocytes 
appeared so low – even in wild-types post-laser – might be that their 
recruitment peaks a lot earlier than 3 days post-laser and therefore any effect of 
CCL2 deficiency on their recruitment may have been missed. The division of 
monocyte phenotypes into distinct ‘inflammatory’ and ‘healing’ subsets may be 
slightly misleading in this context – the retinal and RPE-choroidal environments 
are highly dynamic and interruption of recruitment of one cell type very likely 
has effects on the recruitment of others. This may have implications for the 
treatment of patients with wet AMD because if the inhibition of chemokine 
pathways is to prove successful in the management of CNV, consideration will 
have to be given to the timing of drug delivery relative to the onset of 
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neovascularisation. The results of work on mice, for example, suggest that 
targeting of CCR2 signalling in humans would be most effective in the first 48 
hours of onset of CNV. 
 
The effect of CCL2 deficiency on CNV was to significantly reduce lesion size 
compared with age-matched wild-types – an effect observed even in CCL2-/- 
mice >18 months old (Figure 34). Even so, significant increases in lesion sizes 
were observed in both CCL2-/- and wild-type animals with age although the 
increase appeared to be attenuated with age in CCL2-deficient animals. It was 
not possible to identify consistent changes in samples of lasered tissue taken 
from the eyes of these animals that might account for the effects of ageing on 
lesion size (Figure 37 and Figure 38). The relative proportions of innate immune 
cell populations in retina at 3 days post-laser remained relatively consistent in 
both CCL2-/- and wild-type mice with age. In the choroid, DC recruitment to CNV 
appeared to decline with age in wild-type mice and remained low in CCL2-/- 
animals. In contrast, granulocyte recruitment to the choroid post-laser more 
than doubled with age in both wild-type and CCL2-/- mice. This observation 
might serve to explain the linear increase in lesion size observed with age in 
both genotypes were it not for the non-linear increase in granulocyte recruitment 
observed in wild-type mice (a 3-fold increase in granulocytes was observed in 
12m animals compared with a 4-fold increase in <4m animals). Even so the 
results were strongly suggestive of a link between enhanced granulocyte 
recruitment to CNV lesions and increased lesion size with age. 
 
One conclusion that could be drawn from the analysis of lasered tissue was that 
the accelerated accumulation in CCL2-/- mice of subretinal macrophages 
appeared not to be associated with a pro-angiogenic effect (otherwise the effect 
of CCL2 deletion on lesion size would have been attenuated with age - this was 
not found to be the case). This finding is in keeping with evidence, derived from 
mice expressing eGFP under the promoter for the c-fms gene, suggesting that 
brain microglia in fact increase expression of both pro- (TNFα, Il-1β, IL-6) and 
anti-inflammatory (Il-10, TGFβ1) cytokines with age and that age-related 
changes in the response to LPS remain in proportion to basal levels of cytokine 
production129. However, the notion that subretinal microglia exert little pro-
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angiogenic effect runs contrary to the findings of Ma et al. who, having 
established that subretinal microglia induce structural and functional changes in 
the RPE, proceeded to isolate retinal microglia from CX3CR1+/GFP mice, activate 
them with LPS and inject them subretinally using a Matrigel model of CNV 
induction. Their results suggested that subretinal microglia exert a ‘strong’ pro-
angiogenic effect on CNV. However the expression profile of microglia cultured 
from young CX3CR1+/GFP mice and LPS-activated before being transplanted 
into genetically different wild-type animals is likely to be very different to that of 
the dystrophic, lipofuscin-laden cells observed in aged animals and it is worth 
noting in this context that spontaneous CNV has not been conclusively 
demonstrated in any of the chemokine knockout models for AMD where 
accelerated accumulation of subretinal microglia is a feature210. 
 
The possibility that changes in innate immune cell populations in the periphery 
might explain the change in CNV size with age was considered. The effects of 
these changes remain unclear however – approximately 3–fold increases in Gr-
1- monocyte/macrophage and DC populations were observed in the spleens of 
both wild-type and CCL2-/- mice with age yet this was not reflected in the 
proportion of cell types recruited locally following CNV-induction despite similar 
increases in lesion size with age. This suggests that whilst changes in the 
proportion of innate immune cells in the periphery do correlate with the chronic 
inflammatory changes observed with age in the eye, the acute inflammatory 
response that follows an event such as induction of CNV by diode laser remains 
largely unchanged. Age-related changes in the cytokine profiles of the various 
recruited cell types that might explain the increase in lesion size cannot be 
excluded but it is more likely - increased granulocyte recruitment to CNV aside - 
that anatomical changes in the RPE and Bruch’s membrane render the aged 
eye more susceptible to larger CNV lesions. Having said this, it has recently 
been established that post-ischaemic neovascularisation is highly dependent on 
monocyte levels in the bloodstream and CCL2/CCR2 signalling is thought to be 
important in regulating circulating levels of both CCR2+ and CCR2- monocytes 
(it is postulated that the impact of disrupted CCL2/CCR2 signalling on CCR2- 
cells is a downstream consequence of a primary effect on CCR2+ cells)187, 188. 
Consequently, the reduced CNV lesion size observed in CCL2-/- mice compared 
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with wild-types may be explained by reduced levels of circulating monocytes as 
inferred from levels observed in the spleen. Similarly, the age-related increase 
in lesion size in both CCL2-/- and wild-type mice may be explained by an 
increase in circulating levels of monocytes with age. If these hypotheses are 
correct, how is a failure to demonstrate increased levels of CCR2- monocytes in 
lasered tissue with age to be explained? This may in fact be due to the highly 
variable nature of the laser CNV model, a feature compounded by the variation 
in resident innate immune cell populations with age in retina and RPE-choroidal 
tissues.  
 
6.3 Targeting innate immune cells in choroidal 
neovascularisation 
 
 
In the final results chapter of this thesis the potential for tyrosine kinase 
inhibitors and CD200R agonists to modulate the neovascular response 
following laser-induction of CNV was explored.  
 
The capacity for the multi-target tyrosine kinase inhibitor pazopanib (delivered 
by oral gavage) to reduce CNV lesion size was confirmed and a biological 
mechanism suggested by an increase in the proportion of Gr-1+ 
monocyte/macrophages in the retinae of young adult mice receiving the 
compound 3 days post-laser. A reduction in the proportion of granulocytes in 
the spleen following prolonged systemic administration of pazopanib was also 
observed, raising the possibility that changes in the peripheral innate immune 
system might contribute to the inhibition of pathological neovascularisation 
through inhibition of tyrosine kinase receptors other than VEGF receptors – 
colony stimulating factor 1 receptors (CSF-1R) for example. CSF-1 regulates 
macrophage Inhibition of CSF-1R appears to be a feature of other small 
molecules primarily designed as PDGFR or VEGFR inhibitors such as sunitinib 
and axitinib – any therapeutic advantage conferred by this, in the context of 
tumour biology at least, remains undetermined189. Further work identified a role 
for pazopanib retained in the uveal tract in inhibiting choroidal 
neovascularisation, thus demonstrating a novel approach to achieving 
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therapeutic levels of drug in the RPE-choroid whilst minimising effects on other 
tissues both systemically and in the eye.  
 
Previous work had suggested that macrophages remain activated in the retina 
and the RPE-choroid for a prolonged period (at least 5 weeks) following 
induction of CNV; it was hypothesised that driving alternative macrophage 
activation by exploiting the CD200R-CD200 axis might result in reduced lesion 
size. Intravitreal delivery of CD200R agonist at the time of peak 
monocyte/macrophage recruitment was found to significantly reduce CNV 
lesion size 2 weeks after induction, a finding associated with a significant 
increase in the proportion of Gr-1- monocyte/macrophages in the retina at 1 
week and granulocytes in the RPE-choroid at 2 weeks. These data indicated 
that it was possible to have an effect on pathological neovascularisation by the 
direct induction of alternative macrophage activation and without VEGFR 
inhibition. Whether the rise in the Gr-1- population observed at 1 week reflected 
changes in the levels of CCR2- monocytes or microglia is unclear. However, 
using immunohistochemistry it was possible to identify Gr-1- F4/80+ CD200R+ 
cells in the retina at this timepoint that were consistent with a microglial 
phenotype. Further work would be necessary to confirm whether induction of 
the CD200R pathway affected the balance of monocyte recruitment at the 3 day 
post-laser timepoint and the functional changes associated with the observed 
shift in cell populations. 
 
Both the proliferation of microglia and the recruitment of monocytes from the 
periphery have been observed following laser-induction of CNV186. 
Distinguishing newly recruited monocytes from the microglial population in the 
retina and RPE-choroid was not a central aim of the work in this thesis but 
passing comment on the relative effects of CCL2 deficiency and the use of 
potential therapeutics on monocyte subsets is very difficult unless this is given 
some consideration. It was not possible to distinguish CCR2- monocytes in 
lasered tissue from proliferating microglia that shared the same surface 
markers. Consequently, confirmation of whether CCR2- monocytes constitute 
the more pro-angiogenic subset in CNV was not possible. Conflicting opinions 
exist in the literature regarding the relative roles of CCR2+ and CCR2- 
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monocytes where pathological neovascularisation is concerned. Models of 
myocardial infarction (essentially ischaemia-reperfusion models) suggest that 
CCR2- monocytes, recruited from day 4 post-injury onwards, constitute the 
more pro-angiogenic subset175. In contrast, work undertaken using the alkali-
induced corneal neovascularisation model suggests that elimination of the same 
CCR2- subset in CX3CR1-/- mice is actually associated with increased lesion 
size and reduced macrophage infiltration208. Recent work in models of hind limb 
ischaemia using CCL2-/-, CCR2-/- and CX3CR1-/- mice, in combination with 
adoptive transfer experiments, suggests that vessel growth correlates most 
strongly with levels of circulating monocytes and that of these cells the CCR2+ 
population is that most involved in angiogensis187, 188. 
 
When one considers the effects of CCR2 deletion on monocyte emigration from 
the bone marrow (CCR2-/- mice being a commonly used model in this context), 
the apparent biphasic nature of monocyte recruitment and the effects of 
CX3CR1 deletion on CCR2+ monocytes – cells which nevertheless express 
some CX3CR1 albeit at low levels - the picture that emerges is one of 
extraordinary complexity. To some extent this was reflected in the observed 
changes in innate immune cell populations following delivery of pazopanib and 
CD200R agonist and in the high proportion of Gr-1+ monocyte/macrophages in 
the spleens and RPE-choroids of JR5558 mice. It is nevertheless interesting to 
note that changes in the proportions of innate immune cells in the retina were 
often associated with an effect on lesion size and this suggests that the immune 
system of the retina plays a role in modulating the development of CNV. 
 
6.4 Conclusions 
 
This thesis established at its outset the innate immune cell populations of the 
retina and RPE-choroid in young, adult wild-type mice.  The retina in particular 
was demonstrated to accumulate Gr-1- macrophages and dendritic cells with 
age. The chemokine CCL2 is expressed by the RPE and upregulated with age 
in the retina and RPE-choroid and from an early age dendritic cell trafficking out 
of the retina appeared to be defective in CCL2-/- mice124. Levels of DCs rapidly 
reached a plateau after which the accumulation of Gr-1- macrophages was 
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observed. The timing of these changes suggests that DCs have an important 
role to play in maintaining the homeostasis of the ageing retina and that 
saturation of this pathway (which may be accelerated in subjects at high risk of 
AMD) results in activation of retinal microglia that are perhaps less able to meet 
the challenge of age-related parainflammation. It was not possible to determine 
whether the macrophages observed to accumulate in the retina with age were 
those identified subretinally using immunohistochemistry but the numbers of 
cells in the subretinal space are few and consequently unlikely to feature 
prominently in the flow cytometric analysis. Changes in innate immune cell 
populations observed in the eye were associated with an increase in the 
proportion of dendritic cells and Gr-1- macrophages in the spleen with age. The 
proportion of DCs in CCL2-/- spleen was significantly reduced and this provided 
further evidence of a role for CCL2 in DC trafficking. Cell tracking studies where 
the cells responsible for clearing subretinally injected Q-dots are identified and 
then traced on their migration to the spleen (in wild-type and CCL2-deficient 
animals) may be helpful in clarifying the role of DCs in maintaining retinal and 
choroidal homeostasis. 
 
DCs and granulocytes were identified as the principle effectors of laser-induced 
CNV at the 3 day timepoint. CCL2 was identified as critical for the recruitment of 
monocyte/macrophage and DC populations - but not granulocytes - following 
laser-induction of CNV. A failure to recruit all innate immune cell populations, 
granulocytes excepted, correlated with smaller lesion sizes in CCL2-/- mice. An 
age-related increase in lesion size in CCL2-deficient mice was still observed 
though lesions were consistently smaller than age-matched wild-types. 
Increased lesion size with age was associated with enhanced granulocyte 
recruitment to the choroid in both wild-type and CCL2-deficient mice. Lower 
numbers of DCs and Gr-1- macrophages were observed in the spleens of 
CCL2-/- mice and these populations increased in size with age in both CCL2-
deficient animals and wild-types. That age-related changes to peripheral innate 
immune cell populations might be responsible for the increase in lesion size 
observed with ageing could not be excluded, however enhanced recruitment of 
DCs and Gr-1- macrophages to CNV with age was not seen. The accelerated 
accumulation of subretinal microglia in CCL2-/- mice was not associated with a 
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tendency to increased lesion size suggesting that subretinal microglia do not 
exert a pro-angiogenic effect. Finally, with regard to identifying a role for a 
particular monocyyte population in CNV development, it was not possible to 
determine whether a failure to recruit the Gr-1+ CCR2+ monocyte subset was a 
feature of CCL2 deficiency. However, changes in the proportions of Gr-1+ and 
Gr-1- monocyte/macrophage populations were observed in the retina following 
the delivery of the RTKI pazopanib and a CD200R agonist, as well as in 
JR5558 mice, suggesting an important role for these cells in the development of 
choroidal neovascularisation. 
 
The use of surface markers to define changes in innate immune cell populations 
has been established for many decades but has its limitations, as the difficulties 
of distinguishing monocyte subpopulations from microglia illustrate. In part this 
reflects the challenge of dissecting populations of cells from a rapidly changing 
and highly plastic milieu - a challenge which, if anything, grows with our 
understanding of the complexity of the immune system and the tools available 
for its investigation. It also derives from the different approaches adopted by 
investigators from seemingly unrelated areas of research in tackling what are 
often very similar pathways. The markers CD11b and Gr-1 are actually used to 
define the heterogeneous myeloid-derived suppressor cell population in tumour 
biology, for example, and the striking parallels between the various monocyte 
populations and those established in tumour biology – the tumour-associated 
and tie-2 expressing macrophage subsets - add a further layer of complexity to 
the immunobiology176. Nevertheless, current therapies for CNV – the VEGFR 
antagonists ranibizumab and bevacizumab - were born out of research into 
therapies for colorectal carcinoma and other tumours; so, at a clinical level at 
least, disparate scientific strategies would appear to have a tendency to 
converge. In reality, cell surface markers not only serve to define cell 
populations but have functional effects of their own that are often not fully 
understood. Of those markers employed in this thesis the surface integrins 
CD11b and CD11c are probably the best characterised, but the others - F4/80 
(thought to be involved in the induction of antigen-specific efferent regulatory T 
cells and peripheral tolerance), Ly6C and Gr-1 - remain something of an enigma 
where their functional roles are concerned. It is interesting to speculate on the 
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purpose of Gr-1 and Ly6C expression in the innate immune system, especially 
given their association with the vasculature of the retina and CNS. Of more 
immediate functional relevance, perhaps, are the patterns of cytokine 
expression associated with particular innate immune cell populations and shifts 
in the proportions of these cells in the retina and RPE-choroid.  
 
Future work will take three directions (in line with the areas explored in this 
thesis): the first will be to further test the hypothesis that DCs are responsible 
for maintaining tissue homeostasis in the sub-RPE and choroidal 
microenvironment and that defective DC trafficking is integral to the 
accumulation of subretinal microglia in ageing wild-type and CCL2-/- mice. The 
phenotype of cells responsible for phagocytosing Q-dot markers injected 
subretinally in mice will be identified. The presence (or absence) of these cells 
in tissues such as the spleen will then be established at specific timepoints 
post-injection. Secondly, the hypothesis that enhanced neutrophil recruitment 
contributes to increased CNV lesion size in aged mice will be tested. 
Neutrophils have been demonstrated to upregulate CCR2 in the context of a 
number of inflammatory conditions and models and the attenuation of increased 
lesion size with age observed in CCL2-deficient animals may be a consequence 
of this76, 85, 211. Neutrophils will be isolated from the bone marrow of young and 
aged mice and their capacity to migrate to CCL2 investigated using a 
chemotaxis assay. Levels of expression of CCR2 on neutrophils derived from 
young and aged mice will be established using flow cytometry. Results may 
inform translational approaches to determining the risk of developing CNV in 
AMD – peripheral blood neutrophils isolated from human subjects with CNV or 
aged individuals may be demonstrated to have increased expression of CCR2 
and enhanced chemotaxis to CCL2 for example. Thirdly the functional changes 
associated with changes in innate immune cell populations following delivery of 
pazopanib and CD200R agonist will be identified using flow cytometry to 
analyse cell populations and intracellular cytokines such as TNF-alpha, IL-10, 
IL-6, IL-4 and IFN-gamma in combination. 
 
It is generally accepted that progress towards answering the key questions in 
AMD research has been hindered by the limitations of experimental models 
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available for study (the absence of maculae in mice for example). More patient-
focused translational approaches to AMD may ultimately prove more successful 
in bridging the gaps in our knowledge. The role of the systemic immune system 
and immunosenscence in AMD has been discussed in this thesis. Over several 
decades the concept of immune privilege has evolved from one based on 
immunological ignorance (maintained by blood-tissue barriers and an absence 
of a lymphatic drainage system) to one based on the complex and dynamic 
interaction of the immune system with specialised tissues such as those of the 
eye. Exploring the role of the wider immune system in AMD and other age-
related pathologies remains a huge challenge that must be met if these 
conditions are to be prevented.  This thesis, in identifying a potential role for 
local and peripheral innate immunosenescence in driving the pathology of AMD, 
serves as a platform on which to build further experimental work and clinical 
studies. Key questions that might be answered with the involvement of patients 
and the acquisition of post-mortem tissue include: Is the accumulation of 
subretinal microglia a feature of normal ageing in humans? Is the accumulation 
of subretinal microglia accelerated in those at risk of AMD and might the 
presence of these cells be associated with a particular phenotype? Are 
numbers of peripheral blood innate immune cells altered in AMD subjects 
compared to age-matched controls and is this associated with detectable 
changes in their function? What is the role of dendritic cells in the development 
or prevention of chronic inflammation in the retina and RPE-choroid? It is hoped 
that by answering at least some of these questions it will be possible to design 
more focused approaches to the study of how patients might best be treated 
and ultimately determine how this debilitating disease might be prevented.
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